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 ABSTRACT 
 
Investigations into the design of analogues of GlcNAc-Ins, the substrate for the enzyme 
GlcNAc-Ins deacetylase (mshB), a therapeutic target on the pathway to mycothiol 
biosynthesis in Mycobacterium tuberculosis are described.  Initial studies directed 
towards the design of a substrate analogue were based on the 3-D structure and a 
proposed mechanism of action of mshB (deduced by Dr. Andrew McCarthy, EMBL).  
The compounds were designed with the aim to produce an analogue which could better 
mimic the natural substrate for mshB (GlcNAc-Ins) for crystallisation and mechanistic 
studies to further improve the knowledge of this enzyme. 
 
A series of fatty acid ester and ether derivatives were designed and synthesised based on 
carbohydrate and non-carbohydrate polyhydroxylated scaffolds with a view to testing 
their antimicrobial activity against microorganisms of concern to the food and healthcare 
industries.  The synthesised compounds, along with their corresponding fatty acid 
monoglyceride antimicrobials, were evaluated for antimicrobial activity against 
Staphylococcus aureus and Escherichia coli.  Of the derivatives synthesised several of the 
carbohydrate based compounds have antimicrobial efficacy comparable with 
commercially available antimicrobials.  The results suggest that the nature of the 
carbohydrate core plays a role in the efficacy of carbohydrate fatty acid derivatives as 
antimicrobials. 
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1. Introduction 
This thesis reports the design and synthesis of novel carbohydrate derivatives both as 
potential mycothiol biosynthetic enzyme substrate mimics and carbohydrate fatty acid 
conjugates with a view to testing their antimicrobial activity against microorganisms 
of concern to the food and healthcare industries. 
   
Carbohydrates are the most abundant and the most diverse biopolymers in nature.  
Due to their highly specific interactions with physiological receptors, they participate 
in many crucial biological processes.  All these processes are potential targets for 
therapeutic intervention and carbohydrate-based drugs are rapidly being engaged by 
the modern biotechnology and pharmaceutical industry.
1
  Chemists and biochemists 
have developed new methods to rapidly synthesise oligosaccharides, enabling them to 
generate complex polysaccharides and analogues of natural products.  Biologists have 
explored the physiological roles of various sugars, discovering that many play 
essential roles in the functioning of the major organ systems and are involved in 
several disease states.  In addition to extending our knowledge, these findings have 
enabled the development of carbohydrate-based drugs and vaccines.
2
  
 
1.1 MEDICINAL CHEMISTRY AND RATIONAL DRUG DESIGN    
The need for ongoing development of new drugs needs little emphasis in light of the 
current global situation of health and disease.  Traditionally, the process of drug 
development has revolved around a screening approach as there can be uncertainty as 
to which compound or approach could serve as a drug therapy.  The structure-assisted 
(“rational”) drug design and discovery process utilizes techniques such as protein 
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crystallography, nuclear magnetic resonance and computational biochemistry to guide 
synthesis of potential drugs.
3,4,5
  Structural information is used to help explain the 
basis of effective inhibition and to improve the potency and specificity of new lead 
compounds.
3
  Rational drug design thus aims to realise a preconceived 
pharmacological activity in a directed way.  This approach is based on the very 
reasonable assumption that if the structure of a natural ligand and its receptor is 
known, molecules which could mimic or antagonise the activity of the natural ligand 
could be synthesised.
6
 
 
The first success story in structure-based design was the antihypertensive drug, 
captopril (Capoten®, Lopirin®, Squibb, now Bristol-Myers Squibb), an angiotensin-
converting enzyme (ACE) inhibitor (Figure 1-1).  The structure of captopril was 
derived in a rational manner from a binding site model, using the 3D information of 
the complex of benzylsuccinate with the closely related zinc proteinase 
carboxypeptidase A.
7
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Figure 1-1 Captopril (Squibb, now Bristol-Myers Squibb).
7
 
 
 
Another successful example of structure-based drug design leading to the 
development of an approved drug is Cimetidine, a histamine H2-receptor antagonist 
that inhibits the production of acid in the stomach.  This was one of the earliest drugs 
developed using a rational drug design approach. 
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1.1.1 Cimetidine – A Rational Approach to Drug Design 
In 1964, Smith Kline & French (now GlaxoSmithKline) initiated an unconventional 
approach to seek a novel type of agent to block the action of histamine (Figure 1-2) as 
a stimulant of gastric acid secretion.  It was hypothesized that histamine as a 
secretagogue acted at a hitherto uncharacterized histamine receptor (later designated 
as H2).
8
 
 
NHN
NH2
 
Figure 1-2 Histamine. 
 
 
Histamine served as the chemical starting point for drug design and systematic 
structural modifications of this compound led to the early antagonists which were all 
imidazole derivatives.  The earliest compound used as an inhibitor of this class of 
histamine H2-receptors was burimamide (Figure 1-3), a thiourea derivative of a 
histamine homologue.  Despite the activity of this compound being rather weak, it 
was used to verify that H2-receptors did indeed mediate gastric acid secretion 
(reported in 1972).
9
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Figure 1-3 Burimamide. 
 
 
The development of burimamide was followed by metiamide (Figure 1-4), which was 
designed to alter the electronic properties of the imidazole ring of burimamide by 
including an electron-releasing methyl group in the imidazole and an electron-
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withdrawing isosteric sulfur replacement for CH2 in the side chain.  Metiamide was 
orally active, however it was suspended from clinical trials due to side effects 
including incidence of granulocytopenia, an abnormally low concentration of 
granulocytes in the blood which can reduce the body's resistance to many infections.
8
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Figure 1-4 Metiamide. 
 
 
The hypothesis that these side effects may have stemmed from the thioureido group 
led to attempts to replace the thiourea moiety.  These investigations led to the 
cyanoguanidine analogue cimetidine (Figure 1-5), in which cyanoimino replaces 
thione sulfur. 
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CN  
Figure 1-5 Cimetidine (Trade name Tagamet®). 
 
 
Cimetidine closely resembled metiamide but did not exhibit the granulocytopenia side 
effect.  It was marketed as Tagamet® at the end of 1976, as the pioneer drug that 
revolutionised the treatment of peptic ulcer disease.
8
 
 
1.1.2 The Role of Combinatorial Chemistry in Rational Drug Design 
Combinatorial Chemistry has impacted greatly on mechanism-based drug discovery 
projects.  Structural or functional information about the target is used to define a 
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generic structure that a putative inhibitor may resemble.  The starting point is not a 
known chemical but rather theoretical pharmacophores.  Combinatorial libraries are 
then used in order to explore this concept and to identify hits that may be used as the 
starting points for the next generation of libraries.  This process requires an extensive 
knowledge of the structure and the biological properties of the target.
10
   
 
The bacterial enzyme peptide-deformylase (PDF) is an example of how the successful 
combination of mechanism-based drug design with focused libraries can lead to the 
development of an entirely new class of antibiotics.  PDF is an essential bacterial 
metalloenzyme which deformylates the N-formylmethionine of newly synthesised 
polypeptides.  Its 3D structure has been determined.
11,12
  To identify novel PDF 
inhibitors, Clements et al. screened a metalloenzymes inhibitor library and identified 
an N-formylhydroxylamine derivative, BB-3497 and a related natural hydroxamic 
acid antibiotic, actonin, as potent and selective inhibitors of PDF (Figure 1-6).
12
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Figure 1-6 Structures of (a) BB-3497 and (b) Actonin, inhibitors of PDF.
12
 
 
 
Actonin and BB-3497 showed minimum inhibitory values (MIC) of 32 μg/mL and 4-
16 μg/mL respectively against Staphylococcus aureus.  Combinatorial libraries played 
a major role in these research discovery projects.
10
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1.1.3 The Role of Carbohydrates in Rational Drug Design     
As bacterial, viral and fungal drug resistance to currently administered treatments 
increases, the need for the development of new therapeutic strategies against 
infectious agents becomes more urgent.  Carbohydrates are ubiquitous and important 
biomoloecules forming much of the structural framework of cells and tissues.  As 
components of glycoproteins, glycolipids and other conjugates, they are key elements 
in a variety of processes such as signalling, cell-cell communication and molecular 
and cellular targeting.
13
  Crucial to the survival of many pathogens are carbohydrate 
structures which are either themselves structurally unique or specific to non-
mammalian organisms.  Indeed inhibition or interference with biosynthesis of 
oligosaccharide materials represents an attractive and potentially highly selective 
strategy for the development of new classes of therapeutic agents.
14
  Carbohydrates 
provide an excellent platform to tailor molecular diversity by appending desired 
substituents at selected positions around the sugar scaffold.  The presence of five 
functionalised and stereo-controlled centres on the sugar scaffolds gives the chemist 
scope to custom design molecules to a pharmacophore model.
15
 
 
1.1.3.1 Heparin 
Heparin is the oldest carbohydrate-based drug and is isolated from animal sources.  It 
has been used clinically as an antithrombotic agent since the 1940s.  Heparin activates 
the serine protease inhibitor antithrombin III (AT), which blocks the two principle 
procoagulant proteases, thrombin and factor Xa, in the coagulation cascade.  The rate 
of inactivation of these proteases by AT can increase by up to 1000-fold as a result of 
the binding of heparin.
16
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This drug is a highly heterogeneous mixture of polysaccharides and is associated with 
severe side effects including bleeding and allergic reactions.  Chemically or 
enzymatically fragmented heparins (low-molecular-weight heparins, LMWHs) are 
also heterogeneous, but have greater bioavailability, longer half-life, more predictable 
anticoagulant activity and fewer side effects.
17
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Figure 1-7 A pentasaccharide sequence of heparin.  This sequence is responsible for binding to 
antithrombin III.
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After the specific pentasaccharide responsible for the anticoagulant property was 
identified in the early 1980s (Figure 1-7), a vast effort lasting more than 10 years 
began to establish a structure-function relationship using synthetic oligosaccharides.
 18
  
As a result of this effort a synthetic pentasaccharide known as Arixtra (fondaparinux 
sodium; GlaxoSmithKline) has been available since 2002.
19
   
 
1.1.3.2 Challenges of Carbohydrate Synthesis    
The structural complexity that makes carbohydrates important in so many biological 
processes sometimes renders their chemical synthesis difficult.  Though it is possible 
to synthesise pure oligosaccharides in the laboratory, the regioselective protection of 
hydroxyl groups and the stereoselective assembly of glycosidic bonds presents a 
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number of challenges for synthetic chemists.
20
  The same regioselectivity challenges 
are also encountered when working with monosaccharides. 
 
The preparation of complex carbohydrates requires the strategic placement of 
protective groups that mask hydroxyl groups.  Whilst the ability to remove one 
protecting group in the presence of another is a key feature, the steric and electronic 
nature of the protecting groups are also important as they greatly influence both the 
reactivity of the building blocks and the outcome of any glycosylation reactions.  The 
properties of the protecting group next to the anomeric centre are very important.  For 
example, whether this group is participating or non-participating plays a significant 
role in the control of glycoside stereochemistry.
21
  Therefore, protecting groups on 
sites near the anomeric centre must be chosen carefully. 
 
The biggest challenges in carbohydrate synthesis are not only concerned with the 
stereoselective glycosylation of two or more sugars.  The preparation of 
monosaccharide derivatives must also be considered.  In this case protecting group 
manipulation is also essential to afford a regioselectively protected saccharide so that 
other functional groups can be introduced at the desired position.  Some protection 
strategies are the same for a number of monosaccharides for example glucose, 
mannose and galactose.  This is generally the case for pathways to free primary 
hydroxyl groups.  Standard methods for the selective protection of this position 
include tritylation or silylation followed by acetylation or benzylation of the 
remaining secondary hydroxyls.  The primary protecting group can then be selectively 
removed.
22
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Since the reactivity differences between secondary hydroxyls are not that large, one-
step selective protection is challenging.  Some methods developed for this purpose 
include Stannyl activation.  By reacting carbohydrate hydroxyl groups with tin oxide 
reagents, stannylene ethers and acetals are formed.  These stannylenes increase the 
nucleophilicity of the oxygens so that successive acylation or alkylation can be 
performed regioselectively.
23
 
 
1.2 ENZYME INHIBITION 
Development of inhibitors that are effective for specific enzymes that are involved in 
pathologically or physiologically important metabolic processes constitutes a viable 
approach for new drug discovery.  In fact a majority of therapeutic agents in current 
use are inhibitors of enzymes.
24
   
 
Enzyme inhibition involves the addition of a molecule that interacts with the enzyme 
in order to change its conformation or directly prevent substrate binding.  In the latter 
case the inhibitor binds to the same site of the enzyme as the substrate.  It binds only 
to the free enzyme and is usually structurally similar to the substrate.  For example, 
succinate is the normal substrate for the enzyme succinate dehydrogenase and 
malonate is an effective competitive inhibitor of this enzyme (Figure 1-8).
25
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Figure 1-8 Substrate and inhibitor for succinate dehydrogenase. 
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Other strategies for enzyme inhibition involve the substrate being replaced with a 
non-cleavable isostere.  For example, the following transition state mimics are 
commonly used to replace cleavable amide bonds (Figure 1-9). 
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Hydroxyethylamine Hydroxyethylene Reduced amide  
Figure 1-9 Structure of some common transition-state isosteres that have been used to replace 
scissile amide bonds in the development of aspartic protease inhibitors.
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1.2.1 Metalloenzymes 
Metals play a role in approximately one-third of known enzymes.  Amino acids in 
peptide linkages possess groups that can form coordinate-covalent bonds with the 
metal atom.  This binding to the metal may affect the enzyme’s structure resulting in 
its active conformation.  The main function of the metal is to serve in electron 
transfer.
27
   
 
Metalloenzymes are among the best studied of enzyme classes and there are excellent 
precedents for the mechanism-based design of their inhibitors.
26
  Given the 
mechanistic resemblance between different metalloenzymes, the tools and knowledge 
developed for identifying inhibitors of one metalloenzyme can be easily applied to 
others of the same class which can eventually reduce the overall time and cost of 
identifying inhibitors of each member of this group.
28
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1.2.2 Zinc Containing Enzymes 
Metal ions are required for the growth of all life forms.
29,30,31,32
  Zinc is one of the 
most abundant divalent metals in living organisms.
33
  It is an essential cofactor of 
many metabolic enzymes and transcription factors. 
31,34,35
  Zinc enzymes are 
metalloproteins with specific enzymatic activity which may contain a single Zn (II) 
ion, several Zn (II) ions or different metal ions including Zn (II).  In principle, the zinc 
ion can be functional and necessary for the catalytic action or structural and therefore 
not involved in the catalytic mechanism but necessary to maintain the protein in the 
proper conformation.  Some zinc enzymes display hydrolytic activity and catalyse 
bond cleavage in which a reactant is water or its H
+
 or OH
-
 components.  Typical of 
this class of enzymes are proteases which hydrolyse peptide bonds and deacetylases 
which catalyse the removal of an acetyl group.
36
 
 
1.2.2.1 Zinc Protease  
All known metalloproteases use a zinc atom to effect amide bond hydrolysis.  
Mechanistically, the zinc-dependent metalloproteases are among the most widely 
studied members of the zinc hydrolase family.  Zinc metalloproteases are involved in 
various key biological roles and as a consequence many of these enzymes are targets 
for the development of therapeutic agents.
37
  
 
The design of metalloprotease inhibitors for adoption as therapeutics has become 
commonplace.  This has also led to a deeper understanding of enzymatic action.   
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Thermolysin was one of the first metalloproteases to have its structure solved 
crystallographically.  This revealed that this enzyme possessed an active-site zinc ion 
that activates the scissile amide bond (Scheme 1-1) toward the attack by water and 
stabilises the resulting tetrahedral intermediate.  Collapse of the tetrahedral 
intermediate reforms the carbonyl group and protonation of the nitrogen from the 
glutamic acid generates the free amine of the cleaved substrate.
38
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Scheme 1-1 Mechanism of hydrolysis of peptides catalysed by the active-site zinc in 
Thermolysin.
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At the centre of metalloprotease inhibitor design is the selection of a functional group 
that will interact with the metal (Figure 1-10).
38
 
 
SH
a b c
d
P
e
HO OH
OO
O O
N
H
O
OH
 
Figure 1-10 (a) Thiols, (b) Hydrated ketones, (c) Hydroxamic acids, (d) Carboxylates, (e) 
Phosphinates.
38
 
 28 
1.2.2.2 Recent Zinc Protease Inhibitors 
Carboxypeptidase A (CPA) serves as a prototypic enzyme of the zinc enzyme 
family.
35
  This enzyme, including its active site structure and catalytic mechanism has 
been intensively studied.  The mechanism is similar to that already outlined in 
Scheme 1-1 for Thermolysin.
40
   
 
This enzyme has also been used as a model for the development of inhibitor design 
strategies that can be applied to other zinc-containing enzymes that are less well 
understood.
41,42
  Min Su Han et al. reported a novel strategy that they developed with 
CPA.
24
  Compounds a-c shown in Figure 1-11 are the potential inhibitors they 
designed for CPA. 
 
CO2HOO
R
a; R = CH3
b; R = CH2Ph
c; R = CH2CH2Ph  
Figure 1-11 Inhibitors for CPA.
24
 
 
 
The inhibitors were synthesised readily and their activity towards CPA was evaluated.  
The compounds inhibited CPA in a time-dependent manner, suggesting that the 
inhibition occurs in an irreversible fashion.
24
  These CPA inhibitors were designed on 
the basis of the following rationale. 
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Scheme 1-2 CPA enzyme inhibition path a.
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The O1 of the inhibitor may be in close proximity to the zinc ion at the active site of 
CPA leading to the formation of a coordinate bond to the metal ion.  Just as 
protonated acetals break down to oxacarbenium ions in acetal hydrolysis, the O1 
coordinated to the metallic Lewis acid may undergo C-O bond cleavage with the 
generation of an oxacarbenium ion intermediate.  The oxacarbenium ion thus 
generated would undergo a bond formation reaction with the carboxylate of Glu-270 
to result in the covalent modification of the catalytic nucleophile (Scheme 1-2).  The 
covalently modified enzyme can no longer perform its enzymatic function. 
 
Alternatively, the reaction path that involves nucleophilic attack of the Glu-270 
carboxylate at the acetal of the inhibitor in an SN2 fashion may also be possible 
(Scheme 1-3).
24
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Scheme 1-3 CPA enzyme inhibition path b.
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1.2.2.3 Zinc Deacetylase 
A typical example of a zinc deacetylase is LpxC.  This enzyme catalyses the second 
step in the biosynthesis of Lipid A, an important outer cell-membrane component 
found in a number of pathogenic bacteria including Escherichia coli and Salmonella 
typhimurium.  LpxC catalyses the removal of an acetate from nitrogen in UDP-3-O-
acyl-N-acetylglucosamine and its inhibition leads to diminished production of Lipid 
A.  Therefore it is an attractive target for antibiotic design.
43
  
 
There are two proposed mechanisms for the reaction catalysed by LpxC.  In the first, 
LpxC might function via a Thermolysin-like mechanism (Section 1.2.2.1).  
Alternatively, there is evidence consistent with the involvement of two residues, 
Glu78 and His265, functioning as a general acid/base pair (Scheme 1-4).
37
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Scheme 1-4 Proposed mechanism for deacetylation catalysed by LpxC.
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In this proposed mechanism, Glu78 accepts a proton from the Zn
2+
-bound water, 
while His265-H
+
 protonates the nitrogen in the intermediate, thus leading to cleavage 
of the amide bond. 
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Recently Robinet et al. investigated the binding of the substrate within the active site 
and the deacetylase mechanism it catalyses and confirmed that LpxC uses a general 
acid/base pair mechanism as indeed both His265-H
+
 and Glu78 are involved.
44
 
 
1.3 TUBERCULOSIS 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(MTB).
45
  Globally, 9.2 million new cases and 1.7 million deaths from TB occurred in 
2006, of which 0.7 million cases and 0.2 million deaths were in HIV-positive 
people.
46
  TB is the major cause of death from a single infectious agent among adults 
in developing countries and there has been a recent revival of TB in the industrialised 
world.
47
  The World Health Organisation (WHO) estimates that approximately one 
third of the world population harbours latent infection with TB and as a result it has 
been declared a global emergency.
46
   
 
The mycobacterium species has been associated with AIDS/HIV and therefore, in 
recent years has attracted unprecedented attention.
48
  The impact of tuberculosis as an 
opportunistic infection on developing countries has been highly significant due to 
increasing incidences of AIDS/HIV in these countries.  For example in sub-Saharan 
Africa where TB notifications have on average trebled since the mid 1980’s.49  
Worldwide roughly 15 million people are already co-infected with HIV and M. 
tuberculosis and 2 million new cases are added each year.
50
 
 
Until approximately 50 years ago, there were no effective therapeutics against TB.  
Whilst the use of antibiotics revolutionised TB treatment, currently strains that are 
resistant to at least one drug have been documented in every country surveyed by the 
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WHO.  Moreover, strains of TB resistant to all major anti-TB drugs have emerged.
45
  
Multidrug-resistant tuberculosis, defined as resistance to the two most important drugs 
isoniazid (Figure 1-12) and rifampicin (Figure 1-13), is a growing problem among 
HIV-infected patients.
51
  The latter of these two drugs was the one most recently 
introduced in 1968.
52
  Decades of misuse of existing antibiotics and poor compliance 
with a prolonged TB drug regimen that involves four different drugs administered for 
two months followed by two drugs for an additional four months have created an 
epidemic of drug resistant TB.
53
   
 
The mechanism of action of isoniazid, as well as mechanisms conferring isoniazid 
resistance are complex.  Evidence suggests that isoniazid inhibits mycolic acid 
biosynthesis.  Mycolic acids are long-chain α-alkyl β-hydroxy fatty acids which are an 
essential component of the mycobacterium cell wall.
54
  Isoniazid (Figure 1-12) is 
activated by the mycobacterial enzyme KatG, a multifunctional catalase-peroxidase.  
Consequently, mutant KatG deficient MTB strains are invariably isoniazid resistant.
55
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Figure 1-12 Structure of Isoniazid.
56
 
 
 
Rifampicin (Figure 1-13), first introduced in 1968 as an antitubercular drug is 
extremely effective against M. tuberculosis and is a key component of anti-TB 
therapy.
57
  However, resistance to rifampicin is increasing because of widespread 
application that results in the selection of mutants resistant to other components 
within short-course chemotherapy.  Rifampicin targets the mycobacterial RNA 
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polymerase.  RNA polymerase is a complex oligomer composed of four different 
subunits (α,β,β’,σ, encoded by rpoA, rpoB, rpoC, and rpoD, respectively) of which 
rifampicin inhibits the essential rpoB gene.
58
  It was found that in E. coli most 
mutants in rpoB appeared to be resistant to all rifampicins tested.
59
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Figure 1-13 Structure of Rifampicin.
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It has been estimated that approximately 1 billion more people will be infected with 
TB in the next 20 years.
60
  Clearly the lack of new anti-tuberculosis drugs is a 
significant problem since the frequency of antibiotic-resistant TB is growing.  In order 
to develop new anti-tuberculosis drugs, novel metabolic pathways or metabolic 
intermediates used by the bacteria have been sought.  One such potential target is 
mycothiol (MSH), the reducing agent exclusively present in the order actinomycetes 
to which M. tuberculosis belongs.
61
   
 
1.3.1 Mycothiol and the MSH Cycle 
Intracellular thiols are biomolecules involved in critical roles in living organisms.  
These roles include controlling intracellular redox potential and acting as cofactors for 
vital detoxification enzymes.
62
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The cysteine-containing tripeptide glutathione acts as a key protective agent in 
eukaryotes and Gram-negative bacteria against damaging peroxides and other reactive 
oxygen species (Figure 1-14).
63
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Figure 1-14 Glutathione.
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Bacteria of the actinomycetes order which include the pathogenic mycobacteria and 
antibiotic producers such as streptomycetes, do not produce glutathione but instead 
use mycothiol.
62
  Mycothiol (1-D-myo-inositol 2-deoxy-2-(N-acetamido-L-cystein-
amido-α-D-glucopyranoside, MSH (Figure 1-15), is a low molecular weight thiol 
produced only by actinomycetes.
64
  MSH comprises one unit 1-myo-D-inositol (myo-
D-Ins), glucosamine (GlcN) and N-acetyl-cysteine. 
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Figure 1-15 Mycothiol.
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MSH is important in that it appears to play an analogous role to glutathione in 
maintaining a reducing intracellular environment and facilitating detoxification from 
alkylating agents and other toxins.
64
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Of all Gram-positive species tested, mycobacteria appear to generate the highest 
levels of MSH.
66
  In mycobacteria biosynthesis of MSH is accomplished in four steps 
by the enzymes termed mshA-D, illustrated in Scheme 1-5.
67
  Recent studies have 
elucidated the initial steps leading to GlcNAc-Ins.
68
  The glycosyl transferase mshA 
catalyses the reaction of UDP-GlcNAc with 1L-Ins-1-P to generate GlcNAc-(α1,1)-
1D-Ins-1-P which is then dephosphorylated by an as yet unidentified phosphatase 
mshA2 to generate GlcNAc-Ins.  GlcN-Ins is then produced from GlcNAc-Ins by the 
deacetylase mshB.  The ligase mshC generates Cys-GlcN-Ins from Cys and GlcN-Ins.  
Finally acetyl transferase mshD catalyses the acetylation of Cys-GlcN-Ins to complete 
the biosynthesis of mycothiol (MSH).
67
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Scheme 1-5 Mycothiol Biosynthetic Pathway.
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MSH plays a significant role in detoxification of thiol-reactive substances including 
formaldehyde, various electrophiles and antibiotics.  Mycothiol S-conjugates derived 
from electrophiles and antibiotics are cleaved by a fifth enzyme known as mycothiol 
S-conjugate amidase (Mca) to release GlcN-Ins which is used to resynthesise MSH 
and also a mercapturic acid which is excreted from the cell (Scheme 1-6).
68
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Scheme 1-6 The role of Mca in mycothiol dependent detoxification.
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Independent studies have demonstrated that chemically or genetically altered strains 
that are deficient in MSH production become hypersensitive to the most currently 
used antitubercular antibiotics and that MSH is indeed essential for viability of M. 
tuberculosis.
64,67,70,71,72
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Collectively, the above observations as well as the absence of mycothiol from 
mammalian cells suggests that molecules that can interfere with MSH associated 
enzymes may have therapeutic potential.
73
  In one study it was observed that 
mycobacterial knockouts lacking mshB activity were more susceptible to reactive 
oxygen species and suggested that compounds directed to inhibit mshB might be able 
to inhibit MSH production.
74
   
 
The total synthesis of mycothiol has been reported (Scheme 1-7).
75
  The approach 
taken for the synthesis of the GlcN-Ins component of MSH entailed the coupling of 
the 1-OH of D-2,3,4,5,6-penta-O-acetyl-myo-inositol (a Scheme 1-7) with O-(3,4,6-
tri-O-acetyl)-2-azido-2-deoxy-α,β-D-glucopyranosyl trichloroacetimidate (b Scheme 
1-7).  Synthesis of a (Scheme 1-7) was pursued from D/L-myo-inositol via literature 
procedures with minor modifications.
76,77,78
  Details of the full synthesis are available 
in the literature.
75
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Scheme 1-7 Synthesis of Mycothiol.
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1.3.2 Crystal Structure of Msh B 
This research project is in collaboration with Dr. Andrew McCarthy, European 
Molecular Biology Laboratory, Grenoble, France.  The 3-D structure and a proposed 
mechanism of action of one of the enzymes of MSH biosynthesis, namely mshB, have 
recently been deduced by McCarthy and co-workers (Figure 1-16).
63
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Figure 1-16 Structure of mshB, a modelled N-acetylglucosamine in the active site is shown in 
sticks, adjacent to the metal-binding site (sphere).
63
 
 
 
When the structure was solved it was considered that compounds which could 
selectively bind to this enzyme, thus interrupting the production of MSH could leave 
M. tuberculosis vulnerable to reactive oxygen species, drugs and other stress factors.  
McCarthy et al. determined the three-dimensional structure of mshB to be a Zn-
dependent deacetylase.  The structure revealed an α/β fold in which helices pack 
against a seven-stranded mostly β-sheet.  Large loops emanating from the C-termini 
of the β-strands enclose a deep cavity which is the location of the putative active site.  
At the bottom of the cavity is a metal-binding site associated with the sequence motif 
AHPDDE that is invariant in all homologues.  An adventitiously bound β-
octylglucoside (BOG) molecule used in crystallisation enabled them to model the 
binding of the true substrate and propose a metal dependent mechanistic model for 
deacetylation.  Sequence comparisons indicate that mshB is representative of a wider 
family of enzymes that act on substituted N-acetylglucosamine residues, including a 
deacetylase involved in the biosynthesis of glycosylphosphalatidylinositol (GPI) 
anchors in eukaryotes.
63
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1.3.3 MshB Proposed Active Site 
The deacetylase mshB was the first enzyme from the mycothiol biosynthesis pathway 
to be characterised.
63
  After crystallisation there were two forms of mshB, one with 
the octyl group of the BOG molecule directed into the hydrophobic region and 
another with the octyl group directed away from the active site into the hydrophilic 
region.  The discovery of BOG molecules bound at equivalent sites on both of the 
mshB molecules in the crystal asymmetric unit clearly identifies this as the probable 
active site, given that the natural substrate is also a modified glucose moiety.
63
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Figure 1-17 BOG molecule-binding mode in mshB.
63
 
 42 
Whilst the active-site BOG molecules are in approximately the same locations in the 
two mshB molecules, they are in different orientations.  The BOG molecule in 
diagram a (Figure 1-17) is oriented with its octyl tail projecting out of the active-site 
pocket in the vicinity of Met98, Glu213 and Asn261, which are contributed by three 
loops that form the active site entrance.  The octyl tail in diagram b (Figure 1-17) 
however, is directed inwards filling a hydrophobic cavity.   
 
Both BOG orientations were tested as a basis for modelling the natural substrate 
GlcNAc-Ins into the active site.  Also included in the model was a metal ion bound to 
His13 N
δ1
, Asp16 O
δ1
 and His147 N
є2
 (Figure 1-18). 
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Figure 1-18 Proposed substrate-binding mode of GlcNAc-Ins in mshB based on molecular 
modelling of BOG molecule. 
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It was immediately apparent that the conformation in diagram b (Figure 1-18) would 
require major reorientation for binding of GluNAc-Ins since the N-acetyl moiety 
partly overlaps the metal site and the inositol ring would project inwards into a 
hydrophobic region.  In contrast, the conformation found in diagram a (Figure 1-18) 
provided an excellent model.
63
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Figure 1-19 Proposed mechanism for deacetylation of GlcNAc-Ins catalysed by mshB.
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As in zinc proteases, for example carboxypeptidase,
40
 the metal-binding site in mshB 
provides only three protein ligands (two His and one carboxylate), leaving vacant 
coordination sites for water and substrate.  In the proposed mechanism (Figure 1-19), 
the carbonyl oxygen atom of the N-acetyl amide bond can bind directly to the metal 
ion.  This is expected to polarise the C=O group as in metalloproteases, leaving a 
partial positive charge on the carbon atom ready for nucleophilic attack by a water 
molecule.  The side-chain carboxylate group of Asp15 is ideally placed to serve as a 
catalytic base that enhances the nucleophilicity of the water molecule.  The tetrahedral 
intermediate that is created by nucleophilic attack of water can in turn be stabilised by 
occupying an additional metal coordination site as in zinc proteases.  This catalytic 
mechanism suggested for mshB is similar in its general features to the mechanism of 
 45 
carboxypeptidase and to the proposed mechanisms of other metal-dependant 
deacetylases.
 40,63
   
 
1.3.3.1 Association of MshB and Mca 
In order to define the protective role of mycothiol for M. tuberculosis, Buchmeier et 
al. constructed a M. tuberculosis mutant in Rv1170, the gene that encodes for the 
major GlcNAc-Ins deacetylase activity (mshB) in the MSH biosynthetic pathway of 
M. tuberculosis.  During exponential growth, the Rv1170 mutant bacteria produced 
approximately 20% of the wild-type levels of MSH.
74
   
 
In the mutant there was a 50-fold increase in GlcNAc-Ins, the immediate precursor 
molecule for the mshB reaction.  Accumulation of GlcNAc-Ins indicated a blockage 
in MSH biosynthesis at the deacetylase (mshB) step.  Levels of MSH and precursor 
compounds were restored to wild-type levels when the mutant was complemented 
with a wild-type copy of the Rv1170 gene.  These results established that the Rv1170 
gene is indeed responsible for the major mshB activity in M. tuberculosis.  However, 
the presence of measurable levels of MSH in the Rv1170 mutant indicated that M. 
tuberculosis produces an additional enzyme with GlcNAc-Ins deacetylase activity that 
can partially substitute for Rv1170 during the synthesis of MSH. 
 
The likely candidate for this second deacetylase activity was proposed to be Rv1082.  
This gene encodes for mycothiol S-conjugate amidase (Mca), which is normally 
responsible for cleaving S-conjugates of mycothiol to regenerate GlcN-Ins and a 
mercapturic acid AcCySR.
79
  Rv1082 has homology throughout its sequence to 
Rv1170 and is 36% identical to the Rv1170 protein.
80
  The minor deacetylase activity 
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of MCA would not be important for most mycobacteria except during times of high 
GlcNAc-Ins concentrations and long generation times, the conditions found in the 
mshB knockout.
74
   
 
In a study by Steffek et al., Mca of M. tuberculosis was cloned and expressed in E. 
coli as a native protein and purified to homogeneity by.
81
  They evaluated the 
GlcNAc-Ins deacetylase activity of Mca and although the activity was small it was 
significant in that it was of a magnitude sufficient to account for the production of 
MSH observed in a M. tuberculosis mutant deficient in the normal deacetylase mshB 
as shown by Buchmeier et al.
74 
 
 
More recently mshB from M. tuberculosis was cloned, expressed, purified and its 
properties characterised by Newton et al.  The substrate specificity of mshB was 
compared to that of M. tuberculosis Mca.  These studies showed that mshB shares 
many properties with its homolog Mca.
82
 
 
Results clearly indicated that the divalent metal ion was essential for the activity of 
mshB.  Analogous results were found with the homologous Mca.
81
  The GlcNAc-Ins 
deacetylase activity of both enzymes was compared and results clearly indicated that 
mshB provided the major deacetylase activity with values 4700-fold greater than those 
of Mca.  Also as expected, the major amidase activity was attributed to Mca, showing 
activity 170-fold greater that mshB.
82
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Due to this additional deacetylase activity compounds which inhibit both mshB and 
Mca would be required to inhibit production of MSH at the deacetylase stage of the 
biosynthesis. 
 
1.3.3.2 Inhibitors of MshB 
Several novel and known natural and synthetic compounds that inhibit Mca with sub 
to low micromolar IC50
 
values have been identified.
 69,83,84
  Metaferia et al. 
demonstrated that a series of
 
 bromotyrosine-derived molecules, exemplified by 
natural products a-c (Figure 1-20) are competitive inhibitors of Mca.
85
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Figure 1-20 Natural product competitive inhibitors of Mca.
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They proposed that a small molecule incorporating features of the natural substrates, 
namely the pseudo disaccharide of MSH, together with those of the competitive 
natural product inhibitors may be able to inhibit not only Mca but also the 
homologous biosynthetic enzyme mshB.
73
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They constructed a small library of compounds built upon a GlcN or a thioglycoside 
scaffold and these were tested for their ability to inhibit both Mca and mshB (a-k, 
Figure 1-21).  Of the compounds tested, sulfamides b and d, homophenylalanine 
trifluoroacetate e, homoserine analogue g and heterocycles h, i, j and k were the 
strongest inhibitors of mshB.  For Mca, a similar pattern emerged where sulfamides a-
d, trifluoroacetate e and its N-Boc analogue f and the same set of heterocycles (h, i, j, 
k) stood out as the best inhibitors, while analogue g was only weakly inhibitory. 
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Figure 1-21 Selection of compounds tested for inhibitory effects against Mca and mshB.
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Although inhibitory concentrations for these compounds remained in the low 
micromolar range (data not shown), the approach was successful in that it allowed the 
construction of the first reported inhibitors of a MSH biosynthetic enzyme, namely 
mshB and these findings could provide the basis for further development of more 
potent inhibitors.
73
 
 
1.4 FATTY ACID DERIVATIVES AS ANTIMICROBIALS 
1.4.1 Food Preservation and Safety 
Food Safety is the assurance that food will not cause harm to the consumer when it is 
prepared and/or eaten according to its intended use.  Foodborne diseases present a 
serious challenge to public health.
86
   
 
Virtually all food products deteriorate at some rate.  The rate of deterioration is 
dependent on the food type, composition, formulation, packaging and storage regime.  
Preservation failure leads to deterioration, the consequences of which can vary 
greatly.  Some minor effects include loss of colour, flavour or texture change within a 
food.  At the other extreme, the most severe forms of deterioration are those 
associated with the presence or multiplication of micro-organisms which can lead to 
the transmission of life-threatening diseases, caused by the most hazardous of the food 
poisoning microorganisms.
 87
 
 
In the production of food it is crucial that proper measures are taken to ensure the 
protection and stability of the product during its shelf-life.
88
  Food additives that 
prevent biological deterioration or antimicrobials are required to ensure that the 
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manufactured foods remain safe and unspoiled.  Antimicrobial food additives as 
defined by the FDA, are additives used to control microorganisms such as bacteria, 
viruses, fungi, protozoa in or on food and food contact materials.
89
 
 
1.4.1.1   Chemical Preservatives 
Food antimicrobials are classified as “preservatives”. Chemical preservatives are 
defined by the FDA as “any chemical that, when added to food tends to prevent or 
retard deterioration thereof, but does not include common salts, sugars, vinegars, 
spices or oils extracted from spices, substances added to food by direct exposure 
thereof to wood smoke or chemicals applied for their insecticidal or herbicidal 
properties.”. 90 
 
1.4.1.2   Natural Antimicrobials 
Alternative food-preservation and processing technologies are being developed to a 
large extent in reaction to consumers’ requirements for foods that are nutritionally 
healthier, more convenient in use (e.g. easier to store and prepare), fresher (e.g. chill-
stored), more natural and therefore less heavily processed (e.g. mildly heated, non-
thermal processes; high-pressure processing, UV processing, pulsed electric field 
treatment, etc), less heavily preserved (e.g. less acid, salt) and less reliant on additive 
preservatives (e.g. sulfite, nitrite, benzoate, sorbate) than previously.
91
  To meet 
consumer demands, food manufacturers are searching for new as well as natural 
alternatives that can assure the safety of their products in the retail chain.
92
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1.4.2 Food and Health Care Industry Concerns 
The greatest threat to the use of antibiotics is the emergence and spread of resistance 
in pathogenic bacteria that cannot be treated by previously successful regimes.  
Antibiotic-resistant bacteria were first identified in the 1940s, but while new 
antibiotics were being discovered at a steady rate, the consequences of this 
phenomenon were slow to be appreciated.
93
  The emergence of antibiotic resistance is 
primarily due to excessive and often unnecessary use of antibiotics in humans and 
animals.
93
 
 
Increasing numbers of hospital-acquired infections have generated much attention 
over the last decade.  Hospitals and particularly intensive care units are an important 
breeding ground for the development and spread of antibiotic resistant bacteria.  This 
is the consequence of exposing to heavy antibiotic use, a high density patient 
population in frequent contact with healthcare staff and the attendant risk of cross 
infection.  Approximately 5-10 % of patients admitted to hospital will develop an 
infection directly related to their hospitalisation.  These infections contribute to over 
90,000 deaths per year in the United States.
94
   
 
During food production and manufacturing, a range of antimicrobials (antibiotics, 
antifungals, sanitizers and food preservatives) are applied to improve efficiency, 
increase safety and to improve quality of the product.  The variety of antimicrobial 
uses at each stage of the food system may create selective pressure that promotes 
antimicrobial resistance.
95
  Strains of foodborne bacterial pathogens that are resistant 
to a variety of antibiotics have become a major health issue.
96
  Some of the antibiotics 
and fungicides used in agriculture have identical chemical counterparts in human 
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medicine, for example the majority of antibiotics used in food animals belong to 
classes of antibiotics that are also used to treat human illness.
95
 
 
Intense animal production in the agricultural industry involves administering livestock 
animals with large quantities of antibiotics to promote growth and prevent infection.  
This practice promotes the selection of antibiotic resistance in bacterial populations.  
The resistant bacteria from agricultural environments may be transmitted to humans, 
causing disease that cannot be treated by conventional antibiotics.
97
  Major scientific 
and medical organizations have concluded that agricultural uses of antibiotics pose a 
threat to public health.
98
 
 
Among the candidate replacements for antibiotics are fatty acids and their 
derivatives.
99
  Some of the microorganisms of public health significance include 
Staphylococcus aureus and Escherichia coli. 
 
1.4.2.1   Staphylococcus aureus 
Staphylococcus aureus is a Gram-positive bacteria.  Infections caused by S. aureus 
include skin infections, pneumonia, food poisoning, toxic shock syndrome and blood 
poisoning.  S. aureus is one of the major infectious disease-causing pathogens in 
humans.
100
   
 
Staphylococcal food poisoning is caused by staphylococcal enterotoxins produced 
during massive growth of S. aureus in food.
101
  Food products that are associated with 
S. aureus include meat and meat products, poultry and egg products and dairy 
products amongst others.  Most food intoxications caused by S. aureus are the result 
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of poor hygiene practices.  In 2000, a total of 14,555 people were reported ill after 
drinking milk in Japan.  Laboratory analysis showed that S. aureus enterotoxins were 
present in a number of packages of milk that had been linked to a dairy company.  
Investigations revealed poor hygiene standards within the company.  It was 
subsequently confirmed that S. aureus strains isolated from pipes containing loose 
connections that had not been included in the automatic cleaning and disinfection 
system, produced the same enterotoxins that were present in the milk.
102
 
 
Most nosocomial and community-acquired infections are caused by S. aureus.
103
  
Indeed, it is one of the most feared pathogens because of their ability to cause 
overwhelming sepsis and death.
104
  Methicillin-resistant S. aureus (MRSA) infection 
first emerged in early 1961 and has become increasingly prevalent, with serious 
infections becoming more widespread during the past 20-25 years.
105
   
 
Vancomycin (Figure 1-22) and other glycopeptide antibiotics are the current mainstay 
of therapy for infections caused by MRSA.  However, the high prevalence of MRSA 
has led to increased use of vancomycin in chronic and seriously ill patients and has 
resulted in the emergence of MRSA with reduced susceptibility to glycopeptides.  
This reduced susceptibility to glycopeptide antibiotics is a serious and ongoing 
concern which extends beyond the hospital setting into the wider community and has 
heightened fears of a pan antibiotic-resistant strain.
106
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Figure 1-22 Structure of Vancomycin.
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1.4.2.2   Escherichia coli 
Escherichia coli is a Gram-negative bacteria that is commonly found in the gut of 
humans and warm-blooded animals.  E. coli is one of the most frequent causes of 
some of the many common bacterial infections, including cholecystitis, bacteremia, 
cholangitis, urinary tract infection (UTI), enteric infections and other clinical 
infections such as neonatal meningitis and pneumonia.
108
   
 
Treatment for clinical cases of E. coli infection has become increasingly complicated 
by the emergence of resistance to most first-line antimicrobial agents, including 
fluoroquinolones.
109
  Fluoroquinolones are a subset of the broad-spectrum antibiotics 
quinlones.  An example of a fluoroquinolones used in treatments against E. coli 
infections is Ciprofloxacin (Figure 1-23). 
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Figure 1-23 Ciprofloxacin. 
 
 
E. coli is by far the most frequent uropathogen accounting for 75-95% of all positive 
cultures in uncomplicated cystitis which affect 40-50% of women in their lifetime.  
Ho et al. showed that resistance rates for several commonly used antibiotics against 
urinary E. coli are now highly prevalent, with resistance to one treatment using co-
trimoxazole reaching 50-60% in Hong Kong.
110
 
 
E. coli can cause severe foodborne disease.  It is transmitted to humans primarily 
through consumption of contaminated foods such as raw or undercooked ground meat 
products and raw milk.
111
   In 2003, two outbreaks of gastrointestinal illness due to E. 
coli O157 occurred in Dublin.  One outbreak was centred around a restaurant 
associated with a hotel.  The outbreak produced five confirmed cases and led to the 
closure of the restaurant upon a review of hygiene measures.  The second outbreak of 
illness occurred at the same time in another hotel, with three confirmed cases of E. 
coli O157.
112
   
 
1.4.3 Fatty Acids 
Fatty acids and their corresponding esters are a natural class of chemicals considered 
to have little or no toxicity and have a long historical record for antimicrobial 
activity.
113
  Despite this, the work carried out with fatty acids was to suffer greatly due 
to the boom in research into antibiotics after the discovery of Penicillin circa 1928.  
 56 
However, interest in this class of natural antimicrobials has re-emerged in recent 
times. 
 
The antimicrobial effects of fatty acids have been well documented.
114,115,116
  The 
antimicrobial action of fatty acids is dependent on their structure and some 
generalisations concerning their effects can be made.  For example long chain fatty 
acids have activity against Gram-positive bacteria, short chain fatty acids are more 
active against Gram-negative bacteria, while the medium chain lauric acid is regarded 
as the most active having reported activity against Gram-positive and Gram-negative 
bacteria.
113
 
 
Lauric acid or dodecanoic acid (C 12) is a medium chain saturated fatty acid (Figure 
1-24).  One of the nutritional and antimicrobial factors in human milk is the presence 
of high levels of lauric acid fats.  Lauric acid has been shown to demonstrate activity 
against a number of bacteria.  For example, lauric acid has been shown to have 
activity against MRSA in combination with gentamicin.
105
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Figure 1-24 Lauric Acid. 
 
 
One study which tested both saturated and unsaturated fatty acids against 
Helicobacter pylori showed that fatty acids with an equivalent carbon number (ECN) 
of 12 were most potent.
117
  The ECN is a property which is often used during 
chromatographic analysis of lipids, similar ECNs imply similar retention times caused 
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by similar molecule size, shape, charge or polarity.  According to Firestone,
118
 ECN is 
defined as: 
 
ECN = CN-2db 
Equation 1-1Equivalent carbon number. 
 
 
ECN is the equivalent carbon number, CN is the number of carbon atoms in the fatty 
acids and db is the number of double bonds.  Therefore the ECNs, for example of 
lauric acid C12:0, myristoleic acid C14:1 and linolenic acid C18:3, are all equal to 
12.
117
 
 
Caprylic acid or octanoic acid (C 8) is a short chain saturated fatty acid (see Figure 
1-25).  Caprylic acid is also found in human milk.  Nair et al. examined the efficacy 
of caprylic acid against a number of pathogens and showed that it exerts antimicrobial 
activity against a wide range of microorganisms including S. aureus, Streptococcus 
agalactiae and Streptococcus dysgalactiae.
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Figure 1-25 Caprylic Acid. 
 
 
1.4.4 Fatty Acid Derivatives 
Esterification of fatty acids with monohydric alcohols such as methanol or ethanol has 
been shown to reduce their antimicrobial activity.  However, in contrast, this was not 
shown to be true when an α-hydroxy fatty acid was esterified and from these initial 
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results it was concluded that some hydrophilic group was necessary for biological 
activity.
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Figure 1-26 α-Hydroxymethyl laurate.120 
 
 
Esterification of fatty acids to polyhydric alcohols such as glycerol was found to 
increase their antimicrobial effectiveness.
120,121
  Monoacylglycerols (MAGs) are 
substances employed in the food and pharmaceutical industries.  Due to their 
amphiphilic nature, they possess emulsifying properties and exhibit inhibitory effects 
against some types of microorganisms.
122
  The most active antimicrobial fatty acid 
derivatives exhibit a balance between hydrophilic and lipophilic groups.
123
 
 
1.4.4.1 Monolaurin 
Monolaurin (trade name Lauricidin
®
), a food grade glycerol monoester of lauric acid 
is a food emulsifier, which in addition to its emulsification properties also possesses 
broad spectrum antimicrobial activity against Gram-positive bacteria, yeasts and 
moulds but generally not against Gram-negative bacteria (Figure 1-27). 
113,124
  
It has been shown that in the presence of lactic acid, monolaurin was able to suppress 
growth of S. aureus on meat products.
122
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Figure 1-27 Monolaurin. 
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The purity of this monoglyceride is very important.  Kabara et al. found that when 
tested against a range of bacteria, the 1,3-dilaurin and trilaurin derivatives were less 
active than the free fatty acid and that only the monoglyceride (1-mono-laurin) proved 
to be more active than the free acid.
120
  Many monoglyceride preparations have a 
number of impurities particularly notable quantities of di and tri esters.  It was found 
that monoglycerides with less than 90% monoester were not effective antimicrobials 
which is why the name Lauricidin
®
 was coined to emphasise its high monoester 
content.
113
 
 
1.4.4.2 Fatty Acid Ether Derivatives 
As mentioned, one of the most active antimicrobial lipids identified to date is 1-
dodecanoyl-glycerol (monolaurin), where the fatty acid dodecanoic acid is esterified 
to glycerol.  However, Ved et al. showed that depending upon incubation conditions, 
the alkylglycerol ether (dodecylglycerol) can be more than 2-fold higher in 
antibacterial activity than monolaurin (Figure 1-28).
 125
 
 
O OH
HO
 
Figure 1-28 Dodecylglycerol. 
 
 
As with monolaurin, there was a marked difference in the activity of dodecylglycerol 
against Gram-positive and Gram-negative bacteria.  The growth of all Gram-positive 
strains tested were inhibited.  However, when Gram-negative bacteria were tested 
there was always some growth, even with greatly increased concentrations of 
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dodecylglycerol and some of the Gram-negative strains were totally unaffected.  
However the data clearly indicated that under the conditions used, dodecylglycerol 
was always more potent than monolaurin (dodecanoylglycerol).  As with previous 
trends, the antibacterial activity of the ethers peaked at a chain length of 12 
carbons.
125
 
 
1.4.5 Carbohydrate Fatty Acid Derivatives 
Carbohydrate fatty acid esters are another class of fatty acid derivatives which have 
broad applications in the food industry.
126,127
  While they are most commonly 
employed as surfactants, their antimicrobial properties have been reported. The use of 
carbohydrate esters is continually increasing as they are completely biodegradable, 
they are not harmful to the environment and they are non-toxic. 
123
  Another attractive 
feature of carbohydrate fatty acid derivatives is the potential to modify their properties 
by controlling the degree of substitution of the carbohydrate, by varying the nature of 
the fatty acid and also the sugar itself. 
 
They are currently being employed in the food, cosmetic and detergent industry.
128
  
Sugar esters are widely used in Japan as antibacterial agents in canned drinks.  The 
most common carbohydrate fatty acid ester utilised to date is sucrose ester, which are 
being produced at about 4000 ton/year.
129
  One study by Kato and Shibasaki showed 
that the sucrose ester of lauric acid was primarily active against Gram-positive 
bacteria and in fact showed that in contrast to data generated for glycerides, the diester 
of sucrose rather than the monoester was more active.  Of the diesters tested, sucrose 
dicaprylate possessed the highest activity.
130
  It has also been shown that diesters of 
sucrose not only have higher antimicrobial activity than their corresponding free fatty 
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acids but also compare favourably in activity with commonly used antimicrobials 
such as parabens, sorbic acid and dehydroacetic acid.
113
  However studies have shown 
that sucrose monoesters are also useful as antimicrobial agents in combination with 
EDTA against the Gram-negative E. coli O157:H7.  Hathcox and Beuchat 
demonstrated that enhanced inhibition of E. coli O157:H7 was achieved by 500 ppm 
sucrose monolaurate combined with 300 ppm EDTA compared to either compound 
used alone.
131
 
 
Other oligosaccharide fatty acid esters have also been synthesised.   Devulapelle et al. 
synthesised pure fatty acid esters of sucrose, maltose and maltriose by an enzyme-
catalysed process and tested these compounds as inhibitors of Streptococcus sobrinus.  
6-O-lauroylsucrose (a Figure 1-29), 6’-O-lauroylmaltose (b Figure 1-29) and 6’’-O-
lauroylmaltriose (c Figure 1-29) at 100 μg/mL showed complete inhibition of S. 
sobrinus in agar plates.  Consequently these sugar esters are potentially of significant 
value in the development of oral-hygiene products.
132
   Although less studied than 
sucrose esters, fatty acid esters of maltose have potential cosmetic and medicinal 
applications as antitumoral agents.
133
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Figure 1-29 6-O-lauroylsucrose (a), 6’-O-lauroylmaltose (b) and 6’’-O-lauroylmaltriose (c).132 
 
 
One study investigating the effect of carbohydrate monoesters reported that among 
those synthesised, galactose laurate, fructose laurate and the reducing 6-O-
lauroylmannose showed the highest inhibitory effect against the growth of 
Streptococcus mutans, while other analogs of hexose laurates showed no activity.
134
  
These findings indicate that the carbohydrate moiety itself markedly affects the 
activity of the fatty acid and therefore further investigation is merited. 
 
Recent work in the area of carbohydrate fatty acid esters has focused on establishing 
an effective regioselective, enzyme catalysed synthesis of sugar derivatives for use as 
surfactants for industrial applications.
135,136
  However relatively few studies have 
examined  role of the carbohydrate in antimicrobial activity.
129,132,137
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1.4.5.1 Enzymatic Synthesis of Carbohydrate Fatty Acid Derivatives 
Ester-cleaving hydrolases from different sources have been successfully used in 
carbohydrate chemistry for regioselective esterification.  Typically lipases are 
employed in esterification, although proteases have also been utilized.
138
  The 
hydrolases used in these processes share in common a similar mechanism which 
involves the formation of an acyl enzyme intermediate.  In general, acylation takes 
place at the less hindered primary hydroxyls.
139
   
 
Lipases are ubiquitous enzymes that catalyse the hydrolysis of fats and oils.  In 
addition to their biological function in bacteria, fungi, plants and higher animals they 
are also used as biocatalysts in numerous industrial processes.  Lipases are the most 
commonly used enzymes in synthetic organic chemistry.
140
 
 
a  RCO2H + R'OH
Lipase
RCO2R' + H2O
b  RCO2R' + R''OH RCO2R'' + R'OH
Lipase
 
Figure 1-30 Reversible lipase-catalysed (a) esterification and (b) transesterification. 
 
 
Lipases and proteases have been isolated from a variety of sources including bacteria, 
yeast and moulds.
135
  Some examples are shown in Table 1-1. 
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Table 1-1 Sources of commercially available lipases/proteases used for esterification/trans-
esterification of sugars. 
 
Sugar or Related 
Compound 
Fatty Acid/Ester Enzyme Enzyme Source 
Glucose Palmitic acid 
 
Lipase P Pseudomonas sp
141
 
Mannose 
 
Divinyl 
decanedioate 
Alkaline protease Bacillus sublilus
142
 
Fructose 
 
Palmitic acid Lipase SP 435 Candida antartica B
136
 
Glycerol Lauric acid 
 
Lipozyme IM Rhizomucor michei
143
 
 
 
 
Enzyme catalysed syntheses are usually specific for the carbohydrate that is being 
esterified and also for the degree of esterification.  For example, Ferrer et al. found 
that lipase from C. antartica B is particularly useful for the preparation of 6,6’-di-
acylsucrose, whereas T. lanuginosus lipase selectively catalyses the synthesis of 6-O-
acylsucrose.
129
 
 
Enzymatic synthesis of sugar fatty acid esters is highly regioselective,
128
 although for 
some carbohydrates two or more minor isomers are sometimes obtained, depending 
on the enzyme used.
134
  This can cause difficulty in specifically and unambiguously 
ascribing antimicrobial activity to a given species, unless purification and 
characterisation is carried out.   
 
For example, as previously mentioned, Watanabe et al. synthesised 23 carbohydrate 
monoesters using lipases and proteases.
134
  These compounds were then assayed for 
their ability to suppress the growth of S. mutans.  Among the carbohydrate esters 
synthesised, fructose laurates showed one of the highest growth-inhibitory effect.  The 
fructose laurate was synthesised by reacting lauric acid with fructose in acetone at 
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60
o
C in a sealed glass tube using immobilised Alcaligenes lipase and was obtained at 
a 51.3% yield.  However, NMR spectra showed that the esters were a mixture of 1-O 
and 6-Oacyl (α and β) esters of fructofuranose (a and b respectively, Figure 1-31) and 
fructopyranose (c Figure 1-31).  This was also reported for the synthesis of 
fructosepalmitate by Candida antartica lipase in 2-methyl-2-butanol by 
Scheckermann et al.
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Figure 1-31 1-O-lauroyl fructofuranose (a), 6-O-lauroyl fructofuranose α/β and 6-O-lauroyl 
fructopyranose (c).
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1.4.6 Antimicrobial Mechanism of Action 
Fatty acids and their esters may have several modes of action that are non-specific. 
Compounds including monolaurin and carbohydrate fatty acid derivatives are thought 
to affect the cell membrane, inhibit respiratory activity and membrane transport.  The 
mode of action and inhibitory effects are reported to be concentration dependent.
113
   
 
Bactericidal concentrations of long chain fatty acids were shown to stimulate oxygen 
uptake of Bacillus megaterium and Micrococcus lysodeikticis at pH 7.4.  Higher 
concentrations of fatty acids produced complete inhibition of oxygen uptake.
145,146
  In 
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contrast, Pseudomonas phaseolicola and E. coli showed a limited response of the 
oxygen uptake mechanism in these bacteria, reflecting the resistance of these bacteria 
to the bactericidal activity of fatty acids.  However, upon partial removal of the cell 
wall these bacteria displayed an increase in sensitivity to inhibition of oxygen uptake.  
This result suggested that cell-wall lipids might be responsible for protecting the 
membrane from the fatty acids.
146
  This finding was also supported by Hamilton on 
the observation that the formation of spheroplasts from Gram-negative bacteria 
rendered them more susceptible to metabolic inhibition by lipid-soluble antibacterial 
agents.
147
 
 
Projan et al. showed that monolaurin at subinhibitory concentrations decreased the 
production of a large number of exoproteins by S. aureus.  They observed that for 
TSST-1 and alpha-hemolysin this decrease was effected at the level of transcription.  
These results implicate signal transduction as the target for exotoxins.  This led them 
to postulate that monolaurin may intercalate into the cytoplasmic membrane and 
subtly modify membrane structure.
148
  They also found that the action of monolaurin 
wass not restricted to S. aureus, it also blocked the induction of vancomycin 
resistance in another pathogen, Enterococcus faecalis.
149
 
 
Tsuchido et al. observed that sucrose esters cause changes in cellular morphology of 
Bacillus subtilis, which induced autolytic processes.
150,151
  It was suggested that sugar 
esters disrupt the cell membrane, thereby altering its permeability and causing leakage 
of cell contents.
132
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2. Design and Synthesis of Potential Msh B Substrate 
Analogs 
 
This chapter presents the design and synthesis of compounds that could mimic 
GluNAc-Ins and selectively bind to mshB. 
 
2.1 DESIGN OF GLCNAC-INS MIMICS 
The initial aim of the project involved the design and synthesis of mycothiol (MSH) 
precursor analogs aimed at mshB.  As discussed in the introduction (Section 1.3.1), 
mshB is a Zn-dependent deacetylase enzyme that catalyses the second step in the 
biosynthesis of mycothiol.  It catalyses the removal of an acetyl group from GlcNAc-
Ins 1, producing GlcN-Ins (Scheme 2-1). 
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Scheme 2-1 Second step in biosynthesis of MSH, catalysed by mshB.
1
 
 
 
The 3-D structure and a proposed mechanism of action of mshB have been deduced 
by McCarthy et al.
2
  A β-octylglucoside (BOG) molecule was used in crystallisation 
and enabled them to model the binding of the true substrate and propose a metal 
dependent mechanistic model for deacetylation. 
 
After crystallisation there were two forms of mshB, one with the octyl group BOG 
molecule directed into the hydrophobic region (diagram a, Figure 1-15) and another 
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with the octyl group directed into the hydrophilic region (diagram b, Figure 1-15).  
Both BOG orientations were used as a basis to represent the natural substrate 
GlcNAc-Ins (1, Figure 2-1) into the active site.  The aim of this project was to design 
and synthesise a compound which could better mimic the natural substrate for mshB 
(GlcNAc-Ins) for crystallisation and mechanistic studies to further improve the 
knowledge of this enzyme. 
 
GlcNAc-Ins is composed of an α-D-glucopyranoside with an amide group at the C-2 
and an inositol group at the anomeric position (Figure 2-1).  The design of the mimic 
compound was based on its structure. 
 
O
OHN
HO
HO
HO
O
HO
HO
HO
OH
OH
1  
Figure 2-1 Natural substrate for mshB, GlcNAc-Ins (1). 
 
 
The mimic compound 2 (Figure 2-2) is also based on an α-D-glucopyranoside scaffold 
with the relevant pharmacophores attached.  It does not contain a scissile amide bond, 
instead there is a methoxy methyl group (MOM) at the C-2 position and 
pentaerythritol replaces the inositol.   
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Figure 2-2 Proposed GlcNAc-Ins mimic compound (2). 
 
 
The MOM group was chosen to replace the amide bond in the mimic compound based 
on work detailed earlier on a novel strategy developed for CPA (Section 1.2.2.2).
3
  
Figure 2-3 depicts a natural substrate of CPA (3)
4
 and a substrate mimic successfully 
used by Min Su Han et al., where an acetal replaces the peptide group (4).
3
  
 
CO2HOO
R
4
R
H
N
CO2
O 3  
Figure 2-3 (3) Typical C-terminal portion of a peptide CPA substrate,
4
 (4) Example of CPA 
substrate mimic.
3
 
 
 
Inositol was not chosen as a component of the mimic compound due to the difficulties 
that would be involved in synthesis.  Lee and Rosazza synthesised D-2,3,4,5,6-penta-
O-acetyl-myo-inositol in a total synthesis of mycothiol (Scheme 1-7).
5
  This synthesis 
is long and cumbersome and in general it has been avoided in the literature during 
synthesis of related compounds, for example Metaferia et al. used a cyclohexyl group 
to replace inositol (Section 1.3.3.2).
6
   There were also problems in the literature with 
the assignment of orientations of the enantiomers of the myo-inositol component of 
GlcNAc-Ins.
7
  Reports on the enantiomers have been in discord.  The correct 
stereochemistry of the components of MSH was reported by Sakuda et al. to be L-
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cysteine, D-glucosamine and 1D-myo-iositol.
8
  However, although subsequent papers 
have maintained the nomenclature for the chirality, many errors in the structures 
drawn for MSH have occurred.
9
   
 
Pentaerythritol was chosen due to its relative ease of synthesis.  It contains four 
equivalent hydroxyl groups and therefore eliminates any requirements for selectivity.  
Also, the only compound available to McCarthy et al. to mimic the binding of the 
natural substrate was the BOG molecule which contains the hydrophobic octyl group 
(Figure 1-14).  A pentaerythritol molecule should better mimic the inositol due to its 
multiple hydroxyl groups.  Figure 2-4 diagram b depicts the mimic compound 2 
which may fit into the hydrophillic region as proposed for the inositol of GlcNAc-Ins 
1 in diagram a.   
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Figure 2-4 (a) Proposed substrate-binding mode of GlcNAc-Ins 2 in mshB based on molecular 
modelling of BOG molecule in Figure 1-17. (b) Possible binding of designed molecule 2. 
 
 
Another advantage of the use of a MOM group at the C-2 position of the mimic 
compound 2 is its potential for inhibition of mshB.  The replacement of the scissile 
amide bond by a non-cleavable isostere may have an inhibitory effect similar to that 
observed with the CPA inhibitors (section 1.2.2.2).  The catalytic mechanism 
proposed for mshB is similar to the mechanism of zinc protease such as 
carboxypeptidase and thermolysin (section 1.2.2.1) and involves deacetylation of the 
C-2 amine.
2
  It is proposed that the mimic compound could undergo a bond formation 
reaction with the carboxylate of the Asp 16 in a similar way to the proposed 
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mechanism for CPA inhibitors discussed in Section 1.2.2.2, resulting in a covalently 
modified enzyme that can no longer perform its function (Scheme 2-2). 
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Scheme 2-2 Possible mechanism for inhibition of mshB by 2. 
 
 
2.2 RETROSYNTHETIC ANALYSIS 
By retrosynthetic analysis it is clear a glycosyl donor and acceptor were required for 
the synthesis of 2. 
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Figure 2-5 Retrosynthetic analysis of 2. 
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The acceptor molecule pentaerythritol 6 was chosen as an alternative to inositol 
(Section 2.1).  The glycoside donor involved creating a good anomeric leaving group 
so that the pentaerythritol molecule could be attached. 
 
2.2.1 Synthesis of Glycosides 
The synthesis of O-glycosides is an important reaction in synthetic organic chemistry.  
The union of a glycosyl donor and an alcohol (glycosyl acceptor) presents major 
challenges.
10
  Though conceptually simple, this operation has presented difficulties 
for chemists for over one hundred years since Köenigs and Knorr published the first 
chemical glycosylation reaction in 1901.
11
 
 
There are many problems inherent in this synthetic transformation.  There are so 
many variables involved that each target compound requires that a particular strategy 
be developed following consideration of the monomers to be bonded and the types of 
inter-unit linkages to be made.
12
  For example, controlling stereoselectivity for 1,2 – 
cis or 1,2 – trans-glycosidic bonds (Figure 2-6). 
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Donor Acceptor 1,2 - cis 1,2 - trans
L = Leaving group
X = OH, NHAc, N3, etc  
Figure 2-6 Possible linkages in the formation of a glycosidic bond.
10
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One of the most useful ways to control the stereochemistry of an anomeric bond is by 
neighbouring group participation of an ester protecting group on the 2 hydroxyl 
(Scheme 2-3).
12
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Scheme 2-3 Neighbouring group participation in glucose. 
 
 
Scheme 2-3 depicts the participation of the carbonyl oxygen of the acetate protecting 
group at the 2 position which stabilises the intermediate glycosyl cation by forming 
the cyclic oxonium ion.  The net result is the nucleophile is forced to attack from the β 
configuration and therefore the newly formed anomeric linkage is trans to the 2-
hydroxyl group.  If a manno starting material is used, which has an axial hydroxyl 
group at the 2 position, the α linkage is specifically formed. 
 
Conversely, donors displaying non-ester groups at C-2 generally favour formation of 
α-anomers due to the anomeric effect.  This is a general phenomenon whereby the 
thermodynamically preferred axial position presides over the less sterically hindered 
equatorial position at the anomeric centre.  When there is an electronegative 
substituent in an axial position at the anomeric centre, a lone pair of electrons on the 
ring oxygen is anti-planar to the C-X bond and can participate in a stabilising two 
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electron interaction (a and b, Scheme 2-4).  This corresponds to an n → σ* interaction 
or partial donation of the oxygen lone pair into the anti-bonding orbital of the C-X 
bond.  The net effect is this electronic delocalisation and therefore it is stabilising.
11
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X = O, Cl, etc  
Scheme 2-4 The anomeric effect. 
 
 
The effect of solvent upon the stereoselectivity of glycosylation reactions is also an 
important factor (Scheme 2-5).  For example even in the presence of a non-
participating group at C-2, the use of acetonitrile as a solvent can allow access to the 
less thermodynamically favoured β-anomer.  This is because acetonitrile is 
nucleophilic itself and can intercept the glycosyl cation initially formed allowing 
access to the α-nitrilium ion intermediate.  The glycosyl acceptor then attacks this ion 
in an SN2 reaction with inversion of configuration.
13
   Ether-type solvents have a 
tendency to shift stereoselectivities towards the formation of cis-glycosides, for 
example diethyl ether and dioxane.  This is rationalised by the preferential formation 
of the β-oxonium ion type intermediate from the oxocarbenium ion.  This 
intermediate then reacts to form the axial glycoside.
14
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Scheme 2-5Effect of solvents on stereoselective outcome of glycosylation reaction.
14
 
 
 
The choice of glycoside donor is in itself crucial for the outcome of the glycoside 
formation or the linking of a sugar unit through nucleophilic displacement of a leaving 
group at the anomeric centre.  Therefore it is of paramount importance that a leaving 
group of one type or another can be introduced at the anomeric centre.  Some 
examples follow. 
 
Thioglycosides are extremely useful as glycosyl donors.  In most of their properties 
these compounds are similar to the O-glycosides, but they show expected differences 
that result from the different properties of sulfur and oxygen.
15
  Thioglycosides are 
stable in aqueous base at normal temperatures but are hydrolysed by aqueous mineral 
acid at a slower rate than the analogous oxygenated glycosides.  They are readily 
prepared from the corresponding anomeric acetates by treatment with a thiol and a 
Lewis acid (Figure 2-7).
11
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Figure 2-7 Thioglycoside formation.
11
 
 
 
 88 
Note the specific formation of β-anomers due to neighbouring group participation 
(Scheme 2-3). 
 
Trichloroacetimidates are a class of glycosyl donors that are accessed directly from 
the hemiacetal by treatment with trichloroacetonitrile and a suitable base.  Depending 
on the type of base used, either α- or β-trichloroacetimidate may be obtained (Figure 
2-8).
11
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Figure 2-8 Trichloroacetimidate formation.
11
 
 
 
Glycosyl trichloroacetimidates undergo nucleophilic displacement reactions with 
predictable stereo-chemical outcome under mild conditions.  Sugar 
trichloroacetimidates with participating groups at C-2 yield 1,2-trans-compounds as 
would be expected.  When non-participating protective groups are selected in 
nonpolar solvents and supported by low temperatures, SN2-type reactions can be quite 
frequently carried out, hence α-trichloroacetimidates yield β-glycosides and β-
trichloroacetimidates yield α-glycosides.12 
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Glycosyl fluorides have been widely used for O-glycosylation reactions.  A notable 
advantage of their use is the high thermal and chemical stability as compared with 
other glycosyl halides, for example glycosyl chlorides, bromides and iodides.
16
  
Glycosyl fluorides are commonly prepared by reaction of a protected sugar with a free 
anomeric hydroxyl group with diethylaminosulfur trifluoride (DAST).
14
  They can 
also be readily synthesised from the corresponding thioglycoside using DAST 
(Scheme 2-6).  Usually α/β-anomeric mixtures of fluorides are obtained, the ratio is 
often solvent dependent.
11
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Scheme 2-6 Glycosyl fluoride formation from thioglycoside.
11
 
 
 
The use of glycals for formation of glycosidic linkages can be valuable as glycals 
minimise protecting group manipulations and may readily be converted into different 
glycosylating agents.  For example epoxidation of these compounds lead to the 
formation of 1,2-anhydrosugars which can subsequently act as glycosyl donors in 
ZnCl2 promoted glycosylations (Scheme 2-7).
14
  One of the advantages of this method 
is that the initial glycoside formed possesses a free hydroxyl group at C-2, available 
for further elaboration. 
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Scheme 2-7 Epoxidation of glycals and subsequent glycosylation.
11
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Glycosyl triflates are important intermediates in modern chemical glycosylation 
methodologies.  In 1998 Crich et al. prepared extremely reactive α-mannosyl triflates 
cleanly and quantitatively at low temperatures from glycosyl sulfoxides or 
thioglycosides
17
 (Scheme 2-8).  Following their recent characterisation using low 
temperature NMR measurements, several methods for glycosylation on the basis of 
pregeneration of glycosyl triflates have been developed.  They are usually generated 
from thioglycosides because of their stability under atmospheric conditions and a 
variety of reaction conditions.
18
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Scheme 2-8 β-mannoside formation from thioglycosides with PhSOTf in CH2Cl2.
17
 
 
 
2.2.2 Regioselective Protection of Carbohydrate Hydroxyl Groups 
Direct one-step protection of a single hydroxyl group of an unprotected saccharide is a 
prominent challenge in carbohydrate chemistry since carbohydrates contain several 
hydroxyl groups of similar reactivity.   
 
Regioselective protection of the primary position is possible since it is in a sterically 
less encumbered environment than the other hydroxyl groups and is therefore more 
nucleophilic.
14
  Standard methods for the selective protection of this position include 
tritylation or silylation with bulky silyl groups.  This is usually followed by protection 
of the remaining secondary hydroxyl groups with an orthogonal protecting group for 
example by acetylation or benzylation.  This is then followed by removal of the 
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primary hydroxyl protecting group allowing selective functionalisation of this 
position.   
 
Another method involves the use of benzyl-type protecting groups at the primary 
hydroxyl.  One of the advantages of using benzyl protecting groups is the mild 
conditions involved in its removal by catalytic hydrogenolysis.  Studies have shown 
that benzyl-type protecting groups, for example a 2-naphthylmethyl group (NAP), 
with different reactivities can be sequentially removed via catalytic hydrogenolysis 
(Scheme 2-9).
19
  The study identified two major factors controlling the removal 
sequence of different benzyl-protecting groups.  These were the electronic properties 
of the aromatic ring and its affinity for the palladium surface.    
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Scheme 2-9 Selective removal of NAP group by catalytic hydrogenolysis in the presence of Bn 
groups (89% yield).
19
 
 
 
The deprotection of the benzyl group was still inhibited after removal of the NAP 
group had completed.  This was subsequently confirmed to be the result of 
competition between the 2-methylnaphthalene by product and the benzyl group for the 
active sites on the palladium. 
 
Unfortunately, since the reactivity difference between the secondary hydroxyl groups 
is not that large, direct one step protection of a single secondary hydroxyl usually 
results in a mixture of differently protected regioisomers.  As a result, given the need 
for separation of these mixtures and subsequent characterisation, this method is rarely 
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used as a protection strategy.
14
  One method used for the regioselective protection of a 
single secondary hydroxyl group in carbohydrates involves the use of stannylating 
agents. 
 
The reaction of hydroxyl groups of saccharides and tin oxide reagents can form 
stannylene ethers and acetals which then enhance the nucleophilicity of the oxygen’s 
in a regioselective way allowing for regioselective acylation or alkylation.  One of the 
most commonly used reagents is dibutyltin oxide (Bu2SnO).
20
 
 
Regioselective benzoylation of carbohydrates using excess Bu2SnO at increased 
reaction temperatures has been performed and shown to yield several benzoate 
derivatives with one or two free hydroxyl groups, for example di- and tri-benzoyl 
derivatives of methyl α-D-glucopyranoside 7a* (Scheme 2-10).21 
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Scheme 2-10 Reagents and Conditions: Bu2SnO, toluene-benzene 1:1, 100
o
C, BzCl (a: 91% yield, 
b: 6% yield).
21
 
 
 
T.l.c. analysis of the reaction using 3 equivalents of BzCl showed that 2,6-di-O-
benzoyl derivative (b, Scheme 2-10) was formed first.  Based on those results, the 
reactivities of the hydroxyl groups in the α-glucoside seemed to be 6-O > 2-O > 3-O > 
4-O.  It is not surprising then to see the protection of the primary hydroxyl groups 
                                                 
*
 Numbering system 7a used here as this was used for publication of antimicrobial compounds 
discussed in Chapter 3. 
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prior to regioselective selection of the 2-OH or 3-OH in some instances in the 
literature (Scheme 2-11). 
 
OO
HO
HO OR
OPh
OO
HO
BzO OR
OPh
Benzene, reflux
Bu2SnO, BzCl
OO
HO
OH
OR
OPh
DMF, 100oC
OO
BnO
OH
OR
OPh
OO
HO
HO
SEt
OPh
OO
BnO
HO
SEt
OPh
CsF, DMF
100oC
Bu2SnO, BnBr
Bu2SnO, BnBr
(85%)
(65%)  
Scheme 2-11 Examples of tin-mediated regioselective benzylation of 4,6-O-benzylidene protected 
sugar derivatives.
14,22
 
 
 
However regioselective protection of one hydroxyl group of free sugars has been 
observed, for example Scheme 2-12 depicts the regioselective protection of methyl α-
D-galactopyranoside 7d
†
 at the 3-OH. 
 
O
HO
HO
HO OMe
OH
O
HO
BnO
HO OMe
OH
BnBr
Dioxane, 100oC
7d a
(71%)
 
Scheme 2-12 Example of regioselective protection of single hydroxyl group in unprotected methyl 
α-D-galactopyranoside.14 
 
 
 
                                                 
†
 Numbering system 7d used here as this was used for publication of antimicrobial compounds 
discussed in Chapter 3. 
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A PhD project recently completed in the School of Food Science and Environmental 
Health involved use of a tin-mediated regioselective method for functionalisation of 
the 2-OH of α glucopyranosides.  This work involved the use of dibutyltin 
dimethoxide.  Solvent and temperature conditions were optimised for both yield and 
selectivity of the 2-OH.
23
 
 
OHO
HO
HO
HO
OHO
HO
RCOO
HO
OMe OMe
Bu2Sn(OMe)2
RCOCl
R = C11H23
7a 8
 
Figure 2-9 Regioselective tin-mediated synthesis.
23
 
 
 
2.3 SYNTHESIS 
A description of compounds synthesised in an attempt to design a synthesis for 
compound 2 will be given in this section.  A glycosyl donor and acceptor were 
designed by retrosynthetic analysis (Section 2.2).  This involved creating a donor with 
a suitable leaving group for a glycosylation reaction and also the regioselective 
attachment of a MOM group at the 2-OH position.  Initially attempts were made at a 
thioglycoside donor for linkage with the pentaerythritol 6.  Following this, attempts 
were made for the regioselective protection of the 2-OH using a MOM group.  This 
was performed using a model compound, methyl α-D-glucopyranoside 7a for 
compound 5 for investigative synthesis. 
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2.3.1 Synthesis of Glycoside Donor 
A glycosyl donor with a suitable anomeric leaving group was needed.  The first 
attempted synthesis was for the preparation of a thioglycoside donor and is outlined 
below (Scheme 2-13).
24
 
 
OHO
HO
HO
HO
OH
OAcO
AcO
AcO
AcO
OAc
OAcO
AcO
AcO
AcO
OHO
HO
HO
HO
OBnO
BnO
BnO
BnO
(i) (ii)
(iii)
(iv)
9 10 11
1213
STol
STolSTol
 
Scheme 2-13 Reagents and Conditions: (i) Ac2O, Py, rt. (41% yield) (ii) p-Thiocresol, CH2Cl2, 0
o
C, 
BF3·Et2O. (15% yield) (iii) Na, MeOH, rt. (iv) DMF anhydr., BnBr, 0
o
C, NaH, rt. (53% yield over 
2 steps)
24
 
 
 
The acetylated derivative 10 of D-glucose 9 was obtained from the reaction of 9 in the 
presence of a 1:1 solution of acetic anhydride and pyridine yielding a  3.5:1 ratio of  
α:β anomers (41% yield).  This ratio was calculated from the 1H NMR spectrum using 
the integration of the anomeric H signals for the α and β isomers.  The H-1α peak was 
observed at 6.33 ppm with a coupling constant of 3.5 Hz and the H-1β peak was 
observed at 5.72 ppm with a coupling constant of 8.5 Hz.  The introduction of a thiol 
leaving group provided 11.  This was achieved by activation with the Lewis acid 
boron trifluoride etherate and displacement with the thiol p-thiocresol, however this 
reaction did not go to completion giving a 15% yield.  Only the β anomer was formed, 
as expected, due to neighbouring group participation of the C-2 acetate.  This was 
confirmed by the 
1
H NMR spectrum.  The coupling constant of the anomeric proton 
was 10.0 Hz indicating an axial-axial coupling.  Signals in the aromatic region were 
 96 
integrating for 4 protons which was in accordance with the presence of only one p-
tolyl group.  Only four singlets were present between 2.00 and 2.10 ppm indicating 
the presence of four acetate groups and another singlet was observed at 2.35 ppm 
signifying the PhCH3.   Additional problems were encountered with purification as the 
starting material 10 and product 11 had very similar mobility by t.l.c. and separation 
was very difficult.  Nevertheless, the deacetylation of pure compound 11 was carried 
out using sodium and methanol to yield 12.  Finally benzylation of crude tetrol 9 gave 
the fully protected thioglycoside 13 (53% yield over 2 steps).   
 
As a result of the poor yield in step (ii) (Scheme 2-13) the synthesis of an alternative 
thioglycoside using cyclohexanethiol was attempted to drive the reaction to 
completion using cyclohexanethiol (Scheme 2-14). 
 
O
AcO
AcO
AcO
AcO OAc
O
AcO
AcO
AcO
AcO
(i)
10 14
SCyc
 
Scheme 2-14 Reagents and Conditions: (i) cyclohexanethiol, CH2Cl2 anhydr., 0
o
C, BF3·Et2O.
24
 
 
 
However the reaction did not go to completion either, as revealed by t.l.c. and 
appeared to give a poorer yield than the previous reaction and was deemed unworthy 
of further pursuit.   
 
Nevertheless using the small amount of glycoside donor available, a glycosylation 
reaction of 13 with pentaerythritol 6 was attempted (Scheme 2-15).  However this 
reaction was unsuccessful and no product was seen by t.l.c.  The insufficient amount 
of material available prohibited further investigation of this reaction. 
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15
O
OH OH
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Scheme 2-15 Reagents and Conditions: (i) Pentaerythritol, 4 Å mol. Sieve, CH2Cl2, NIS, TMSOTf. 
 
 
2.3.2 Regioselective Derivatisation at 2-OH using Model Compound Methyl α-
D-glucopyranoside 
 
It was decided that a model compound for 5 should be explored to ensure it would be 
possible to selectively derivatise an α-glycoside at the 2-OH before further effort was 
made on the synthesis of the glycosyl donor.  Methyl α-D-glucopyranoside 7a was 
used for this purpose (Figure 2-10). 
 
7a
O
HO
HO
HO
HO O
OHHO
OH
5
O
HO
HO
HO
HO OMe
 
Figure 2-10 (5) α-Glycoside (7a) Methyl α-D-glucopyranoside. 
 
 
From this compound, different syntheses were attempted in an effort to attach the 
MOM group at the 2 hydroxyl group.  Several attempts were made. 
 
2.3.2.1 Attempted Regioselective Derivatisation of Model Glycoside Methyl α-D-
glucopyranoside 
 
Initially it was decided that based on previous work in the school (Section 2.2.2) an 
attempt would be made at tin mediated regioselective derivatisation of the α-glycoside 
7a (Scheme 2-16).
23
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HO
HO
HO OMe
O
HO
HO
HO
O OMe
(i)
O
7a 16
OHO
HO
O OMe
O
OO
17
(i)
 
Scheme 2-16 Reagents and Conditions: (i) Bu2Sn(MeO)2, dioxane, reflux, then BrCH2OCH3. (94% 
yield)
23
 
 
 
This reaction was performed using bromomethyl methylether and dibutyltin 
dimethoxide in dioxane and gave a disubstituted derivative presumed to be 17 (94% 
yield).  The 
1
H NMR spectrum indicated the presence of two MOM groups from two 
AB doublets at 4.83 and 4.88 ppm arising from OCH2OMe.  Also three methyl signals 
were observed between 3.40 and 3.45 ppm.  Although the exact position of the MOM 
groups could not be identified, it was suspected these groups had attached at the 6- 
and 2-OH position (17, Scheme 2-16).  Following this it was decided that the number 
of free hydroxyl groups should be reduced before attaching the MOM group.
14  
This 
was achieved by use of 4,6-O-benzylidene protecting group (Scheme 2-17). 
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O
HO
HO
HO
HO OMe
OO
HO
O OMe
O
7a
19
(iii)
OO
O
O OMe
O
O
20
(ii) or
Ph
Ph
(i) OO
HO
HO OMe
18
Ph (ii) or
(iii)
 
Scheme 2-17 Reagents and Conditions: (i) pTSA, PhCH(OMe)2, MeCN anhydr., rt.
25
 (93% yield) 
(ii) dioxane, DMAP, Bu2Sn(OMe)2, BrCH2OCH3, reflux. (85% yield)
23
 (iii) Bu2SnO, PhH, then 
Bu4NI, BrCH2OCH3, reflux.
26
 (65% yield) 
 
 
The benzylidene protected derivative 18 was obtained from the reaction of 7a in the 
presence of p-toluenesulfonic acid and benzaldehyde dimethyl acetal in acetonitrile 
(93% yield).  This was verified by 
1
H NMR.  Signals in the aromatic region were 
integrating for 5 protons, equivalent to 1 benzylidene.  Also only one singlet was 
observed at 5.53 ppm representing CHPh, this was integrating for one proton thereby 
verifying the presence of only 1 benzylidene.  Two broad singlets were also observed 
at 2.47 and 3.00 ppm indicating the presence of 2 free OH groups.  The following tin-
mediated reaction was again performed using bromomethyl methylether and 
dibutyltin dimethoxide in dioxane and gave the disubstituted derivative 20, as shown 
by the NMR spectra which identified two MOM groups present with two AB doublets 
at 4.81 and 4.80 ppm representing the two OCH2O signals and also two singlets at 
3.45 and 3.42 ppm.  The two singlets were integrating for 3 protons each for each 
OCH2OCH3 group (85% yield).   
 
After this a second method for the same reaction was employed using dibutyltin 
oxide.
26
  NMR verified this reaction also gave the disubstituted product (65% yield)  
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observed in the previous reaction and so an attempt was made to achieve selectivity 
using a benzyl protecting group instead of the MOM group since similar reactions had 
been seen in the literature (Scheme 2-18).
14
  
 
OO
HO
BnO OMe
21
PhOO
HO
HO OMe
18
Ph (i) or
(ii)
 
Scheme 2-18 Reagents and Conditions: (i) Bu2SnO, PhH, then Bu4NI, BnBr, reflux. (ii) 
Bu2Sn(OMe)2, PhH, then Bu4NI, BnBr, reflux.
26
 
 
 
Both tin-mediated methods yielded several products observed by t.l.c. presumed to be 
mixtures of regioisomers 21, 22 and 23 (Scheme 2-19). 
 
OO
HO
HO OMe
OO
HO
BnO OMe
(i) OO
BnO
HO OMe
18 21 22
OO
BnO
BnO OMe
+ +
23
(ii)
Ph Ph Ph Ph
 
Scheme 2-19 Reagents and Conditions: (i) Bu2SnO, PhH, then Bu4NI, BnBr, reflux. (ii) 
Bu2Sn(OMe)2, PhH, then Bu4NI, BnBr, reflux. 
 
 
A synthesis replacing the ether group with a benzoyl ester was attempted given the 
previous use of esters for selectively at the 2-OH using a tin-mediated method.
23
  This 
is outlined below (Scheme 2-20). 
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Scheme 2-20 Reagents and Conditions: Dioxane, Bu2Sn(OMe)2, BzCl, rt. (23% yield)
23
 (ii) DMF 
anhdr., BnBr, 0
o
C, then NaH, rt. (79% yield) 
 
 
The regioselective benzoylation of 7a resulted in the formation of 2 products observed 
by t.l.c. presumed to be a mono and disubstituted derivative.  One product appeared to 
be of a greater quantity by t.l.c. and was isolated by chromatography to verify which 
isomer it was.  This was confirmed to be a monoester by mass spectrometry which 
was obtained in a 23% yield (Scheme 2-20).  A conclusive analysis by NMR could 
not be obtained due to the free hydroxyl groups splitting the signals.  As a result, 
coupling constants could not be calculated in an effort to identify the peaks and 
overlapping of the signals meant the COSY was of no further help.  Consequently the 
exact position of the benzoyl group was unknown.  A D2O exchange was performed, 
however this did not further elucidate the position of the benzoyl group. 
 
For NMR simplification and structural clarification it was decided to protect the 
remaining free hydroxyls followed by removal of the benzoyl group before attaching 
the MOM.  The attempted benzylation of the remaining free hydroxyls resulted in the 
removal of the benzoyl group leaving the fully benzylated derivative 26 (79% yield).  
This was confirmed by the NMR spectrum.  Four AB doublets were observed at 4.89, 
4.82, 4.66 and 4.54 ppm indicating the presence of 4 benzyl groups.  Also the H-2 
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signal was not shifted further downfield than the other signal which would have been 
expected due to the presence of an ester group.  Mass spectrometry data also 
established this finding.   
 
Given the production of 2 products observed by t.l.c., problems with verification of 
the position of the ester and the poor yield obtained, benzylidene-protected derivative 
18 was used prior to an attempt to selectively derivatise the 2-OH in an effort to 
reduce the number of free hydroxyl groups (Scheme 2-21).  
 
OO
HO
HO OMe
OO
HO
BzO OMe
(i) (ii) OO
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O OMe
O
OHO
HO
HO
O OMe
O
18 27 30
16
(iii) (iv)
(v) (vi)
Ph Ph Ph
 
Scheme 2-21 Reagents and Conditions: (i) Dioxane, Bu2Sn(OMe)2, BzCl, rt.
23
 (ii) TIPSOTf, 2,6-
lutidine, CH2Cl2. (iii) NaOH, MeOH, rt. (iv) BrCH2OCH3, NaH, THF (v) THF anhydr., 0
o
C, 
TBAF, rt.
27
 (vi) MeOH, TsOH.
25
 
 
 
However, the regioselective benzoylation reaction of 18 gave the disubstituted 
derivative 31 in a 48% yield (Scheme 2-22).  
1
H NMR verified the presence of three 
aromatic groups as the signals in this area were integrating for 15 protons.  In 
addition, the H-2 and H-3 signals had both been shifted downfield by at least 1 ppm as 
would be expected if ester groups were attached to both these positions. 
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Scheme 2-22 Reagents and Conditions: (i) Dioxane, Bu2Sn(OMe)2, BzCl, rt. (48% yield)
23
 
 
 
Following this, the tin mediated method was abandoned as it was considered too 
difficult to obtain single isomers using the α-methyl glucopyranoside 7a. 
 
2.3.3 Glycoside Donor Synthesis from Diacetone-D-Glucose 
Studies using 7a as a model for 5 indicated that it would be difficult to differentiate 
between the 2-OH and 3-OH position after the glycosylation reaction and therefore it 
would be wise to have these two hydroxyl groups differentiated prior to glycosylation.  
It was considered that diacetone-D-glucose, commercially available from Sigma, 
could be used due to its protection of all but the 3-OH.  This free hydroxyl could 
therefore be orthogonally protected before removal of the acetonides thus opening the 
molecule into its pyranose form,
28
  from which it was envisaged that a suitable 
glycosyl donor could be synthesised. 
 
The first three steps of this synthesis were completed on small scale as part of an 
undergraduate research project (Scheme 2-23).
29
  Diacetone-D-glucose 32 was 
benzylated at its free hydroxyl using benzyl bromide in DMF anhydrous at 0
o
C, 
before being opened into its pyranose form by removal of the cyclic acetals by 
Amberlite-IR 120 (H
+
) in water to give 34.  Mass spectrometry verified the presence 
of 34 however other compounds including D-glucose 9 and 3-O-Bn diacetone 
derivative 33 were also present indicating the benzylation of 32 in step (i) and the 
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deprotection of 33 in step (ii) had not completed.  Nonetheless, compound 35 was 
synthesised after acetylation of crude 34 in a 1:1 solution of pyridine and acetic 
anhydride.  At this step mass spectrometry also verified the presence of other 
compounds including pentaacetate 10 (Scheme 2-13).  Co-elution due to similar 
mobility by t.l.c. possibly led to the presence of these compounds after purification by 
chromatography. 
 
O
O
O
O
O
HO
32
(i) O
HO
HO
BnO
HO OH
O
AcO
AcO
BnO
AcO OAc
34
35
O
O
O
O
O
BnO
33
(ii)
(iii)
 
Scheme 2-23 Reagents and Conditions: (i) BnBr, NaH, DMF anhdr. (ii) H2O, IR 120 (H
+
).
28
 (iii) 
Py, Ac2O. 
 
 
Despite the purity issues encountered in the undergraduate project, this method was 
believed to merit further investigation and a scale up of the reactions was performed.  
However upon scale up (10 g of starting material) similar problems occurred.   
 
After several attempts compound 35 could only be obtained in a small percentage 
with the majority of product being an unidentified mixture.  This was possibly due to 
the problems encountered on small scale whereby a number of compounds were 
observed by mass spectrometry after step (ii).  It was also noted that the ratio of alpha 
to beta anomers had also changed on scale up with the small scale reaction yielding a 
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1:5 ratio of α:β anomers of 35 and the large scale yielding a  2.5:1 ratio of  α:β 
anomers of 35.  These ratios were calculated as in Scheme 2-13 from the 
1
H NMR 
spectrum using the integration of the anomeric H signals for the α and β isomers.  The 
1
H NMR spectrum of 35 from the small scale reaction showed H-1α as a doublet at 
6.32 ppm with a coupling constant of 3.5 Hz.  H-1β was also a doublet at 5.65 ppm 
with a coupling constant of 8.0 Hz.  The 
1
H NMR spectrum of 35 from the large scale 
reaction showed H-1α as a doublet at 6.31 ppm with a coupling constant of 3.5 Hz.  
H-1β was also a doublet at 5.65 ppm with a coupling constant of 8.0 Hz.    
 
It was then decided to purify compound 34 prior to acetylation, however this 
compound was only soluble in water and so chromatography was not possible.  Due to 
this, a precipitation was attempted from water and acetone, however only a slight 
cloudiness was observed. 
 
Following this, different methods to cleave the acetonide groups from compound 33 
were attempted (Scheme 2-24).   
 
O
HO
HO
BnO
HO OH
34
O
O
O
O
O
BnO
33
(i)
(ii) (iii)
 
Scheme 2-24 Reagents and Conditions: (i) 1M HCl:THF (1:1) rt.
30
 (ii) MeOH, Cat I2, rt.
30
 (iii) 
60% aq. AcOH rt.
31
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The first method involved using a 1:1 solution of 1M HCl and THF at room 
temperature,
30
 however two products with significantly different t.l.c. mobilities were 
observed and believed to be a mixture of 34 and 36 (Figure 2-11).   
 
The second method attempted used catalytic amounts of iodine in the presence of 
methanol.
30
  Again this method yielded two products as observed by t.l.c. 
 
The third and final method involved stirring the compound in a 60 % aqueous solution 
of acetic acid however two products were still observed.
31
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Figure 2-11 Mixture of products possibly formed after attempted deprotection of acetonides from 
33. 
 
 
Due to the difficulties encountered it was decided that a new approach should be 
adopted, however time constraints of the project at this stage did not allow for further 
investigation in this area.  Nevertheless the following schemes (Section 2.3.4) 
highlight further possible attempts for future endeavours. 
 
2.3.4 Future Work for the Preparation of a Possible Mimic for GlcNAc-Ins 
The following examples outline possible alternative syntheses that could be 
investigated to obtain a mimic compound for GlcNAc-Ins 1. 
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2.3.4.1 Glucosamine  
Glucosamine consists of a glucose molecule functionalised at the 2-OH with an amine 
group.  This compound may be of use as a starting material for the synthesis of a 
glycosyl donor due to the fact that the C-2 is already isolated and it is commercially 
available from Sigma.   
 
It is envisioned that the C-2 amine could be converted to a non-participating group 
prior to an attempted glycoside formation.  For example, the amine could be 
converted to an azide
32
 which has been shown repeatedly in the literature to not 
participate in glycoside formation hence leading to preferential formation of the 
thermodynamically stable α-glycoside (Scheme 2-25).33,34,35,36 
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AcO
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a b
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Donor
(i)
(ii)
 
Scheme 2-25 Reagents and Conditions: (i) imidazole-1-sulfonyl azide hydrochloride, K2CO3, 
CuSO4.5H2O, MeOH, rt. (ii) Ac2O, Py, rt.
32
 
 
 
The past use of thioglycosides where a cyclohexyl group replaces inositol in the 
synthesis of inhibitors for Mca and mshB
37
 may also be functional in the construction 
of a mimic of compound 1.  The cyclohexyl group is hydrophobic and so this may 
bind in the hydrophobic pocket of the enzyme as was the case for the BOG molecule 
(diagram b, Figure 1-17). 
 
Following formation of thioglycoside b using cyclohexyl mercaptan and BF3·Et2O in 
dichloromethane, a MOM group would need to be introduced at the C-2 amine.  Prior 
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to this, removal of the acetate groups followed by replacement with the non-migratory 
benzyl groups to give c (Path A, Scheme 2-26), would be necessary to prevent 
migration of the acetates to the amine after reduction of the azide.  After manipulation 
of the protecting groups reduction of the azide to the amine may be possible in the 
presence of the benzyl groups by hydrogenation using Lindlar catalyst.
38,39
  
Subsequent conversion to the alkoxyamine using MOMCl and NaH in THF, followed 
by global deprotection may yield an appropriate mimic for compound 1 (d, Scheme 
2-26). 
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Scheme 2-26 Reagents and Conditions: (i) cyclohexyl mercaptan, CH2Cl2, 0
o
C, BF3·Et2O. (ii) Na, 
MeOH, rt. (iii) BnBr, NaH, DMF.
30
 (iv) Lindlar catalyst, H2, EtOH.
38,39
 (v) CH3OCH2Cl, NaH, 
THF.
30
 (vi) EtOH, Pd-C, H2.
30
 (vii) Pentaerythritol, 4 Å mol. Sieve, CH2Cl2, NIS, TMSOTf. 
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Alternatively a glycosylation reaction with b and pentaerythritol 6 (Path B, Scheme 
2-26) may give glycoside e.  Subsequent manipulation of protecting groups, reduction 
of the azide to the amine, introduction of the MOM group and global deprotection 
could be carried out following steps (ii) to (vi) (Path A, Scheme 2-26) to yield another 
alternative mimic g for GlcNAc-Ins 1.  
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3. Design and Synthesis of Carbohydrate Fatty Acid 
Derivatives 
 
This project involves the design and synthesis of novel carbohydrate and 
polyhydroxylated non-carbohydrate fatty acid derivatives for evaluation as 
antibacterial agents, with a view to examining the effect of variation of the 
hydrophilic moiety on antimicrobial activity. 
 
3.1 DESIGN OF CARBOHYDRATE FATTY ACID DERIVATIVES 
A PhD project recently completed in the School of Food Science and Environmental 
Health, lead to the development of a synthetic route to monosaccharides, 
functionalised with a range of fatty acids at the 2-OH position.  A series of fatty acid 
esters of methyl α-D-glucopyranoside (a-e and 8, Figure 3-1) and other sugars 
including lactose and α-D-glucuronic acid derivatives, were synthesised using 
dibutyltin dimethoxide as stannylating agent and were screened for antibacterial 
activity against a Gram-positive (S. aureus) and Gram-negative (Salmonella agona) 
bacteria.1   
 
O
HO
HO
HO
RCOO OMe
a; R = C17H35
b; R = C15H31
c; R = C13H27
8; R = C11H23
d; R = C9H19
e; R = C7H15  
Figure 3-1 Methyl α-D-glucopyranoside 7a functionalised at the 2-OH with a range of fatty acid 
esters.
1
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Preliminary results indicated that only the laurate derivative of methyl α-D-
glucopyranoside (8, Figure 3-1) had a significant inhibitory effect on the growth of S. 
aureus, while the other sugars and chain lengths (a-e, Figure 3-1) had little effect on 
the growth.  None of the ester derivatives had a notable effect on the growth of S. 
agona and is in accordance with previous studies.2
,3,4 
 
The aim of this project was to synthesise similar carbohydrate fatty acid derivatives, 
functionalised at the 2-OH via a tin-mediated method.  These compounds could then 
be tested for antimicrobial activity using methods developed and implemented on site 
in the School of Food Science and Environmental Health.  Regioisomers of these 
compounds would also be synthesised via a chemical route focusing on caprylic and 
lauric acids conjugated at the 6-hydroxyl position of various sugars.  These 
compounds could then be tested to compare the activity of the different regioisomers 
and to further investigate whether the antimicrobial activity of fatty acid compounds 
can be enhanced with a carbohydrate delivery system.  In addition, non-carbohydrate 
polyhydroxylated fatty acid derivatives would also be synthesised and analysed for 
antimicrobial activity in an effort to simplify both the structure and synthesis of these 
compounds. 
 
Therefore chemical syntheses were designed to produce a range of fatty acid 
derivatives.  This was to allow investigation of the effects of carbohydrate versus non-
carbohydrate cores, the monosaccharide core itself (and the anomeric configuration 
with respect to glucopyranoside), the length of fatty acid chain, the glycoconjugate 
linkage and the number of fatty acids attached to the hydrophilic core on antimicrobial 
activity. 
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These compounds were tested as inhibitors of both a Gram-positive (S. aureus) and a 
Gram-negative (E. coli) microorganism of concern to the food and healthcare 
industries.  The methodology employed and antimicrobial results from antimicrobial 
activity analyses will be reported and discussed in Chapter 4.   
 
3.1.1 Carbohydrate Fatty Acid Ester Derivatives 
Based on the preliminary results from the previous project in the School, whereby the 
lauroyl ester derivative 8 (Figure 3-1) had significantly greater efficacy against the 
growth of S. aureus than that of any other carbohydrate or fatty acid tested, it was 
decided to investigate whether similar results would be observed using a different 
regioisomer of this same compound, where the fatty acid ester would be attached at a 
different position on the carbohydrate.  The primary hydroxyl was chosen for this 
approach (Figure 3-2).  This position was chosen as it could be isolated chemically via 
a straightforward protection strategy prior to esterification.  Moreover, the 
development of a suitable enzymatic route to the desired fatty acid ester derivative 
may be possible at this position, in the event of active derivatives being identified. 
 
O
O
HO
HO
HO OMe
O
37a  
Figure 3-2 Methyl 6-O-lauroyl-α-D-glucopyranoside (37a). 
 
 
Whilst the antimicrobial activity of carbohydrate fatty acid ester derivatives has been 
well documented, few studies have investigated the potential role of the carbohydrate 
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moiety in antimicrobial activity.5
,6,7  This study aims to further elucidate this role 
through development of synthetic routes allowing the effects of structural differences 
on antimicrobial activity to be investigated.  Therefore variations of compound 37a 
using different sugar cores were synthesised.  In an effort to explore the effect of 
structural differences in the carbohydrate on antimicrobial activity, the β-anomer 7b 
(Figure 3-3) was chosen for esterification.  In compound 7a (Figure 3-3) the anomeric 
methoxy group is axial however in compound 7b this group is equatorial.  The use of 
both these sugars in the formation of fatty acid derivatives would allow for studies 
into the effect of anomeric configuration on the antimicrobial activity of the 
carbohydrate fatty acid derivatives.  
 
O
HO
HO
HO
HO
OMe
7b
O
HO
HO
HO
HO OMe
7a  
Figure 3-3 Methyl α-D-glucopyranoside (7a) and methyl β-D-glucopyranoside (7b). 
 
 
Furthermore, examination of the effects of structural changes in the configuration of 
the hydroxyl groups of the carbohydrate might also assist in further clarification of 
any possible role of the sugar moiety in activity of these derivatives.  Figure 3-4 
illustrates the sugars chosen for this purpose.   
 
O
HO
HO
HO
OH
OMe
7c
O
OH
HO
HO OMe
7d
OH
O
HO
HO
HO
HO OMe
7a  
Figure 3-4 Methyl α-D-glucopyranoside (7a), methyl α-D-mannopyranoside (7c) and methyl α-D-
galactopyranoside (7d). 
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Methyl α-D-mannopyranoside (7c) was chosen as the secondary hydroxyl at the C-2 
position is axial, as is the hydroxyl group at the C-4 position in methyl α-D-
galactopyranoside (7d) compared with the hydroxyl groups of methyl α-D-
glucopyranoside (7a) which are all equatorial.   
 
3.1.2 Carbohydrate Caprylic Ester Derivative 
As discussed in the introduction (Section 1.4.3), chain length has a significant effect 
on the activity of both fatty acids and their derivatives.8  Caprylic acid has been shown 
to exert antimicrobial activity against a wide range of microorganisms including S. 
aureus.9  This study also showed the ability of caprylic acid and monocaprylin, the 
glycerol monoester of caprylic acid to inhibit Gram-negative bacteria E. coli in bovine 
milk. Monocaprylin was the more effective of the two against E. coli.  Kato and 
Shibasaki showed that the sucrose diester of caprylic acid had potent antimicrobial 
activity against certain Gram-positive bacteria and fungi.10  It was of particular interest 
to synthesise a caprylic ester carbohydrate derivative as well as a lauroyl ester 
carbohydrate derivative to allow comparison against both Gram-positive and Gram-
negative bacteria.  Compound 7a was chosen for esterification with caprylic acid to 
give the sugar ester derivative 38a (Figure 3-5) for comparison with the lauroyl 
derivative 37a (Figure 3-5). 
 
O
O
HO
HO
HO OMe
H23C11
O
37a
O
O
HO
HO
HO OMe
H15C7
O
38a  
Figure 3-5 Methyl 6-O-lauroyl-α-D-glucopyranoside (37a) and methyl 6-O-octanoyl-α-D-
glucopyranoside (38a). 
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3.1.3 Carbohydrate Alkyl Ether Derivatives 
In addition to investigating the role of the carbohydrate moiety in antimicrobial 
activity, the glycoconjugate linkage may also play a role.  Ruzin et al. reported a 
monolaurin esterase activity in association with the S. aureus cell membrane and 
cytoplasm.11  However another study that investigated the antimicrobial effect of the 
ether derivative of glycerol dodecylglycerol indicated an increase in activity against 
Gram-positive bacteria compared with the commercially available antimicrobial 
monolaurin under certain conditions.12  Ether bonds tend to have a higher chemical 
and metabolic stability than esters, therefore the development of a synthesis route for 
carbohydrate alkyl ether derivatives (39a and 39b, Figure 3-6) was warranted to allow 
comparison of antimicrobial efficacy with the carbohydrate ester derivatives, for 
example 37a. 
 
O
O
HO
HO
HO
H23C11
39a
O
O
HO
HO
HO
H15C7
39b
OMe
OMe
 
Figure 3-6 Methyl 6-O-dodecanyl-α-D-glucopyranoside (39a) and methyl 6-O-dodecanyl-β-D-
glucopyranoside (39b). 
 
 
3.1.4 Di-lauroyl monosaccharide Derivative 
As previously mentioned in Section 1.4.5, studies have shown that the sucrose ester of 
lauric acid had potent antimicrobial activity against certain Gram-positive bacteria 
and fungi.10  This study also found that in contrast to findings with glycerides the 
diester of sucrose was more active than the monoester.   
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OH  
Figure 3-7 Structure of Sucrose. 
 
 
Sucrose (Figure 3-7) is a disaccharide of glucose and fructose.  It was of interest to 
investigate whether a diester of a monosaccharide might exhibit similar activity 
therefore the di laurate of methyl α-D-glucopyranoside was chosen (40 Figure 3-8).  
The 4- and 6-OH positions were chosen for comparison with the monoesters 
derivatised at the 6-OH and as these positions could be easily selected regioselectively 
using a benzylidene group. 
 
O
O
HO
HO OMe
40
OC11H23
O
C11H23
O
 
Figure 3-8 Methyl 4,6-di-O-lauroyl α-D-glucopyranoside. 
 
 
3.1.5 Non-carbohydrate Polyhydroxylated Ester Derivatives 
To explore whether the structure and therefore the synthesis of these ester derivatives 
could be simplified and still retain their antimicrobial activity, pentaerythritol 6 was 
chosen to synthesise a non-carbohydrate lauroyl derivative (41 Figure 3-9).  
Pentaerythritol was specifically chosen due to its number of hydroxyls.  After 
monoacylation three free hydroxyls would remain and therefore this compound would 
have the same number of free hydroxyl groups as the monoester carbohydrates and 
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would hence be useful for comparative studies.  This compound also gave scope for 
investigation of di, tri and tetra ester derivatives for comparison with the carbohydrate 
derivatives such as 40 (Figure 3-8). 
 
OHO
HO OH
C11H23
O
41  
Figure 3-9 Mono lauroyl pentaerythritol. 
 
 
3.1.6 Strategies for the Regioselective Synthesis of Carbohydrate Fatty Acid 
Derivatives 
 
3.1.6.1 Enzymatic Synthesis of Carbohydrate Fatty Acid Esters 
Whilst enzymatic syntheses of carbohydrate fatty acid esters has been shown to be 
highly regioselective13 there is also evidence for the production of isomers for some 
carbohydrates depending on the enzyme used (Section 1.4.5.1).14  The possibility of 
the presence of isomers makes it difficult to unequivocally attribute antimicrobial 
activity to any given compound without purification.  However isolation of individual 
regioisomers by chromatography may prove difficult.   
 
In addition, the presence of regioisomers may hinder the activity of compounds that 
may otherwise exhibit inhibitory affects as was the case for the presence of isomers in 
monoglycerides discussed in the introduction (Section 1.4.4.1), whereby 
monoglycerides with less than 90% monoester were not effective antimicrobials.8   
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A chemical approach was chosen to ensure pure regio-defined compounds were 
obtained.  Thus compound purity or lack thereof could be explicitly ruled out as an 
influence on any antimicrobial results obtained.  Also a suitable route to ether 
derivatives was necessary and this was not possible via an enzymatic approach. 
 
3.1.6.2 Tin-Mediated Regioselective Synthesis of Carbohydrate Fatty Acid Esters 
In the previous project mentioned above (Section 3.1), compounds were designed and 
synthesised that involved the fatty acid ester being attached at the 2-hydroxyl position 
using a tin-mediated regioselective synthesis (Scheme 3-1).  Solvent and temperature 
conditions were optimised for both yield and selectivity of the 2-OH. 
 
O
HO
HO
HO
O OMe
8
O
HO
HO
HO
HO OMe
7a
Bu2(SnOMe)2
RCOCl
R = C11H23
R
O
 
Scheme 3-1 Regioselective tin-mediated synthesis of methyl α-D-glucopyranoside functionalised at 
the 2-OH.
1
 
 
 
 In the current work, this method was attempted for the synthesis of 2-O-fatty acid 
esters for comparison with 6-O-derivatives against S. aureus and E. coli.  However, a 
new approach was needed as the synthesis could not be repeated on large scale and 
further investigation was not merited based on the difficulties previously encountered 
during the attempted regioselective derivatisation of model compound 7a for 
glycoside 5 (Section 2.3.2.1). 
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3.1.6.3 Protection Strategy for the Regioselective Synthesis of Carbohydrate Fatty 
Acid Derivatives 
 
It was clear that an enzymatic synthesis was not an appropriate approach for the 
compounds that were needed and the level of purity required in this study.  A direct 
esterification of compound 7a with lauroyl chloride was attempted as part of an 
undergraduate research project however this method yielded regioisomers.15  A 
chemical approach via a protection/deprotection strategy would allow for the 
synthesis of compounds functionalised at the primary hydroxyl of the 
monosaccharides chosen, with either an ester or ether group.  These compounds 
would then be purified and characterised to ensure that purity was not a concern 
during antimicrobial evaluation.  Some of the possible approaches to regioselective 
functionalisation of the primary hydroxyl of monosaccharides are discussed chapter 2 
(Section 2.2.2). 
 
3.2 SYNTHESIS 
A description of the synthesis of compounds that were tested for antimicrobial activity 
against S. aureus and E. coli follows.  The synthesis of these compounds was 
performed chemically via protection strategies with subsequent purification and 
characterisation to afford pure regio-defined carbohydrate and non-carbohydrate fatty 
acid derivatives for antimicrobial evaluation. 
 
3.2.1 Synthesis of Monoester Carbohydrate Derivatives 
The first attempt to make a lauroyl derivative was based on tin-mediated 
regioselective synthesis to attach the lauroyl ester at the 2-hydroxyl position 
previously mentioned in section 3.1.6.2. 
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HO
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C11H23
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HO
HO
OMeHO
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i O
O
HO
HO
O OMe
O
C11H23
+
H23C11
O
42  
Scheme 3-2 Reagents and Conditions: (i) Bu2Sn(OMe)2, dioxane, DMAP, Lauroyl chloride, rt. 
 
 
The selectivity of the 2-hydroxyl was attempted using dibutyltin dimethoxide in 
dioxane with lauroyl chloride at room temperature.  Two compounds were obtained, 
one with the fatty acid attached at the 2-OH position only (8 Scheme 3-2) and another 
at both the 2- and 6-OH positions (42 Scheme 3-2).  The 
1
H NMR spectrum of 8 
showed the H-2 peak at 4.71 ppm.  This was similar in the spectrum for compound 42 
where H-2 was at 4.69 ppm.  The difference was noted in the H-6 peak of 42 which 
was shifted downfield by approximately 1 ppm indicating the presence of the ester 
group at this position.  The integration of the aliphatic peaks present in the spectrum 
of 42 also indicated the presence of 2 lauroyl chains. 
 
An alternative method was used for the synthesis of regioisomers of compound 8.  
This alternative synthesis involved the attachment of the fatty acid at the primary 
hydroxyl group at C-6 through a series of protection / deprotection steps. 
 
Initially the synthesis commenced with the protection of the primary hydroxyl using a 
trityl protecting group prepared from 7a (Scheme 3-3) using triphenylmethyl chloride 
in pyridine, as this group was known to show selectivity for primary hydroxyls over 
secondary hydroxyls.16  The secondary hydroxyls required protection with an 
orthogonal protecting group allowing for the selective removal of the trityl group.  
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Benzyl ethers were chosen as they are non-migratory and would therefore not move to 
the 6-OH after deprotection of the trityl group.  Benzyl ethers are also readily 
removed by catalytic hydrogenation after esterification of the primary hydroxyl.  
These mild conditions were ideal since the ester should be stable in this environment.  
Furthermore, purification is not necessary after hydrogenation as filtration of the 
catalyst and evaporation of the solvent and toluene by-product may isolate the 
compound.  Compound 43 was obtained in a 37% yield after purification by 
chromatography.  Proton NMR indicated the presence of the aromatic groups with 
multiple signals between 6.85 and 7.47 ppm.  The integration of the aromatic region 
indicated that 6 aromatic groups were present.  The 
13
C NMR / DEPT verified the 
presence of the CPh3 of the trityl group with a quaternary C at 86.3 ppm. 
 
O
OH
HO
7a
(i) O
OTr
BnO
43
HO
OMe
BnO
BnO OMeHO
(ii)
 
Scheme 3-3 Reagents and Conditions: (i) Py anhydr., TrCl, imidazole, 40
o
C. (ii) DMF anhydr., 
NaH, BnBr, rt. (37% yield over 2 steps).
16
  
 
 
Due to the low yield at this stage it was decided to replace the trityl group with a 
triisopropylsilyl (TIPS) group.  A general synthesis for the production of the mono 
ester sugars is shown in Scheme 3-4 and is based on the following carbohydrate 
starting materials: 7a methyl α-D-glucopyranoside, 7b methyl β-D-glucopyranoside, 
7c methyl α-D-mannopyranoside and 7d methyl α-D-galactopyranoside. 
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BnO
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O
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O
(iii,iv) (v)
O
O
HO
38a
C7H15
O
(v)
O
O
HO
37a-d
OMe
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C11H23
O
OMeBnO
HO OMe
BnO
HO
 
Scheme 3-4 Reagents and Conditions: (i) DMF anhydr., TIPSCl, imidazole, rt.
17
 (ii) DMF anhydr., 
NaH, BnBr, rt.
16
 (iii) THF anhydr., 0
o
C, TBAF, rt.
17
 (iv) Py anhydr., DMAP, Lauroyl Cl, rt.
18
 (v) 
EtOH, Pd-C, H2.
16
 (vi) Py anhydr., DMAP, Octanoyl Cl, rt. 
 
 
This strategy started with the selective protection of the primary hydroxyl of sugars 
7a-d with a TIPS group.  The reagent used was triisopropylsilyl chloride as this 
method should introduce this group to primary hydroxyls selectively over secondary 
hydroxyls.16  The silyl derivatives were then fully protected with benzyl groups and 
purified by chromatography to give 44a-d.  
1
H NMR for each derivative verified the 
presence of 15 protons in the aromatic region.  The TIPS group could be seen as 
multiple signals between 1 and 1.3 ppm for each compound.   
 
The removal of the TIPS group by tetrabutylammonium fluoride in THF allowed for 
the esterification of the free 6-OH position with either lauroyl chloride to yield 45a-d 
or octanoyl chloride to yield 46a.  At this stage a careful purification by 
chromatography was performed so that the material after hydrogenation of the benzyl 
groups would not require further purification by chromatography.  The replacement of 
the TIPS group with a lauroyl group was established by proton NMR as the H-6 
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signals were generally shifted downfield by approximately 0.5 ppm.  This was also 
noted for the caprylic group in compound 46a.  Also the presence of the aliphatic 
chain was identified from several characteristic peaks appearing between 0.88 and 2.5 
ppm.  A difference was observed here in the integration of these peaks for compound 
46a which verified the variation in chain length.  Further confirmation was obtained 
from the IR spectrum which showed peaks for each ester derivative in the region for 
carboxyl groups generally between 1730 and 1740 cm
-1
.   
 
Removal of the benzyl groups form 45a-d and 46a by catalytic hydrogenation led to 
the unprotected carbohydrate esters 37a-d and 38a.  Confirmation of the removal of 
the benzyl groups was obtained from the NMR spectrum as no aromatic signals were 
observed, however the aliphatic signals arising from the fatty acid remained.  Also 
evidence that the ester groups had not been removed was observed in the IR spectrum 
where the peaks had remained in the carboxyl group region.  The percentage yields of 
each of the characterised compounds in Scheme 3-4 are shown in Table 3-1. 
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Table 3-1 Percentage yields of compounds 44a-d, 45a-d, 37a-d, 46a and 38a. 
 
Carbohydrate 
 
 
 
(1) 
2,3,4-tri-
O-Bn-6-
O-TIPS  
 
(2) 
2,3,4-tri-
O-Bn-6-
O-
lauroyl  
(3) 
6-O-
lauroyl  
 
 
(4) 
2,3,4-tri-
O-Bn-6-
O-
octanoyl 
(5) 
6-O-
octanoyl  
 
 
(6) 
O
HO
OH
HO
HO
OMe  
(7a) 
 
44a 
 
85% 
 
45a 
 
72% 
 
 
37a 
 
86% 
 
46a 
 
63% 
 
38a 
 
73% 
 
O
HO
OH
HO
HO
OMe
 
(7b) 
 
44b 
 
80% 
 
45b 
 
70% 
 
37b 
 
75% 
  
 
O
HO
OH
HO
OH
OMe
 
(7c) 
 
44c 
 
51% 
 
45c 
 
64% 
 
37c 
 
75% 
  
 
O
HO
OHHO
HO
OMe  
(7d) 
 
44d 
 
50% 
 
45d 
 
60% 
 
37d 
 
86% 
  
 
 
3.2.2 Synthesis of Ether Carbohydrate Derivatives 
The first attempt at an ether derivative synthesis was carried out following the same 
procedure as for the ester using the TIPS and benzyl protecting groups.  After removal 
of the TIPS the dodecanyl ether was then attached using 1-chlorododecane and NaH 
in DMF to give 48 (35% yield over 2 steps).  The presence of the ether group was 
verified by aliphatic peaks between 0.88 and 1.55 ppm.  Integration of these peaks 
indicated 25 protons.  The benzyl protecting groups were then removed by catalytic 
hydrogenation.  However the dodecanyl ether was also removed during this process 
(Scheme 3-5).      
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BnO
44a
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O
BnO
48
C11H23
O
O
HO
39a
C11H23
(i,ii)
(iii)
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HO
7a
(iii)
BnO
BnO
BnO
BnO
HO
HO
HO
HOOMe OMe OMe
OMe
 
Scheme 3-5 Reagents and Conditions: (i) THF anhydr., 0
o
C, TBAF, rt.
17
 (ii) DMF anhydr., 1-
chlorododecane, 0
o
C, NaH, rt.
 19
 (35% yield over 2 steps) (iii) EtOH, Pd-C, H2.
16
 
 
 
Time constraints did not allow for an attempted optimisation of the hydrogenation 
step of this synthesis for example by utilising different catalysts or varying the H2 
pressure.  Instead a different protecting group was used in place of the benzyl groups 
for the synthesis of the ether derivatives.   
 
The second synthesis also utilised the 6-O-TIPS intermediate however this diverged 
from the ester synthesis with an alternative secondary hydroxyl protecting group, 
namely the paramethoxybenzyl (PMB) group (Scheme 3-6).  PMB groups were 
chosen to replace the benzyls as these were also non-migratory, they could be safely 
attached in the presence of the TIPS and their subsequent removal did not require 
catalytic hydrogenation.16  The sugars were fully protected with PMBs using 
paramethoxy benzyl chloride, NaH and tetrabutylammonium iodide in THF and DMF 
to yield 50a-b after purification by chromatography.  The PMB groups were verified 
to be present by proton NMR showing 12 protons in the aromatic region and also the 
PhOCH3 groups around 3.77 ppm.   
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Removal of the TIPS group gave the free primary hydroxyl.  Following this the lauric 
ether group was attached using 1-chlorododecane and NaH in DMF and purification 
by chromatography gave the fully protected pure ether derivatives 51a-b.  
Confirmation of the ether group attached at C-6 of both sugars was obtained by NMR 
spectra as for compound 48.    
 
Finally oxidative cleavage of the PMB groups with cerric ammonium nitrate gave the 
mono-dodecanyl sugars 39a-b which were purified by chromatography.  Again the 
NMR spectra indicated the complete removal of the PMB groups since no aromatic 
signals were observed. 
 
O
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HO
7a-b
(i,ii)
HO
HO OMe
O
OTIPS
PMBO
50a-b
PMBO
PMBO OMe
O
O
PMBO
51a-b
PMBO
PMBO OMe
C11H23
(iii,iv)
O
O
HO
39a-b
HO
HO OMe
C11H23
(v)
 
Scheme 3-6 Reagents and Conditions: (i) DMF anhydr., TIPSCl, imidazole, rt.
17
 (ii) DMF anhydr., 
THF anhydr., 0
o
C, NaH, PMBCl, TBAI, rt.
20
 (iii) THF anhydr., 0
o
C, TBAF, rt.
17
 (iv) DMF 
anhydr., 1-chlorododecane, 0
o
C, NaH, rt.
19
 (v) MeCN:H2O 3:1, CAN, rt.
21
 
 
 
The percentage yields of each of the compounds synthesised in Scheme 3-6 are shown 
in Table 3-2. 
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Table 3-2 Percentage yields of compounds 50a-b, 51a-b and 39a-b. 
 
Carbohydrate 
 
 
 
(1) 
2,3,4-tri-
O-PMB-
6-O-
TIPS  
(7) 
2,3,4-tri-
O-PMB-6-
O-
dodecanyl 
(8) 
6-O-
dodecanyl  
 
 
(9) 
O
HO
OH
HO
HO
OMe  
(7a) 
 
50a 
 
59% 
 
51a 
 
50% 
 
39a 
 
73% 
 
O
HO
OH
HO
HO
OMe
 
(7b) 
 
50b 
 
61% 
 
51b 
 
85% 
 
39b 
 
76% 
 
 
In an effort to make a more convergent route with common intermediates for ester and 
ether derivatives, an attempt was made to synthesise the ester derivatives via the same 
approach used for the ethers using PMB groups.  7b was used for this synthesis 
(Scheme 3-7). 
 
O
OTIPS
PMBO
50b
O
O
PMBO
52
C11H23
O
O
O
HO
37b
C11H23
O
OMe
OMe
OMe
PMBO
PMBO PMBO
PMBO
HO
HO
(iii)
(i)
(ii)
O
OH
HO
7b
OMeHO
HO
(iii)
 
Scheme 3-7 Reagents and Conditions: (i) THF anhydr., 0
o
C, TBAF, rt.
17
 (ii) Py anhydr., DMAP, 
Lauroyl Cl, rt. (85% yield over 2 steps) (iii) MeCN:H2O 3:1, CAN, rt.
21
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This synthesis commenced in the same way as Scheme 3-6 however after removal of 
the TIPS group the lauroyl ester was attached instead of the ether to give 52.  The 
presence of the ester was verified by IR which showed a peak at 1737 cm
-1
 and 
1
H 
NMR with the aliphatic peaks between 0.88 and 2.32 ppm.  However on removal of 
the PMB groups using cerric ammonium nitrate in acetonitrile and water, the ester 
was also cleaved. 
 
3.2.3 Synthesis of Diester Carbohydrate Derivative 
A new method was needed to selectively derivatise the carbohydrate at 2 positions as 
the TIPS group was only useful for selective protection of primary hydroxyls.  Cyclic 
acetals have been successfully used for this type of protection.  They are favoured for 
their ease of preparation leading to high yields of derivatives, their inertness to a 
variety of reagents and also synthetic ease and high yields for deprotection.22   
 
The method used to synthesise a di lauroyl derivative 40 is shown in Scheme 3-8.  
The 4 and 6-OH positions of methyl α-D-glucopyranoside 7a were protected with a 
benzylidene group using benzaldehyde dimethyl acetal.  This group was chosen as it 
was known to selectively protect the 4- and 6-OH positions.  It was also stable to the 
conditions necessary for a benzylation reaction and the benzyl groups were also stable 
to its removal.16  The remaining free hydroxyls were then converted to benzyl ethers 
to give 23 which was then purified by chromatography (95% yield over 2 steps).  The 
1
H NMR spectrum integrated correctly for aromatic peaks between 7.22 and 7.50 
ppm. The presence of a singlet at 5.54 arising from CHPh was verification of a 
benzylidene group, while two AB doublets between 4.82 and 4.85 ppm arising from 
OCH2Ph verified the presence of 2 benzyl groups.   
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Removal of the benzylidene acetal using catalytic TsOH in MeOH enabled the 
esterification of the 4 and 6-OH to give 53 (38% yield over 2 steps).  This product 
was again very carefully purified by chromatography so that the material after 
hydrogenation of the benzyl groups would not require further purification by 
chromatography.  Proton NMR showed H-4 and H-6 had been shifted downfield by 
approximately 0.5 to 1 ppm.  Aliphatic peaks were observed between 0.88 and 2.36 
ppm and integrated correctly.  IR showed a peak in the carboxyl region at 1743 cm
-1
.   
 
Finally removal of the benzyl groups by catalytic hydrogenation gave the diester 
derivative 40 in a 75% yield.  Evidence for the loss of the benzyl groups was seen in 
the proton NMR where no aromatic signals were observed however the aliphatic 
signals had remained.  IR verified the presence of hydroxyls with a peak at 3456 cm
-1
 
and the esters with a peak at 1737 cm
-1
.  
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53
OC11H23
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O
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Scheme 3-8 Reagents and Conditions: (i) pTSA, PhCH(OMe)2, MeCN anhydr., rt.
20
 (ii) DMF 
anhydr., NaH, BnBr, rt.
16
 (95% yield over 2 steps) (iii) MeOH, TsOH.
20
  (iv) Py anhydr., DMAP, 
Lauroyl Cl, rt. (38% yield over 2 steps) (v) EtOH, Pd-C, H2.
16
 (75% yield) 
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3.2.4 Synthesis of Pentaerythritol Ester Derivatives 
Direct esterification of pentaerythritol 6 was performed using lauroyl chloride and 
DMAP in pyridine at room temperature.  The pentaerythritol and derivatives were 
viewed using a potassium permanganate t.l.c. stain which indicated that 3 products 
had been obtained from the reaction, however a large amount of starting material had 
still unreacted.  In order to push the reaction to completion a total of three equivalents 
of lauroyl chloride were added and the solution was heated to 50
o
C.  After 24 hours 
all starting material had reacted and three products were obtained.  These were 
isolated by chromatography to yield the 3 non-sugar derivatives 41, 54 and 55 shown 
in Scheme 3-9 (14%, 29% and 6% yields respectively). 
 
OHHO
HO OH
6
OHO
HO OH
C11H23
O
OO
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C11H23
O
H23C11
O
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O O
C11H23
O
H23C11
O
C11H23H23C11
O O
(i)
(i)
(i)
41
54
55
 
Scheme 3-9 Reagents and Conditions: (i) Py anhydr., DMAP, Lauroyl Cl, rt. (41: 14% yield, 54: 
29% yield, 55: 6 % yield) 
 
 
Mass spectrometry indicated the presence of one lauroyl group for compound 41.  The 
1
H NMR showed a singlet integrating for two protons at 4.11 ppm arising from the 
CH2OC=OC11H23 indicating there was only 1 lauroyl group attached.  Further 
evidence for this was observed from peaks between 3.61 and 3.80 ppm which were 
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integrating for 9 Hs.  These corresponded to three CH2OH and three hydroxyl protons.  
The aliphatic signals between 0.88 and 2.34 ppm integrated for 23 protons signifying 
1 lauroyl group.  FTIR showed peaks at 3462 and 1737 cm
-1
 representing the OH 
groups and ester group respectively. 
 
For compound 54 mass spectrometry indicated the presence of two lauroyl groups.  
The 
1
H NMR singlet at 4.11 ppm integrated for 4 protons indicating 2 lauroyl groups 
attached.  A singlet at 3.58 ppm integrated for 4 protons arising from each CH2OH.  A 
broad singlet at 3.22 ppm integrated for 2 protons arising from the 2 free hydroxyl 
groups.  Finally the aliphatic signals integrated for 46 protons verifying the presence 
of 2 lauroyl groups.  Again FTIR showed peaks at 3351 and 1739 cm
-1
 signifying the 
OH groups and lauroyl groups respectively. 
 
For compound 55 mass spectrometry verified the presence of 4 lauroyl groups.  The 
1
H NMR singlet at 4.11 ppm integrated for 8 protons signifying 4 lauroyl groups 
attached.  No signals were observed corresponding to any free hydroxyl groups or 
CH2OH groups.  Aliphatic signals integrated for 92 protons indicating the presence of 
4 lauroyl groups.  FTIR showed a peak at 1735 cm
-1
 for the ester groups however no 
peaks were observed in the alcohol region. 
 
3.2.5 Synthesis of Diacetone D-Glucose Fatty Acid Derivatives 
For further comparative study, synthesis of an ether derivative using a reducing sugar 
was attempted whereby there would be a free hydroxyl at the anomeric position 
instead of a methyl group.  This was attempted using diacetone-D-glucose 32 which 
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would also have allowed for the synthesis of derivatives for evaluation in two steps.  
Scheme 3-10 illustrates the attempt made.   
 
An ether was to be attached at the 3-OH of diacetone-D-glucose (32 Scheme 3-10).  
This reaction was successfully performed using 1-chlorododecane in the presence of 
NaH in DMF to give 56 (Scheme 3-10) which was purified by chromatography to 
give an 89% yield.  
1
H NMR verified the presence of the aliphatic groups as before 
and no signal was observed in the OH region of the IR spectrum.   
 
An attempt to deprotect the sugar so it would open into its pyranose form was made.   
This compound would be different from the other ether derivatives since it was a 
reducing sugar and also it would be derivatised at a different position, namely the 
secondary hydroxyl group at C-3.  This rationale was not applied for the production of 
an ester derivative since under the conditions necessary for the removal of the 
acetonide groups the ester would likely be also removed.16 
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Scheme 3-10 (i) DMF anhydr., 1-chlorododecane, 0
o
C, NaH, rt.
19
 (89% yield) . (ii) H2O, IR 120 
(H
+
).
19
 
 
 
Unfortunately the same problems as before in the synthesis of a glycoside donor from 
diacetone-D-glucose in Chapter 2 (Section 2.3.3) were encountered when an attempt 
was made to remove the acetonide groups since t.l.c. indicated the presence of 2 
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products.  Due to the difficulties previously encountered with this reaction and time 
limitations, no further attempts were made to complete this reaction. 
 
Nevertheless since a pure sample of compound 56 had been obtained in high yield and 
with relative ease, it was decided to also make the ester derivative of this protected 
sugar for subsequent antimicrobial analysis.  The ester was attached to the 3-OH of 
diacetone-D-glucose 32 in the same way as with the other sugars using lauroyl 
chloride in the presence of DMAP in pyridine to give 58 (Scheme 3-11).  This was 
purified by chromatography giving a 79% yield. 
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Scheme 3-11 Reagents and Conditions: (i) Py anhydr., DMAP, Lauroyl Cl, rt. (79% yield). 
 
 
Aliphatic signals in the 
1
H NMR again verified the presence of the lauroyl group.  A 
peak observed at 1747 cm
-1
 in IR spectrum also verified the presence of the ester 
group and again as with the ether derivative 56, no peaks were observed in the OH 
region. 
 
3.3 POSSIBLE FUTURE SYNTHESIS OF CARBOHYDRATE FATTY ACID DERIVATIVES 
To further optimise the syntheses with respect to a shorter route, increased yields of 
the fatty acid derivatives, or indeed highlighting other potentially useful compounds, 
the following alternative syntheses could be explored. 
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3.3.1 Alternative Carbohydrates and Fatty Acids for Further Investigation into 
the Antimicrobial Activity of Carbohydrate Fatty Acid Derivatives 
 
The synthesis of carbohydrate fatty acid derivatives utilising alternative sugar groups 
may be of interest.  For example the BOG molecule discussed in the introduction 
(Section 1.3.2) may also be used for the attachment of the ether and ester groups 
(Figure 3-10). 
 
O
O
HO
R = C11H23
R
O
OHO
HO
O
O
HO
R
OHO
HO
a b
 
Figure 3-10 Octyl 6-O-lauroyl-β-D-glucopyranoside (a) and octyl 6-O-dodecanyl-β-D-
glucopyranoside (b). 
 
 
These compounds would also have an alkyl ether chain at the anomeric position as 
well as functionalisation at the primary hydroxyl by either an ester (a Figure 3-10) or 
ether (b Figure 3-10).  Although these compounds would have two alkyl chains, the 
three secondary hydroxyl groups would remain free conceivably maintaining the 
hydrophilic / hydrophobic balance and retaining water solubility which was shown to 
be crucial for antimicrobial evaluation and will be discussed in Chapter 4.  
 
Alternative strategies could involve the attachment of different types of fatty acids.  
For example unsaturated fatty acids.  As discussed in the introduction (Section 1.4.3) 
in a study by Sun et al. saturated and unsaturated fatty acids and monoglycerides were 
tested for antimicrobial activity against the H. pylori.23  Of the unsaturated fatty acids 
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tested, the most potent possessed an equivalent carbon number of 12 discussed in 
section 1.4.3.  These were myristoleic acid (a Figure 3-11) and linolenic acid (b 
Figure 3-10).  The attachment of these unsaturated fatty acids to a carbohydrate 
moiety may also be of considerable interest in investigations into identification of 
active compounds. 
 
O
OH
a
O
OH
b  
Figure 3-11 Myristoleic acid (a) and linolenic acid (b). 
 
 
Other alternative chain lengths of saturated fatty acids might also be of interest.  
Although results from the previous project showed only lauric acid to exhibit 
significant inhibition of S. aureus and the literature generally considers C12 most 
active, fatty acids with carbon chain lengths of 11 or 13 were not tested.  These chain 
lengths may show inhibitory effects as their chain lengths only differ from lauric acid 
by one carbon (Figure 3-12). 
 
O OH O OH
a b  
Figure 3-12 Undecanoic acid (a) and tridecanoic acid (b). 
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3.3.2 Alternative Strategies for the Chemical Synthesis of Carbohydrate Fatty 
Acid Derivatives 
 
One alternative to the current synthesis of the monoester derivatives is the use of a 
benzylidene protected sugar (a, Scheme 3-12).  The advantages of using cyclic acetals 
as protecting groups are discussed in Section 3.2.3.  Reductive cleavage of the 
benzylidene yields a benzyl ether and a free hydroxyl group.  Depending on the 
reagents used, either the 4-OH or the 6-OH is left free.   
 
The use of LiAlH4 and AlCl3 in a mixture of dichloromethane and ether yield the 
2,3,4-O-Bn derivative b (Scheme 3-12).24  The free OH may then be esterified 
followed by hydrogenation of the benzyl groups to yield an ester derivative 
conjugated at the 6-OH.   
 
Another NaCNBH3 and HCl in ether could be used to yield the 2,3,6-O-Bn derivative 
d (Scheme 3-12).24  This intermediate may then be used to attach the ester at a new 
position followed by removal of the benzyl ethers to yield e (Scheme 3-12) which 
would allow for the comparison of two regioisomers. 
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Scheme 3-12 Alternative synthesis of ester derivatives by reductive cleavage of benzylidene.
24,25 
 
 
Also, a similar synthesis could be performed using a 4-methoxybenzylidene protected 
derivative (Scheme 3-13) for 4-O and 6-O ether derivatives.  The 4,6-di-O-protected 
derivative can be synthesised using 4-methoxy benzaldehyde dimethyl acetal, in the 
presence of camphorsulfonic acid. 26  
 
O
HO
HO
O
OPMB
b
O
HO
HO
HO
HO
a
4-MeOC6H4CH(OMe)2
CSA, MeCN
R = Me or Oct
OR OR
 
Scheme 3-13 Formation of 4-Methoxybenzylidene protected derivative.
26
 
 
 
The 4,6-di-O-p-methoxybenzylidene derivative could then be protected with PMB 
groups on the remaining free hydroxyls.  Reductive cleavage of the p-
methoxybenzylidene group may be performed to yield either the 4-O-p-
methoxybenzyl ether or 6-O-p-methoxybenzyl ether, depending on the reagents and 
 141 
solvent used (Scheme 3-14).26  The b and d (Scheme 3-14) regioisomers respectively, 
could then be used to attach the desired ether at the 4- and 6-OH positions 
respectively.   Removal of the PMB groups would give the c and d regioisomers for 
evaluation and comparison. 
 
O
PMBO
PMBO
O
OPMB
O
PMBO
PMBO
PMBO
HO
O
PMBO
PMBO
HO
PMBO
a
b
d
O
HO
HO
HO
R'O
O
HO
HO
R'O
HO
c
e
NaCNBH3
TFA, DMF
3A MS, 0oC
NaCNBH3
TMSCl, MeCN
3A MS, rt
(i)
(ii)
OR
OR OR
OR OR
 
Scheme 3-14 Alternative synthesis of ether derivatives by reductive cleavage of p-
methoxybenzylidene.
26
 
 
 
3.3.3 Enzymatic Synthesis 
Certain enzymes have been shown to exhibit selectivity for the same hydroxyl group 
on several different sugars.  For example the lipase from Thermomyces lanuginosus 
displays a notable selectivity for only one hydroxyl group in the acylation of sucrose, 
maltose, leucrose and maltriose.27 
 
Several commercially available lipases have been used for the regioselective acylation 
of the primary hydroxyl group in reducing monosaccharides in different solvents.  For 
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example porcine pancreatic lipase (PPL) catalysed acylation of sugars with activated 
esters of carboxylic acids in pyridine (Scheme 3-15).28  
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PPL
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O
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HO OH
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ROCO
+ (Cl3)CH2OH
 
Scheme 3-15 PPL-catalysed regioselective esterification of glucose.
28
  
 
 
The non-reducing sugar methyl β-D-glucopyranoside (7b Scheme 3-16) has also been 
successfully esterified with α-hydroxy acid, malic acid (a Scheme 3-16) by an 
enzymatic synthesis utilising alkaline protease from Bacillus subtilis as a catalyst for 
trans-esterification.29  Malic acid has two free carboxylic groups enabling the 
production of isomers (a and b Scheme 3-16). 
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Scheme 3-16 Synthesis of β-methylglucoside malate.29 
 
 
As described in section 3.1.6.1 an enzymatic synthesis was not appropriate for the 
development of several different sugar fatty acid ester derivatives as a single method 
has not been developed for variation in the sugar moiety.   However if a library of 
carbohydrate fatty acid ester derivatives were obtained and analysed for antimicrobial 
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activity, an appropriate enzymatic synthesis may then be utilised upon identification 
of the most active compounds.   
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4. Antimicrobial Activity Evaluation of Fatty Acid Derivatives 
In this chapter, evaluation of the antimicrobial activity of the fatty acid derivatives 
synthesised as described in Chapter 3 are reported and discussed. 
 
4.1 EVALUATION OF ANTIMICROBIAL ACTIVITY 
Minimum inhibitory concentrations (MICs) are defined here as the lowest 
concentration of an antimicrobial that will inhibit the growth of a microorganism after 
overnight incubation.  MICs are used by diagnostic laboratories mainly to confirm 
resistance, but more often as a research tool to determine the in vitro activity of new 
antimicrobials.
1
 
 
The traditional method of determining MIC is the broth dilution technique, where 
serial dilutions of antimicrobials are incorporated into the broth media in either the 
wells of microtiter plates or in cultural tubes.  The micro broth dilution method is an 
adaption of the broth dilution method using small volumes.  It utilises microtiter 
plastic plates containing 96 wells.  The advantage of this system is that it utilises 
small volumes of reagents and allows a large number of bacteria or compounds to be 
screened for resistance or activity relatively quickly.
 2
   
 
4.1.1 Bacteria and Cultural Conditions 
The bacteria used in this study were Staphylococcus aureus ATCC 25923 and 
Escherichia coli ATCC 25922.  Stock cultures were maintained in tryptic soy broth 
(TSB, Sharlau Chemie, Spain) supplemented with 20% glycerol at -70°C.   Cultures 
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were routinely grown by subculturing 100 μL of stock culture into 9 ml TSB and 
incubating at 35°C for 18 h.    
 
Cultures were then maintained on tryptic soy agar (TSA, Sharlau Chemie, Spain) 
plates at 4°C.  Working cultures were prepared by inoculating a loop of pure culture 
into TSB and incubating at 35ºC for 18 h.  A bacterial suspension was prepared in 
saline solution (NaCl 0.85%, BioMérieux, France) equivalent to a McFarland
 
standard 
of 0.5, using the Densimat photometer (BioMérieux, SA, France), to obtain a 
concentration of 1x10
8
 cfu/mL.  This suspension was then serially diluted in TSB to 
obtain a working concentration of  1x10
6
 cfu/mL. 
 
4.1.2 Preparation of Test Compounds 
 
4.1.2.1 Fatty Acid and Monoglyceride Standards 
The saturated fatty acids lauric and caprylic acid as well as their corresponding 
monoglycerides, monolaurin and monocaprylin (Sigma-Aldrich ~99% purity) were 
used as standards in this study (Table 4-1). 
 
Standard stock solutions (100 mM) of the fatty acids and monoglycerides were 
prepared in sterile hydroalcoholic diluent (ethanol-distilled water, 1:1) and stored at -
20
o
C.  Stock solutions were diluted in TSB to obtain working concentrations.  The 
final concentration of ethanol (5% and 10%), corresponding to the highest 
concentration of compound used (10 mM for the Gram-positive and 20 mM for the 
Gram-negative bacteria) had a negligible effect on bacteria viability. 
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Table 4-1 Fatty acids and monoglycerides used as standards in antimicrobial activity assays. 
 
Name Compound 
 
Lauric acid C11H23
O
HO  
 
Monolaurin O
OH
OH
H23C11
O
 
 
Caprylic acid 
 
C7H15
O
HO  
 
Monocaprylin O
OH
OH
H15C7
O
 
 
 
4.1.2.2 Fatty Acid Derivatives 
A series of fatty acid derivatives were synthesised.  Table 4-2 and Table 4-3 show the 
fatty acid derivatives assessed for antimicrobial activity.  Standard stock solutions 
(100 mM) of the fatty acid derivatives were prepared in sterile hydroalcoholic diluent 
(ethanol-distilled water, 1:1) and stored at -20
o
C.  Stock solutions were diluted in TSB 
to obtain working concentrations. 
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Table 4-2 Glucopyranoside, mannopyranoside and galactopyranoside derivatives tested for 
antimicrobial activity. 
 
Compound Category Name Compound 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glucopyranoside 
 
 
Methyl 6-O-lauroyl-α-D-
glucopyranoside (37a) 
 
 
Methyl 6-O-lauroyl-β-D-
glucopyranoside (37b) 
 
 
 
Methyl 6-O-octanoyl-α-D-
glucopyranoside (38a) 
 
 
Methyl 6-O-dodecanyl-α-D-
glucopyranoside (39a) 
 
 
Methyl 6-O-dodecanyl-β-D-
glucopyranoside (39b) 
 
 
Methyl 4,6-di-O-lauroyl-α-D-
glucopyranoside (40) 
O
O
HO
C11H23
O
OMe
HO
HO  
O
O
HO
C11H23
O
OMeHO
HO  
O
O
HO
C7H15
O
OMe
HO
HO  
O
O
HO
C11H23
OMe
HO
HO  
O
O
HO
C11H23
OMeHO
HO  
O
O
HO
HO OMe
OC11H23
O
C11H23
O
 
 
Mannopyranoside 
 
Methyl 6-O-lauroyl-α-D-
mannopyranoside (37c) O
HO
HO
OHOH23C11
O
OMe  
 
Galactopyranoside 
 
Methyl 6-O-lauroyl-α-D-
galactopyranoside (37d) O
O
HO
C11H23
O
HO
HO OMe  
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Table 4-3 Pentaerythritol and Diacetone-D-Glucose Derivatives Tested for Antimicrobial 
Activity. 
 
Compound Category Name Compound 
 
 
 
 
 
Pentaerythritol 
 
Mono lauroyl 
pentaerythritol (41) 
 
 
Di lauroyl pentaerythritol 
(54) 
 
Tetra lauroyl 
pentaerythritol (55) 
OHO
HO OH
C11H23
O
 
OO
HO OH
C11H23
O
H23C11
O
 
OO
O O
C11H23
O
H23C11
O
C11H23H23C11
O O  
 
 
 
 
Diacetone-D-Glucose 
1,2:5,6 di-O-
isopropylidene-3-O-
dodecanyl-α-D-
glucofuranose (56) 
 
1,2:5,6 di-O-
isopropylidene-3-O-
lauroyl-α-D-glucofuranose 
(58) 
O
O
O
O
O
O
H23C11  
O
O
O
O
O
O
H23C11
O
 
 
 
4.1.3 Antimicrobial Activity Assays 
Working test compounds and standards were serially diluted in sterile TSB to a final 
volume of 100 µL within the 96-well plate.  100 µL of freshly prepared inoculum of 
the organism under study was added to each appropriate well, the final volume in each 
well was 200 µL.  The final concentration of each microorganism in each well was 
approximately 5x10
5
 cfu/mL and the concentration range of chemical compounds was 
from 1:2 to 1:256.  Each concentration was assayed in duplicate.   
 
The following controls were used in the microplate assay for each organism and test 
compound;  
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Blank: uninoculated media without test compound to account for changes in the 
media during the experiment. 
Negative control: uninoculated media containing only the test compound to assess 
background noise.  
Positive control 1: inoculated media without compound to evaluate the microbial 
growth under optimal conditions.  
Positive control 2: inoculated media without compound but including the 
corresponding sugar/pentaerythritol to evaluate any effect of the sugar/pentaerythritol 
alone. 
Positive control 3: inoculated media without compound but with the equivalent 
concentration of ethanol used to dissolve the test compound thereby assessing any 
activity of the alcohol.  
 
The 96-well plates were incubated at 35°C for 18 hours in a microtiterplate reader 
(PowerWave microplate Spectrophotometer, BioTek) and effects were monitored by 
measuring the optical density (OD) at 600 nm for each well every 20 minutes with 20 
seconds agitation before each OD measurement.  Each experiment was replicated 
three times.  
 
4.1.4 Minimum Inhibitory Concentration Determination 
 
The MIC was defined as the lowest concentration of compound that showed no 
increase in OD values for all the replicates compared to the negative control after 18 
hours.  Subtraction of the absorbance of the negative control eliminated interferences 
due to possible changes in the media. 
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4.2 RESULTS 
Two non-carbohydrate polyhydroxylated fatty acid ester derivatives, seven 
carbohydrate fatty acid ester derivatives and three carbohydrate long chain alkyl ether 
derivatives, together with their corresponding polyhydric alcohols, fatty acids and 
monoglycerides as controls, were tested against a Gram-positive bacteria, 
Staphylococcus aureus, and a Gram-negative bacteria, Escherichia coli, to assess their 
antimicrobial activity. 
 
The efficacy of the derivatives and controls were compared using Minimum 
Inhibitory Concentration (MIC) values.  The polyhydric alcohols (carbohydrates and 
pentaerythritol) showed no antimicrobial activity or growth promoting effects for the 
microorganisms under the conditions used (results not shown). 
 
The data in Table 4-4 show that the monoglycerides monolaurin and monocaprylin 
had greater activity compared to the free fatty acids lauric acid and caprylic acid 
against S. aureus.  Of the monoglycerides and free fatty acids tested, monolaurin had 
the lowest MIC values for S. aureus, with a value of 0.04 mM compared to a value of 
0.63 mM for lauric acid.  Furthermore, monocaprylin showed MIC values of 2.5 mM 
against S. aureus compared to the value of 5.0 mM for caprylic acid.  With respect to 
E. coli, monolaurin showed less inhibitory effect than lauric acid with values of 20 
mM and 10 mM respectively.  In contrast, monocaprylin showed activity against E. 
coli at concentrations of 6.25 mM compared with caprylic acid value of 12.5 mM.  All 
fatty acid derivatives showed greater antimicrobial activity against S. aureus than E. 
coli. 
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Table 4-4 MIC values of fatty acid derivatives and controls. 
 
Compound 
Category 
Compound Name S. aureus 
ATCC 25923 
E. coli 
ATCC 25922 
 
 
Control 
Compounds 
Lauric acid 
 
Monolaurin 
 
Caprylic acid 
 
Monocaprylin 
0.63 mM 
 
0.04 mM 
 
5 mM 
 
2.5 mM 
10 mM 
 
20 mM 
 
12.5 mM 
 
6.25 mM 
 
 
 
 
 
 
 
Glucose 
Derivatives 
Methyl 6-O-lauroyl-α-D-
glucopyranoside (37a) 
 
Methyl 6-O-lauroyl-β-D-
glucopyranoside (37b) 
 
Methyl 6-O-octanoyl-α-D-
glucopyranoside (38a) 
 
Methyl 6-O-dodecanyl-α-D-
glucopyranoside (39a) 
 
Methyl 6-O-dodecanyl-β-D-
glucopyranoside (39b) 
 
Methyl 4,6-di-O-lauroyl-α-D-
glucopyranoside (40) 
 
0.31 mM 
 
 
0.04 mM 
 
 
2.5 mM 
 
 
0.04 mM 
 
 
2.5 mM 
 
 
ND
*
 
 
20 mM 
 
 
20 mM 
 
 
12.5 mM 
 
 
20 mM 
 
 
20 mM 
 
 
ND 
Mannose 
Derivatives 
Methyl 6-O-lauroyl-α-D-
mannopyranoside (37c) 
 
0.04 mM 
 
20 mM 
Galactose 
Derivatives 
Methyl 6-O-lauroyl-α-D-
galactopyranoside (37d) 
 
>10 mM 
 
>20 mM 
 
 
Pentaerythritol 
Derivatives 
Mono lauroyl pentaerythritol 
(41) 
 
Di lauroyl pentaerythritol (54) 
 
Tetra lauroyl pentaerythritol 
(55) 
 
>10 mM 
 
ND 
 
ND 
 
 
>20 mM 
 
ND 
 
ND 
 
 
 
Diacetone 
Derivatives 
1,2:5,6 di-O-isopropylidene-3-
O-dodecanyl-α-D-
glucofuranose (56) 
 
1,2:5,6 di-O-isopropylidene-3-
O-lauroyl-α-D-glucofuranose 
(58) 
 
> 10 mM 
 
 
> 10 mM 
 
> 20 mM 
 
 
> 20 mM 
 
 
                                                 
*
 Not determined due to insolubility. 
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Among the sugar fatty acid esters and the sugar alkyl ethers prepared, methyl 6-O-
dodecanyl-α-D-glucopyranoside 39a, methyl 6-O-lauroyl-α-D-mannopyranoside 37c 
and methyl 6-O-lauroyl-β-D-glucopyranoside 37b showed the best inhibitory effects 
for S. aureus, with MIC values of 0.04 mM.  The next derivative in order of efficacy 
was methyl 6-O-lauroyl-α-D-glucopyranoside 37a, with a value of 0.31 mM.   
 
Methyl 6-O-octanoyl-α-D-glucopyranoside 38a was comparable to monocaprylin 
against S. aureus with values of 2.5 mM.  This compound was also more active than 
any of the lauric acid derivatives against E. coli.  Methyl 6-O-dodecanyl-β-D-
glucopyranoside 39b gave similar results to 38a for S. aureus with values of 2.5 mM. 
 
The galactopyranoside ester derivative 37d, the mono-lauroyl pentaerythritol 41 and 
both the ether and ester derivatives of diacetone-D-glucose 56 and 58, were the least 
active compounds tested, all with comparatively negligible MIC values of >10 mM 
for S. aureus and >20mM for E. coli. 
 
 The di-substituted methyl 4,6-O-lauroyl-α-D-glucopyranoside 40 did not show any 
activity comparable with either the monoglycerides or indeed the mono-substituted 
sugar derivatives against either bacteria due to poor solubility in water, as was the 
case for the non-sugar compounds di-lauroyl pentaerythritol 54 and tetra-lauroyl 
pentaerythritol 55. 
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4.3 DISCUSSION 
In this study the effect of polyhydroxylated fatty acid derivatives as inhibitors of a 
Gram-positive (S. aureus) and a Gram-negative (E. coli) microorganism of concern to 
the food and healthcare industries were evaluated.  Several of the synthesised 
compounds have antimicrobial efficacy comparable with commercially available 
antimicrobials against S. aureus.  
 
The effect of carbohydrate versus non-carbohydrate hydrophilic cores (carbohydrate 
and pentaerythritol laurates), the degree of substitution (monoester and diester), the 
monosaccharide core (glucopyranoside, mannopyranoside and galactopyranoside), the 
anomeric configuration (α and β glucopyranoside), the type of fatty acid carbohydrate 
linkage (ester and ether) and the length of fatty acid chain (lauric and caprylic) on 
antimicrobial activity were studied.  Two protected sugar derivatives were also tested 
for comparative studies. 
 
As with the monoglycerides and free fatty acids, all of the fatty acid derivatives that 
were found to be active, showed greater antimicrobial activity against S. aureus than 
against E. coli.  
 
The non-carbohydrate pentaerythritol monoester 41, which has the same number of 
free hydroxyl groups as the carbohydrate monoester derivatives, showed negligible 
activity against both the microorganisms tested.  The result may suggest that 
hydrophilicity alone is not the only requirement involved in the choice of polyhydric 
alcohol used in the synthesis of these derivatives to achieve the desired antimicrobial 
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efficacy.  This result also indicates the possibility that the carbohydrate moiety could 
play an important role in the antimicrobial activity of these compounds. 
 
The degree of substitution of these derivatives was also shown to be crucial as the 
non-sugar pentaerythritol diester 54 and pentaerythritol tetraester 55 and the 
carbohydrate methyl α-D-glucopyranoside diester 40 were much less soluble in water 
than the monoesters.  As a consequence, no antimicrobial activity results for these 
compounds could be measured.  Although the diester of sucrose was shown to possess 
higher activity than the monoester in a study conducted by Kato and Shibasaki,
3
 the 
results obtained in this current study clearly show the necessity of three free hydroxyl 
groups to ensure solubility of monosaccharides in order to measure activity of these 
derivatives. 
 
With regard to investigating the effect of different sugar cores, the results showed that 
the lauric ester derivative of methyl α-D-mannopyranoside 37c and methyl β-D-
glucopyranoside 37b, showed higher activity than any other ester derivatives against 
S. aureus, supporting the observation that whilst the degree of hydrophilicity may be 
important, the nature of the carbohydrate core itself is important in the antimicrobial 
efficacy of the derivatives and the orientation of these free hydroxyl groups is 
essential for the level of antimicrobial efficacy.  These conclusions are consistent with 
results of an earlier study by Watanabe et al.
4
 
 
Further evidence supporting this observation is seen in the results for the lauric ester 
anomers of methyl glucopyranoside 37a and 37b.  A marked difference was observed 
between these compounds when they were tested against S. aureus with the beta 
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configuration (37b) showing higher activity.  The lauric ether anomers of methyl 
glucopyranoside 39a and 39b also showed a marked difference in activity when tested 
against S. aureus, with the alpha configuration showing much higher activity.   
 
In addition, the difference in activity between the ester and ether conjugates of the 
same carbohydrate showed that for the methyl α-D-glucopyranoside derivatives, the 
ether derivative 39a was more active than the ester 37a, however for methyl β-D-
glucopyranoside, the ester 37b was more active than the ether 39b.  These results 
indicate that, in combination with other factors, the nature of the bond conjugating the 
fatty acid to the carbohydrate could play some role in antimicrobial activity. 
 
The importance of the chain length of the fatty acid ester was investigated using both 
lauric and caprylic derivatives.  The lauric ester derivative 37a showed much higher 
activity against S. aureus compared with the corresponding caprylic ester derivative 
38a.  Conversely, the caprylic ester derivative 38a showed higher activity against the 
Gram-negative bacteria E. coli, compared with the lauric derivative 37a.  This trend 
was also observed for the monoglyceride controls and is in accordance with general 
trends observed for medium and short chain fatty acids.
5
 
 
The protected sugars, diacetone ether derivative 56 and diacetone ester derivative 58, 
both gave negligible results against both organisms.  This result is further evidence of 
the necessity of hydroxyl groups for the antimicrobial activity of these fatty acid 
derivatives.
6
   
 
 158 
In conclusion, these results suggest that the nature of the carbohydrate core plays a 
role in the efficacy of some carbohydrate fatty acid derivatives as antimicrobials, and 
that therefore, further optimisation may be possible.  However, to define the complex 
relationship between the carbohydrate moiety, the alkyl chain length and the nature of 
the glycoconjugate bond, further studies are warranted using a wider range of Gram-
positive and Gram-negative microorganisms to eliminate species and strain effects.  
This work provides a framework on which further studies can be based. 
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5. Experimental 
All air and moisture-sensitive reactions were performed under an inert nitrogen 
atmosphere.  All reactions performed under a hydrogen atmosphere were performed 
in a Parr Hydrogenator Apparatus.  Toluene, benzene and dichloromethane reaction 
solvents were freshly distilled from calcium hydride and anhydrous DMF, THF, 
pyridine and acetonitrile were purchased from Sigma Aldrich.  T.l.c. was performed 
on aluminium sheets precoated with Silica Gel 60 (HF254, Fluka) and spots visualised 
by UV and charring with H2SO4-EtOH (1:20).  Flash Column Chromatography was 
carried out with Silica Gel 60 (0.040-0.630 mm, E. Merck) and using stepwise solvent 
polarity gradient correlated with t.l.c. mobility.  Chromatography solvents used were 
ethyl acetate (Riedel-deHaen), methanol (Riedel-deHaen) and petroleum ether (b.p. 
40-60 
o
C, Fluka).  Optical rotations were determined with an AA-% Series Optical 
Activity Ltd Polarimeter.  NMR spectra were recorded with Varian Inova 300 and 
Varian NMRAS 400 spectrometers.  Chemical shifts are reported relative to internal 
Me4Si in CDCl3 ( 0.0) for 
1
H and CDCl3 (δ 77.0) for 
13
C.  Coupling constants are 
reported in hertz.  FTIR spectra were recorded with a Nicolet FT-IR 5DXB infrared 
spectrometer, samples were prepared in a KBr matrix.  Low-resolution electrospray-
ionisation mass spectra were measured in the positive-ion mode on a Micromass 
Quattro tandem quadropole mass spectrometer.  The D-glucose, methyl-α-D-
glucopyranoside, methyl-β-D-glucopyranoside, methyl-α-D-mannopyranoside, 
methyl-α-D-galactopyranoside, diacetone-D-glucose, pentaerythritol, 1-
chlorododecane, lauroyl chloride and octanoyl chloride were purchased from Sigma 
Aldrich. 
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O
AcO
AcO
AcO
AcO OAc
10
 
D-Glucose penta acetate (10) - D-Glucose (20 g, 0.11 mol) was dissolved in a solution 
of pyridine / acetic anhydride (1:1, 250 mL) and the mixture was stirred for 24 h.  The 
solution was concentrated in vacuo and the resulting residue was dissolved in ethyl 
acetate (200 mL).  The solution was then washed with water followed by sat. aq. 
NaHCO3.  It was then dried over NaSO4 anhydrous, filtered and concentrated under 
diminished pressure.  The crude pentaacetate was recrystallised from hexane / ethyl 
acetate / methanol to afford 10 as a white crystalline solid mixture of anomers.  (17.52 
g, 41%); []D 63.1º
 
(c 0.19, CHCl3); Anal. Calcd. for C16H22O11: C, 49.23; H, 5.68;  
Found: C, 49.48; H, 5.69;  NMR data were in agreement with that previously 
reported.
1
 
 
O
AcO
AcO
AcO
AcO
11
STol
 
p-Tolyl 2,3,4,6-O-acetyl-1-thio-β-D-glucopyranoside (11) - Glucose pentaacetate 10 
(1.1 g, 2.8 mmol) and p-thiocresol (1.7 g, 15.4 mmol) were dissolved in 
dichloromethane (12 mL).  The solution was cooled to 0
o
C.  Boron trifluoro etherate 
(1.9 mL, 15.4 mmol) was added and the mixture was stirred for 24 h.  The solution 
was then diluted with dichloromethane (10 mL), washed with sat. aq. NaHCO3, 
followed by water.  The mixture was then dried over MgSO4 anhydrous and 
concentrated in vacuo.  The resulting residue was purified by flash column 
chromatography to afford the tetra-acetate 11 as a white crystalline solid.
1
  (0.185 g, 
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15%);  []D -3.5º
 
(c 0.01, CHCl3);  
1
H NMR (400MHz, CDCl3): δ 7.41-7.10 (ms, 4H, 
aromatic CH), 5.21 (apt t, 1H, J2,3 9.5, J3,4 9.5, H-3), 5.03 (apt t, 1H, J4,5 10.0, H-4), 
4.94 (apt t, 1H, J1,2 10.0, H-2), 4.64 (d, 1H, H-1), 4.20 (apt t, 2H, J5,6a 2.5, J5,6b 4.5, H-
6a,6b), 3.71 (ddd, 1H, H-5), 2.35 (s, 3H, PhCH3), 2.10, 2.09, 2.02, 2.00 (each s, 12H, 
each COCH3);  Anal. Calcd. for C21H26O9S: C, 55.50; H, 5.77; Found: C, 55.25; H, 
6.16;  LRMS: Found, 477.0; required 477.49; [M+Na]
+
. 
 
O
HO
HO
HO
HO
12
STol
 
p-Tolyl 1-thio-β-D-glucopyranoside (12) - Tetra-acetate 11 (0.185 g, 0.41 mmol), was 
dissolved in methanol (2 mL) and elemental sodium (0.005 g) was added.  The 
mixture was stirred for 24 h, at which point ion exchange resin (IR 120+) was added 
portion wise until the solution was neutralised.  The reaction mixture was then filtered 
and concentrated under reduced pressure to afford the crude tetrol 12 (0.076 g, 65% 
crude) as a white crystalline solid.
1
  []D 36.3º
 
(c 0.01, CHCl3);  LRMS: Found, 309.0; 
required 309.34; [M+Na]
+
. 
 
O
BnO
BnO
BnO
BnO
13
STol
 
p-Tolyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (13) - Tetrol 12 (0.076 g, 
0.27 mmol) was dissolved in DMF anhydrous (0.5 mL) and benzyl bromide (0.15 mL, 
1.2 mmol) was added.  The mixture was cooled to 0
o
C and sodium hydride (60% 
dispersion in mineral oil) (0.06 g, 1.5 mmol) was added portion wise.  The solution 
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was stirred for 24 h and methanol (0.5 mL) was added to quench the solution, which 
was stirred for a further 15 min.  The solution was concentrated in vacuo and 
dissolved in ethyl acetate.  The mixture was then washed with brine, dried over 
MgSO4 anhydrous, filtered and concentrated under diminished pressure.  The 
resulting benzylated residue was purified by flash column chromatography to afford 
the fully protected thioglycoside 13 as a white crystalline solid.  (0.14 g, 53% over 2 
steps);  NMR data were in agreement with that previously reported.
1
  LRMS: Found, 
669.2; required 669.83; [M+Na]
+
. 
 
O
AcO
AcO
AcO
AcO
14
SCyc
 
Cyclohexanethiol-2,3,4,6-tetra-O-acetyl-1-thio--D-glucopyranoside (14) - Glucose-
penta-acetate 11 (1.0 g, 2.56 mmol) and cyclohexanethiol (1.9 mL, 0.02 mol) were 
dissolved in dichloromethane (12 mL).  The solution was cooled to 0C and boron 
trifluoro etherate (1.5 mL, 15.3 mmol) was added.
1
  The mixture was stirred for 24 h 
at which point t.l.c. indicated that this reaction did not go to completion. 
 
O
BnO
BnO
BnO
BnO
15
O
OH OH
OH
 
Pentaerythritol 2,3,4-tetra-O-benzyl--D-glucopyranoside (15) - To a stirred solution 
containing 13 (0.1 g, 0.2 mmol) and activated 4 Å powdered molecular sieves in 
dichloromethane (8 mL) at room temperature, pentaerythritol (0.06 g, 0.44 mmol), N-
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iodosuccinimide (0.1 mL, 0.5 mmol) and trimethylsilyl triflate (0.031 mL, 0.17 
mmol) were added.  T.l.c. indicated this reaction did not complete and insufficient 
material prohibited further investigation. 
 
O
MOMO
HO
HO
MOMO
17
OMe
 
Methyl 2,6-di-O-lauroyl-α-D-glucopyranoside (17) - Methyl α-D-glucopyranoside 7a 
(0.97 g, 5 mmol) was dissolved in dioxane (40 mL).  A catalytic amount of 4-
dimethylaminopyridine and dibutyltin dimethoxide (1.47 mL, 6.4 mmol) was added to 
the solution.  The mixture was kept at reflux and a solution of bromomethyl 
methylether (0.61 mL, 7.5 mmol) in dioxane (10 mL) was added dropwise over 1 h.
2
  
The reaction was allowed to stir for 24 h, concentrated in vacuo and purified by 
chromatography.  (1.326 g, 94%);  
1
H NMR (400MHz, CDCl3): δ 4.88 (AB d, 2H, J 
6.0, OCH2O), 4.83 (AB d, 2H, J 4.0, OCH2O), 4.74 (d, 1H, J1,2 7.0, H-1), 4.16 (dd, 
2H, J 5.0, J 10.0 H-6), 4.03 (apt t, 1H, J2,3 9.0, J3,4 9.0 H-3), 3.75 (m, 1H, H-5), 3.52 
(m, 1H, H-2), 3.26 (apt t, 1H, J4,5 9.5, H-4), 3.45-3.40 (overlapping signals, 9H, each 
OMe), 1.26 (br s, 2H, each OH); 
13
C NMR (CDCl3): δ 104.1 (d, C-1), 99.9, 93.7 (each 
t, each OCH2O), 80.7, 72.8, 71.2, 68.7 (each d), 62.5 (t, C-6), 57.4, 55.2 (each q, each 
OCH3).  LRMS: Found, 305.1; required 305.29; [M+Na]
+
. 
 
OO
HO
HO
18
OMe
OPh
 
Methyl 4,6-O-benzylidene-α-D-glucopyranoside (18) - A solution of methyl α-D-
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glucopyranoside 7a (1 g, 5.2 mmol), p-toluenesulfonic acid (10 mg) and 
benzaldehyde dimethylacetal (1.5 mL, 10.3 mmol) in acetonitrile anhydrous (25 mL) 
was stirred for 24 h at room temperature.  Trimethylamine (0.5 mL) was added to 
neutralise the solution which was then stirred for 1 h.
3
  The product was filtered off as 
a white solid, washed with petroleum ether and dried.  (1.37 g, 93%).  []D 8.3º
 
(c 
0.01, CHCl3);  
1
H NMR (400MHz, CDCl3): δ 7.54-7.27 (ms, 5H, aromatic H), 5.53 (s, 
1H, CHPh), 4.78 (d, 1H, J1,2 4.0, H-1), 4.29 (dd, 1H, J 3.5, J 9.0 H-6), 3.92 (apt t, 1H, 
J2,3 9.0, J3,4 9.0 H-3), 3.84-3.62 (overlapping signals, 3H, H-2,5,6), 3.48 (apt t, 1H, J4,5 
9.5, H-4), 3.45 (s, 3H, OMe), 2.47, 3.00 (each br s, 2H, OH);  LRMS: Found, 305.1; 
required, 305.29; [M + Na]
+
. 
 
OO
MOMO
MOMO
20
OMe
OPh
 
Methyl 2,3-di-O-methoxymethyl-4,6-O-benzylidene-α-D-glucopyranoside (20)  
Method using dibutyltin dimethoxide.
2
 - Methyl 4,6-O-benzylidene-α-D-
glucopyranoside 18 (0.178 g, 0.63 mmol) was dissolved in dioxane (5 mL).  A 
catalytic amount of 4-dimethylaminopyridine and dibutyltin dimethoxide (0.2 mL, 
0.82 mmol) was added to the mixture which was kept at reflux.  A solution of 
bromomethyl methylether (0.08 mL, 0.94 mmol) in dioxane (4 mL) was then added 
dropwise over 1 h.  The mixture was allowed to stir for 24 h and was concentrated 
under reduced pressure and purified by chromatography (petroleum ether-EtOAc) to 
yield 20.  (0.198 g, 85%);  []D 16.8º
 
(c 0.4, CHCl3);  FTIR (KBr): 2932, 1372, 182, 
1186, 1116, 1099, 695 cm
-1
;  
1
H NMR (400 MHz, CDCl3): 7.49-7.27 (ms, 5H, 
aromatic H), 5.54 (s, 1H, CHPh), 4.83 (d, 1H, J1,2 3.5, H-1), 4.81, 4.80 (each AB d, 
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4H, J 6.0, J 6.5, OCH2O), 4.28 (dd, 1H, J5,6a 4.5, J6a,6b 10.0, H-6a), 4.12 (apt t, 1H, J2,3 
9.5, J3,4 9.0, H-3), 3.85 (m, 1H, H-5), 3.71 (apt t, 1H, J5,6b 10.5, H-6b), 3.64 (dd, 1H, 
H-2), 3.56 (apt t, 1H, J4,5 9.5, H-4), 3.45, 3.42 (each s, 6H, each OCH2OCH3), 3.35 (s, 
3H, OMe);  
13
C NMR (CDCl3): δ 141.8 (s, aromatic C), 133.5, 132.7, 130.6 (each d, 
each aromatic CH), 106.0, 104.4 (d, C-1, CHPh), 102.4, 101.8 (each t, each OCH2O), 
86.1, 83.0, 78.5, 66.8 (each d), 73.6 (t, C-6), 60.3, 60.0, 59.8 (each q, each OCH3);  
LRMS: Found, 393.2; required, 393.39; [M + Na]
+
;  Anal. Calcd. for C18H26O8: C, 
58.37; H, 7.08. Found: C, 57.99; H, 7.01. 
Method using dibutyltin oxide.
4
 - Methyl 4,6-O-benzylidene-α-D-glucopyranoside 18 
(1 g, 3.5 mmol) and dibutyltin oxide (0.97 g, 3.4 mmol) were dissolved in benzene 
anhydrous (120 mL) and stirred for 16 h with azeotropic removal of water.  After 16 h 
the reaction was stopped and the solution was concentrated to 80 mL, after which 
bromomethyl methylether (0.6 mL, 7.35 mmol) and tetrabutylammonium iodide (1.31 
g, 3.54 mmol) were added and the mixture was refluxed for a further 16 h.  The 
solution was then concentrated in vacuo and purified by chromatography (petroleum 
ether-EtOAc) to yield 20.  (0.824 g, 65%);  []D 8.8º
 
(c 0.3, CHCl3);  FTIR (KBr): 
2927, 1372, 1281, 1184, 1115, 1100, 1051, 695 cm
-1
;  
1
H NMR (400 MHz, CDCl3): 
7.48-7.33 (ms, 5H, aromatic H), 5.53 (s, 1H, CHPh), 4.83 (d, 1H, J1,2 3.5, H-1), 
4.78, 4.77 (each AB d, 4H, J 6.0, J 6.5, OCH2O), 4.28 (dd, 1H, J5,6a 4.5, J6a,6b 10.0, H-
6a), 4.11 (apt t, 1H, J2,3 9.5, J3,4 9.5, H-3), 3.80 (m, 1H, H-5), 3.74 (apt t, 1H, J5,6b 
10.0, H-6b), 3.64 (dd, 1H, H-2), 3.55 (apt t, 1H, J4,5 9.5, H-4), 3.45, 3.42 (each s, 6H, 
each OCH2OCH3), 3.34 (s, 3H, OMe);  
13
C NMR (CDCl3): δ 141.7 (s, aromatic C), 
133.5, 132.7, 130.6 (each d, each aromatic CH), 105.9, 104.4 (d, C-1, CHPh), 102.3, 
101.8 (each t, each OCH2O), 86.1, 82.9, 78.5, 66.7 (each d), 73.5 (t, C-6), 60.2, 59.9, 
59.8 (each q, each OCH3);  LRMS: Found, 393.1; required, 393.39; [M + Na]
+
;  Anal. 
 167 
Calcd. for C18H26O8: C, 58.37; H, 7.08. Found: C, 57.98; H, 7.08. 
 
OO
HO
BnO
21
OMe
O
Ph
 
Methyl 2-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (21)  
Method using dibutyltin oxide.
4
 - Methyl 4,6-O-benzylidene-α-D-glucopyranoside 18 
(0.84 g, 3.0 mmol) and dibutyltin oxide (1.5 g, 6.0 mmol) were dissolved in benzene 
anhydrous (100 mL) and allowed to stir for 16 h with azeotropic removal of water.  
After 16 h the reaction was stopped and the solution was concentrated to 
approximately 70 mL, after which benzyl bromide (0.36 mL, 3.0 mmol) and 
tetrabutylammonium iodide (1.1 g, 3.0 mmol) were added and the mixture was 
refluxed for a further 16 h.  The solution was then concentrated in vacuo.  T.l.c. 
verified the presence of several products. 
Method using dibutyltin dimethoxide.
4
 - Methyl 4,6-O-benzylidene-α-D-
glucopyranoside 18 (0.8 g, 2.8 mmol) and dibutyltin dimethoxide (1.3 g, 5.6 mmol) 
were dissolved in benzene anhydrous (100 mL) and allowed to stir for 16 h with 
azeotropic removal of water.  After 16 h the reaction was stopped and the solution 
was concentrated to approximately 70 mL, after which benzyl bromide (0.36 mL, 3.0 
mmol) and tetrabutylammonium iodide (1.0 g, 3.0 mmol) were added and the mixture 
was refluxed for a further 16 h.  The solution was then concentrated under diminished 
pressure.  T.l.c. verified the presence of several products. 
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O
OMe
24
1x OBz
3x OH
 
Methyl monobenzoyl-α-D-glucopyranoside (24) -Methyl α-D-glucopyranoside 7a 
(0.97 g, 5 mmol) was dissolved in dioxane (40 mL).  A catalytic amount of 4-
dimethylaminopyridine and dibutyltin dimethoxide (1.47 mL, 5.5 mmol) was added.  
The reaction mixture was kept at room temperature and a solution of benzoyl chloride 
(0.64 mL, 5.5 mmol) in dioxane (10 mL) was added dropwise over 1 h.
2
  The reaction 
was stirred for 24 h and was then concentrated in vacuo and purified by flash 
chromatography (petroleum ether-EtOAc) to yield 24.  (0.338 g, 23%);  []D 67.4º
 
(c 
0.02, CHCl3);  FTIR (KBr): 3465, 3229, 2993, 2947, 1726, 1796, 1095, 764, 710 cm
-1  
1
H NMR (400 MHz, CDCl3): 8.05-7.39(ms, 5H, aromatic H), 4.93 (d, 1H, J1,2 3.5, 
H-1), 4.85-4.79 (overlapping signals, 2H), 4.06-3.90 (overlapping signals, 2H), 3.76-
3.70 (overlapping signals, 2H), 3.60-3.46 (overlapping signals, 2H), 3.32 (s, 3H, 
OMe);  LRMS: Found, 321.0; required, 321.29; [M + Na]
+
;  Anal. Calcd. for 
C14H18O7: C, 56.37; H, 6.08. Found: C, 56.67; H, 5.74. 
 
OBnO
BnO
BnO
BnO OMe
26
 
Methyl 2,3,4,6-tetra-O-benzyl-α-D-glucopyranoside (26) - Compound 24 (0.338 g, 1.1 
mmol) was dissolved in DMF anhydrous (8.0 mL).  Benzyl bromide (0.65 mL, 5.5 
mmol) was added to the solution.  The mixture was cooled to 0
o
C and sodium hydride 
(0.264 g, 6.6 mmol) was added portion wise.  The reaction was stirred for 24 h at 
room temperature after which methanol (8.0 mL) was added to quench the solution 
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which was stirred for a further 15 min.  The reaction mixture was concentrated in 
vacuo and the resulting benzylated residue was dissolved in ethyl acetate.  The 
solution was washed with brine, dried over MgSO4 anhydrous, filtered and 
concentrated under diminished pressure.  The residue was purified by flash 
chromatography (petroleum ether-EtOAc) to yield 26.  (0.48 g, 79%);  
1
H NMR 
(400MHz, CDCl3): δ 7.34-7.11 (ms, 20H, aromatic H), 4.89, (AB d, 2H, J 11.0, 
OCH2Ph),  4.82, (AB d, 2H, J 3.5, OCH2Ph),  4.66 (AB d, 2H, J 13.0, OCH2Ph), 4.63 
(d, 1H, J1,2 4.0, H-1), 4.54 (AB d, 2H, J 12.0, OCH2Ph), 3.98 (apt t, 1H, J2,3 9.5, J3,4 
9.0, H-3), 3.75-3.62 (overlapping signals, 4H, H-4,5,6), 3.56 (dd, 1H, H-2), 3.37 (s, 
3H, OCH3);  
13
C NMR (CDCl3): δ 139.3, 139.2, 138.6, 138.5 (each s, each aromatic 
H), 128.45, 128.39, 128.36, 128.14, 127.97, 127.9, 127.85, 127.7, 127.6 (each d, each 
aromatic CH), 98.2 (d, C-1), 82.1, 79.9, 77.7, 68.5 (each d), 75.8, 75.0, 73.5, 73.4 
(each t), 70.1 (t, C-6), 55.2 (q, OCH3);  LRMS: Found, 577.2 required, 577.67; [M + 
Na]
+
. 
 
OO
BzO
BzO OMe
27
OPh
 
Methyl 2,3-di-O-benzoyl-4,6-O-benzylidene-α-D-glucopyranoside (27) - Methyl 4,6-
O-benzylidene-α-D-glucopyranoside 18 (0.496 g, 1.8 mmol) was dissolved in dioxane 
(20 mL).  A catalytic amount of 4-dimethylaminopyridine and dibutyltin dimethoxide 
(0.5 g, 2.0 mmol) was added.  The reaction mixture was kept at room temperature and 
a solution of benzoyl chloride (0.25 mL, 2.0 mmol) in dioxane (5.0 mL) was added 
drop wise over 1 h.
2
  The mixture was then concentrated in vacuo and purified by 
chromatography to yield 27 (0.422g, 48%);  []D 85.4º
 
(c 0.05, CHCl3);  FTIR (KBr): 
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3066, 1720, 1384, 1333, 1277, 1244, 1116, 1097, 690 cm
-1
;  
1
H NMR (400MHz, 
CDCl3): δ 8.01-7.31 (overlapping signals, 15H, aromatic H), 6.06 (apt t, 1H, J2,3 10.0, 
J3,4 10.0, H-3), 5.57 (s, 1H, CHPh), 5.26 (dd, 1H, J1,2 3.5, H-2), 5.19 (d, 1H, H-1), 
4.39 (dd, 1H, J6a,6b 10.0, J5,6b 5.0, H-6b), 4.09 (m, 1H, H-5), 3.95-3.84 (overlapping 
signals, 2H, H-4,6a), 3.45 (s, 3H, OMe);  LRMS: Found, 513.0 required, 513.5; [M + 
Na]
+
;  Anal. Calcd. for C28H26O8: C, 68.56; H, 5.34. Found: C, 68.33; H, 5.43. 
 
O
HO
HO
BnO
HO
34
OH
 
3-O-benzyl-(α/β)-D-glucopyranoside (34) - Sodium hydride (1.8 g, 46.1 mmol) was 
added to a solution of  diacetone-D-glucose 32 (10 g, 36.4 mmol) in DMF anhydrous 
(100 mL) and benzyl bromide (5.5 mL, 46.1 mmol) at 0
o
C.  The reaction mixture was 
allowed to warm to room temperature and was stirred for 5 h.  The solution was 
cooled to 0
o
C and methanol (20 mL) was added dropwise.  The reaction mixture was 
concentrated in vacuo.  The residue was taken up in Et2O and water was added.  It 
was then dried over MgSO4 anhydrous, filtered and concentrated under reduced 
pressure.  Amberlite-IR 120 (H
+
) (20 g) was added to a suspension of the resulting 
residue in H2O (100 mL).  The mixture was then stirred at reflux for 4 h, filtered and 
concentrated in vacuo to yield 34 as yellow crystals.
5
  (6.36 g, 63.6% crude);  FTIR 
(KBr): 3522, 2921, 2852, 1374, 1276, 1175, 1110, 1061 cm
-1
;  LRMS: Found, 293.1 
required, 293.28; [M + Na]
+
. 
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O
AcO
AcO
BnO
AcO
35
OAc
 
1,2,4,6-tetra-O-acetyl-3-O-benzyl-(α/β)-D-glucopyranoside (35) - Crude compound 34 
(1 g, 3.7 mmol) was  added to a pyridine / acetic anhydride solution (1:1, 7 mL).  The 
mixture was stirred overnight concentrated in vacuo and the residue was dissolved in 
ethyl acetate.  The resulting solution was then washed with water followed by sat. aq. 
NaHCO3.  The mixture was dried over NaSO4 anhydrous, filtered and finally 
concentrated under reduced pressure before being purified by chromatography to 
yield compound 35.  (0.54 g, 33.3%);  []D 2.8º
 
(c 0.11, CHCl3);  FTIR (KBr): 2921, 
2852, 1743, 1713, 1374, 1276, 1110, 1061 cm
-1
; 
 1
H NMR (400MHz, CDCl3): δ 7.35-
7.24 (ms, 5H, aromatic CH), 6.31 (d, 1H, J1α,2α 3.5, H-1α), 5.65 (d, 1H, J1β,2β 8.0, H-
1β), 5.19-5.12 (overlapping signals, 3H, H-4α,6αa,2β), 5.06 (dd, 1H, J2α,3α 10.0, H-
2α), 4.68 (AB d, 2H, J 11.5, OCH2Ph), 4.24-4.19 (overlapping signals, 3H, H-4β,6β), 
4.14-3.95 (overlapping signals, 3H, H-3α,5α,6αb), 3.80-3.73 (overlapping signals, 2H, 
H-3β,5β), 2.16-1.97 (ms, 12H, each OCOCH3); LRMS: Found, 461.1 required, 
461.43; [M + Na]
+
;  Anal. Calcd. for C21H26O10: C, 57.53; H, 5.98. Found: C, 57.91; 
H, 6.12. 
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Lauroylation of methyl α-D-glucopyranoside 7a: 
 
O
HO
HO
HO
HO OMe
Cl C11H23
O
+
A B  
 
Methyl α-D-glucopyranoside 7a (0.97 g, 5 mmol) was dissolved in dioxane (40 mL). 
Dibutyltin dimethoxide (2.4 mL, 10.5 mmol) was added to the solution.  The mixture 
was kept at room temperature and a solution of lauroyl chloride (1.2 mL, 5 mmol) in 
dioxane (10 mL) was added dropwise over 1 h.  The mixture was stirred overnight.
2
 
The solution was then concentrated in vacuo and the following products were isolated 
by chromatography (petroleum ether-EtOAc): 
 
O
HO
HO
HO
O
8aH23C11
O OMe
 
Methyl 2-O-lauroyl-α-D-glucopyranoside (8a) - (0.273 g, 15%);  1H NMR (400MHz, 
CDCl3): δ 4.89 (d, 1H, J1,2 3.0, H-1), 4.71 (m, 1H, H-2), 4.62 (br s, 1H, OH), 3.91-
3.80 (overlapping signals, 3H, H-3,5,6b), 3.71-3.56 (overlapping signals, 2H, H-4,6a), 
3.36 (s, 3H, OMe), 2.39 (t, 2H, J 7.0, J 7.5, aliphatic OCOCH2C10H21), 2.05, 1.80 
(each br s, 2H, each OH), 1.67-1.43 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.41-1.09 
(overlapping signals, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, J 5.5, J 7.0, 
aliphatic OCOC10H20CH3);  
13
C NMR (CDCl3): δ 174.1 (s, C=O), 97.2 (d, C-1), 73.1, 
71.6, 71.1, 69.9 (each d), 61.3 (d, C-6), 55.2 (q, OMe), 34.2, 31.9, 29.63, 29.52, 
29.33, 29.07, 24.9, 22.7 (each t, each aliphatic CH2), 14.1 (q, aliphatic CH3); LRMS: 
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Found, 399.3 required, 399.48; [M + Na]
+
;  Anal. Calcd. for C19H36O7: C, 60.61; H, 
9.64. Found: C, 60.97; H, 9.63. 
 
O
O
HO
HO
O
42H23C11
O
H23C11
O
OMe
 
Methyl 2,6-O-lauroyl-α-D-glucopyranoside (42) - (0.274 g, 9.8%);  []D 43º
 
(c 0.01, 
CHCl3); FTIR (KBr): 3522, 2921, 2852, 1743, 1715, 1415, 1374, 1276, 1110, 1061 
cm
-1
;  
1
H NMR (400MHz, CDCl3): δ 4.92 (d, 1H, J1,2 3.5, H-1), 4.69 (dd, 1H, J2,3 
10.0, H-2), 4.55 (dd, 1H, J6a,6b 12.0, J5,6b 4.0, H-6b), 4.33-4.22 (m, 1H, H-6a), 3.97 
(apt t, 1H, J3.4 9.5, H-3), 3.75 m, 1H, H-5), 3.43-3.37 (overlapping signals, 4H, H-4, 
OMe), 3.20, 2.63 (each br s, 2H, each OH), 2.41-2.36 (m, 4H, each aliphatic 
OCOCH2C10H21), 1.80-1.53 (m, 4H, each aliphatic OCOCH2CH2C9H19), 1.46-1.09 
(overlapping signals, 32H, each aliphatic OCOC2H4C8H16CH3), 0.98-0.86 (m, 6H, 
each aliphatic OCOC10H20CH3);  LRMS: Found, 581.5 required, 581.79; [M + Na]
+
;  
Anal. Calcd. for C31H58O8: C, 66.63; H, 10.46. Found: C, 66.70; H, 10.20. 
 
O
TrO
BnO
BnO
BnO
43
OMe
 
Methyl 2,3,4-tri-O-benzyl-6-O-triphenylmethyl-α-D-glucopyranoside (43) - A 
solution of methyl α-D-glucopyranoside 7a (5 g, 25 mmol) in pyridine anhydrous (50 
mL) was treated with triphenylmethyl chloride (10.7 g, 38.55 mmol) and imidazole (5 
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g, 75 mmol) and was heated to approximately 40
o
C.  The suspension was allowed to 
stir for 24 h and was then concentrated in vacuo.
6
  The crude trityl protected product 
was dissolved in DMF anhydrous (50 mL) and cooled to 0
o
C.  NaH (4 g, 100 mmol) 
was added portion wise.  BnBr (9 mL, 75 mmol) was added to the solution which was 
then allowed to warm to room temperature and stir for 24 h.  Methanol (20 mL) was 
added to quench the mixture which was stirred for 1 h.  The solution was concentrated 
under diminished pressure, dissolved in ethyl acetate and washed with water.  It was 
dried over anhydrous MgSO4 and concentrated under reduced pressure.  The fully 
protected sugar was then purified by chromatography (petroleum ether-EtOAc) to 
give 43 (6.59 g, 37%);  []D 22.1º
 
(c 0.07, CHCl3);  FTIR (KBr): 1597, 1491, 1460, 
1449, 899, 745, 696 cm
-1
;  
1
H NMR (400MHz, CDCl3): δ 7.47-6.85 (ms, 30H, 
aromatic H), 4.89 (AB d, 2H, J 10.5, OCH2Ph),  4.79 (AB d, 2H, J 12.0, OCH2Ph), 
4.76 (d, 1H, J1,2 3.5, H-1), 4.50 (AB d, 2H, J 10.5, OCH2Ph), 3.97 (apt t, 1H, J2,3 9.5, 
J3,4 9.5, H-3), 3.81 (m, 1H, H-5), 3.64-3.59 (overlapping signals, 2H, H-2,4), 3.50 (dd, 
1H, J5,6a 2.0, J6a,6b 10.0, H-6a), 3.44 (s, 3H, OCH3), 3.19 (dd, 1H, J5,6b 5.0, H-6b);  
13C NMR (CDCl3): δ 144.0, 138.7, 138.3, 137.9 (each s, each aromatic C), 128.8, 
128.6, 128.5, 128.43, 128.38, 128.3, 128.2, 128.1, 128.0, 127.97, 127.90, 127.85, 
127.8, 127.7, 127.5, 126.9 (each d, each aromatic CH), 97.9 (d, C-1), 86.3 (s, CPh3), 
82.3, 80.2, 78.2, 70.3 (each d), 75.9, 74.9, 73.4 (each t, each CH2Ph), 62.6 (d, C-6), 
54.9 (q, OMe);  LRMS: Found, 729.4; required, 729.86; [M + Na]
+
. 
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Methyl 2,3,4-tri-O-benzyl-6-O-triisopropylsilyl-α-D-glucopyranoside (44a) - A 
solution of 7a (5 g, 25 mmol) in DMF anhydrous (120 mL) was treated with 
triisopropylsilyl chloride (15 mL, 75 mmol) and imidazole (5 g, 75 mmol) and 
allowed to stir at room temperature for 24 h.  The crude TIPS protected intermediate 
was then concentrated in vacuo and dissolved in ethyl acetate.  It was washed with 
10% HCl, water, followed by sat. aq. NaHCO3 and finally sat. aq. NaCl.  It was then 
dried over anhydrous MgSO4 and concentrated under reduced pressure.
7
  The crude 
product was dissolved in DMF anhydrous (50 mL) and cooled to 0
o
C.  NaH (5 g, 125 
mmol) was added portion wise.  BnBr (9 mL, 75 mmol) was added and the mixture 
was allowed to warm to room temperature and stir for 24 h.  Methanol (20 mL) was 
added to quench the mixture which was stirred for 1 h.  The fully protected sugar was 
then concentrated in vacuo and dissolved in ethyl acetate.  The solution was washed 
with water, dried over anhydrous MgSO4 and concentrated under diminished pressure. 
The resulting residue was purified by chromatography (petroleum ether-EtOAc) to 
give 44a.  (13.2 g, 85%);  []D 10.7º
 
(c 0.07, CHCl3);  FTIR (KBr): 2923, 1733, 1498, 
1455, 909, 884, 791, 695 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 7.36-7.27 (ms, 15H, 
aromatic H), 4.91, (AB d, 2H, J 11.0, OCH2Ph),  4.78, (AB d, 2H, J 11.0, OCH2Ph),  
4.74 (AB d, 2H, J 12.0, OCH2Ph), 4.61 (d, 1H, J1,2 3.5, H-1), 3.99 (apt t, 1H, J2,3 9.5, 
J3,4 9.5, H-3), 3.84 (d, 2H, J5,6 4.5, H-6a,6b), 3.64 (m, 1H, H-5), 3.55-3.49 
(overlapping signals, 2H, H-2,4), 3.37 (s, 3H, OCH3), 1.10-1.02 (ms, 18H, each TIPS 
CH3), 0.88 (m, 3H, each TIPS CH);  
13
C NMR (CDCl3): δ 139.1, 138.7, 138.5 (each s, 
each aromatic C), 128.65, 128.63, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8 (each d, 
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each aromatic CH), 98.0 (d, C-1), 82.5, 80.5, 78.1, 76.1 (each d), 76.1, 75.3, 73.6 
(each t, each CH2Ph), 62.9 (t, C-6), 55.0 (q, OCH3), 18.3, 18.2 (each q, each TIPS 
CH3), 12.2 (each d, each TIPS CH);  LRMS: Found, 643.3; required, 643.9; [M + 
Na]
+
. 
 
O
TIPSO
BnO
BnO
BnO
44b
OMe
 
Methyl 2,3,4-tri-O-benzyl-6-O-triisopropylsilyl-β-D-glucopyranoside (44b) - 
Treatment of 7b (4.5 g, 23.17 mmol) as described for 7a gave 44b.  (8.7 g, 80%);  [
]D 23º
 
(c 0.01, CHCl3);  FTIR (KBr): 2863, 1730, 1497, 1454, 1399, 1277, 882, 802, 
751, 697. cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 7.37-7.28 (ms, 15H, aromatic H), 
4.90, 4.88, 4.83 (each AB d, 6H, J 11.0, OCH2Ph), 4.30 (d, 1H, J1,2 7.5, H-1), 4.00-
3.90 (overlapping signals, 3H, H-5,6), 3.66 (m, 1H, H-3), 3.53 (s, 3H, OCH3), 3.41 
(m, 1H, H-2), 3.34 (m, 1H, H-4), 1.26-1.05 (ms, 21H, TIPS);  
13
C NMR (CDCl3): δ 
138.98, 138.92, 138.7 (each s, each aromatic C), 128.69, 128.65, 128.62, 128.5, 128.3, 
128.2, 128.0, 127.9, 127.8 (each d, each aromatic CH), 104.7 (d, C-1), 84.9, 82.9, 
77.8, 76.2 (each d), 76.0, 75.3, 75.0 (each t, each CH2Ph), 62.7 (t, C-6), 56.9 (q, 
OCH3), 18.3, 18.2 (each q, each TIPS CH3), 12.3 (d, TIPS CH);  LRMS: Found, 643.3 
required, 643.9 [M + Na]
+
. 
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Methyl 2,3,4-tri-O-benzyl-6-O-triisopropylsilyl-α-D-mannopyranoside (44c) - 
Treatment of 7c (4 g, 20 mmol) as described for 7a gave 44c.  (6.5 g, 51%);  []D 
25.5º
 
(c 0.05, CHCl3);  FTIR (KBr): 3056, 2864, 1496, 1363, 1324, 970, 882, 790, 
734, 696 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 7.38-7.24 (multiple signals, 15H, each 
aromatic H), 4.79 (AB d, 2H, J 11.0, OCH2Ph), 4.72 (AB d, 2H, J 12.0, OCH2Ph), 
4.71-4.64 (overlapping signals, 3H, OCH2Ph, H-1), 3.95 (dd, 1H, J2,3 2.0, J3,4 11.0, H-
3), 3.93-3.87 (overlapping signals, 3H, H-4,6a,6b), 3.76 (dd, 1H, J1,2 2.5, H-2), 3.59 
(dd, 1H, J  5.5, J  7.0, H-5), 3.31 (s, 3H, OMe), 1.12-1.04 (multiple signals, 21H, 
TIPS);  
13
C NMR (CDCl3): δ 138.68, 138.61, 138.4 (each s, each aromatic C), 128.3, 
128.2, 127.9, 127.67, 128.63, 127.5, 127.4 (each d, each aromatic CH), 98.5 (d, C-1), 
80.3, 76.7, 74.9, 73.3 (each d), 75.1, 72.5, 72.1 (each t, each CH2Ph), 63.2 (t, C-6), 
54.4 (q, OMe), 18.0, 17.9 (each q, each TIPS CH3), 12.3 (each d, each TIPS CH2);  
LRMS: Found, 638.5 required, 638.9; [M + H2O]
+
. 
 
44d
O
BnO
BnO
OMe
BnO
OTIPS
 
Methyl 2,3,4-tri-O-benzyl-6-O-triisopropylsilyl-α-D-galactopyranoside (44d) - 
Treatment of 7d (4.0 g, 20.0 mmol) as described for 7a gave 44d.  (6.4 g, 50%);  []D 
20.6º
 
(c 0.07, CHCl3);  FTIR (KBr): 3030, 2865, 1496, 1454, 1350, 1194, 1054, 882, 
793, 734, 696 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ; 7.41-7.22 (multiple signals, 15H, 
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each aromatic H), 4.82 (AB d, 2H, J 12.0, OCH2Ph), 4.71 (AB d, 2H, J 11.5, 
OCH2Ph), 4.77 (AB d, 2H, J 12.0, OCH2Ph), 4.68 (d, 1H, J1,2 3.5, H-1), 4.04 (dd, 1H, 
J2,3 10.0, H-2), 3.95-3.92 (overlapping signals, 2H, H-3,5), 3.74-3.64 (overlapping 
signals, 3H, H-4,6), 3.36 (s, 3H, OMe), 1.12-0.86 (multiple signals, 21H, TIPS);  
13
C 
NMR (CDCl3): δ 137.9, 137.7, 137.5 (each s, each aromatic C), 127.33, 127.28, 
127.22, 127.15, 127.06, 126.62, 126.48, 126.45 (each d, each aromatic CH), 97.6 (d, 
C-1), 78.1, 75.4, 74.0, 70.1 (each d), 73.7, 72.5, 72.2 (each t, each CH2Ph), 61.4 (t, C-
6), 54.1 (q, OMe), 16.94, 16.93 (each q, each TIPS CH3), 10.8 (each d, each TIPS 
CH2);  LRMS: Found, 638.5 required, 638.9; [M + H2O]
+
. 
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Methyl 2,3,4-tri-O-benzyl-6-O-lauroyl-α-D-glucopyranoside (45a) - Compound 44a 
(3.0 g, 4.8 mmol) was dissolved in THF anhydrous (80 mL) and was cooled to 0
o
C.  
Tetrabutylammonium fluoride (1 g, 4 mmol) was added and the solution was allowed 
to warm to room temperature and stir for 1 h.
7
  It was then concentrated in vacuo and 
approximately 1 mmol of the resulting 6-OH residue was dissolved in pyridine 
anhydrous (25 mL).  A catalytic amount of 4-dimethylaminopyridine and lauroyl 
chloride (0.29 mL, 1.22 mmol) were added and the solution was allowed to stir at 
room temperature for 24 h.
8
  It was then concentrated under reduced pressure and the 
resulting benzylated ester derivative was purified by chromatography (petroleum 
ether-EtOAc) to give 45a.  (0.47 g, 72%);  []D 7.5º
 
(c 0.02, CHCl3);  FTIR (KBr): 
2924, 2853, 1738, 1603, 1502, 1454, 1249, 1072 cm
1
;  
1
H NMR (400 MHz, CDCl3): δ 
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7.35-7.26 (ms, 15H, aromatic H),  4.92, (AB d, 2H,  J 10.5, OCH2Ph),  4.72, (AB d, 
2H,  J 10.5, OCH2Ph),  4.64  (AB d, 2H, J 12.0, OCH2Ph), 4.59 (d, 1H, J1,2 3.5, H-1), 
4.27 (d, 2H, J5,6 3.5, H-6a,6b), 4.01 (apt t, 1H, J2,3 9.5, J3,4 9.0,  H-3), 3.82 (d apt t, 
1H, J4,5 10.0, H-5), 3.53 (dd, 1H, H-2), 3.48 (apt t, 1H, H-4) 3.37 (s, 3H, OCH3), 2.35 
(m, 2H, aliphatic OCOCH2C10H21), 1.61 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.28-
1.24 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.87 (m, 3H, aliphatic 
OCOC10H20CH3);  
13
C NMR (CDCl3): δ 171.1 (s, C=O), 138.6, 138.1, 137.9 (each s, 
each aromatic C), 128.5, 128.48, 128.46, 128.1, 128.03, 127.98, 127.90, 127.7 (each 
d, each aromatic CH), 98.0 (d, C-1), 88.0, 79.9, 77.6, 68.6 (each d), 75.8, 75.1, 73.4 
(each t, each CH2Ph), 60.4 (t, C-6), 55.2 (q, OCH3), 34.2, 31.9, 29.8, 29.6, 29.5, 29.3, 
29.2, 24.9, 22.7, 21.1 (each t, each aliphatic CH2), 14.2 (q, aliphatic CH3);  LRMS: 
Found, 669.39; required, 669.85; [M + Na]
+
;  Anal. Calcd. for C40H54O7: C, 74.27; H, 
8.41. Found: C, 73.98; H, 8.30.  
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Methyl 2,3,4-tri-O-benzyl-6-O-lauroyl-β-D-glucopyranoside (45b) - Treatment of 44b 
(3.0 g, 4.8 mmol) as described for 44a gave 45b.  (2.2 g, 70%);  []D 8.3º
 
(c 0.03, 
CHCl3);  FTIR (KBr): 2924, 2853, 1739, 1497, 1454, 1356, 1151, 1070, 735 cm
-1
;  
1
H 
NMR (400 MHz, CDCl3): δ 7.36-7.24 (ms, 15H, aromatic H), 4.87, 4.84, 4.72 (each 
AB d, 6H, J 10.5, OCH2Ph), 4.37 (d, 2H, J5,6 11.5, H-6a,6b), 4.31 (d, 1H, J1,2 8.0, H-
1), 4.25 (m, 1H, H-5), 3.67 (apt t, 1H, J2,3 8.5, J3,4 8.5, H-3), 3.56 (s, 3H, OCH3), 3.54 
(m, 1H, H-4), 3.43 (dd, 1H, H-2), 2.32 (m, 2H, aliphatic OCOCH2C10H21), 1.62 (m, 
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2H, aliphatic OCOCH2CH2C9H19), 1.26-1.24 (ms, 16H, each aliphatic 
OCOC2H4C8H16CH3), 0.88 (t, 3H, J 6.0, J 7.0, aliphatic OCOC11H23CH3);  
13
C NMR 
(CDCl3): δ 173.6 (s, C=O), 138.43, 138.42, 137.8 (each s, each aromatic C), 128.8, 
128.5, 128.4, 128.38, 128.34, 128.26, 128.11, 128.07, 127.97, 127.92, 127.8, 127.7, 
127.69, 127.64, 127.5 (each d, each aromatic CH), 104.7 (d, C-1), 84.6, 82.3, 77.6, 
72.9 (each d), 75.7, 75.1, 74.8 (each t, each OCH2Ph), 62.9 (t, C-6), 57.1 (q, OCH3), 
34.2, 31.9, 29.6, 29.5, 29.3, 29.2, 29.1, 24.9, 24.7, 22.6 (each t, each aliphatic CH2), 
14.1 (q, aliphatic CH3);  LRMS: Found, 669.2 required, 669.9 [M + Na]
+
;  Anal. 
Calcd. for C40H54O7: C, 74.27; H, 8.41. Found: C, 73.91; H, 8.79.  
 
OBnO
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Methyl 2,3,4-tri-O-benzyl-6-O-lauroyl-α-D-mannopyranoside (45c) - Treatment of 
44c (6.2 g, 10.0 mmol) as described for 44a gave  45c.  (4.1 g, 64%);  []D 23.3º
 
(c 
0.04, CHCl3);  FTIR (KBr): 3031, 2924, 2853, 1737, 1496, 1454, 1362, 1066, 1027, 
970, 909, 735, 697 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 7.38-7.25 (multiple signals, 
15H, each aromatic H), 4.77 (AB d, 2H, J 10.5, OCH2Ph), 4.74 (d, 1H, J1,2 2.0, H-1), 
4.72 (AB d, 2H, J 12.5, OCH2Ph), 4.61 (s, 2H, OCH2Ph), 4.38 (dd, 1H, J5,6a 2.5, J6a,6b 
12.0, H-6a), 4.33 (dd, 1H, J5,6b 5.0, H-6b), 3.94-3.88 (overlapping signals, 2H, H-3,4), 
3.78 (dd, 1H, J2,3 2.5, H-2), 3.76 (m, 1H, H-5), 3.31 (s, 3H, OMe), 2.32 (t, 2H, J 7.5, J 
7.5, aliphatic OCOCH2C10H21), 1.61 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.31-1.54 
(ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.91-0.86 (m, 3H, aliphatic 
OCOC10H20CH3);  
13
C NMR (CDCl3): δ 173.7, (s, C=O), 138.32, 138.21, 138.17 
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(each s, each aromatic C), 128.4., 128.38, 128.33, 128.05. 127.90, 127.76, 127.63, 
127.23 (each d, each aromatic CH), 98.9 (d, C-1), 75.2, 74.6, 74.4, 69.9 (each d), 80.1, 
72.6, 72.1 (each t, each CH2Ph), 63.3 (t, C-6), 54.8 (q, OCH3), 34.2, 33.9, 31.9, 29.61, 
29.48, 29.44, 29.33, 29.27, 29.17, 29.07, 24.9, 24.7, 23.8, 22.7, 21.1 (each t, each 
aliphatic CH2), 14.1 (q, aliphatic CH3);  LRMS: Found, 664.6 required, 664.9; [M + 
H2O]
+
;  Anal. Calcd. for C40H54O7: C, 74.27; H, 8.41. Found: C, 74.35; H, 8.25. 
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Methyl 2,3,4-tri-O-benzyl-6-O-lauroyl-α-D-galactopyranoside (45d) - Treatment of 
44d (5.7 g, 9.2 mmol) as described for 44a gave 45d.  (3.6 g, 60%);  []D 27.8º
 
(c 
0.09, CHCl3);  FTIR (KBr): 3030, 2924, 2853, 1738, 1496, 1454, 1350, 1099, 1049, 
735, 696 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 7.41-7.23 (multiple signals, 15H, each 
aromatic H), 4.83 (AB d, 2H, J 12.0, OCH2Ph), 4.81 (AB d, 2H, J 11.5, OCH2Ph), 
4.77 (AB d, 2H, J 12.0, OCH2Ph), 4.68 (d, 1H, J1,2 3.5, H-1),  4.16 (dd, 1H, J 7.5, J 
11.5, H-4), 4.07-4.03 (overlapping signals, 2H, H-2,5), 3.94 (dd, 1H, J 3.0, J 10.0 H-
6a), 3.86-3.84 (overlapping signals, 2H, H-3,6b),  3.35 (s, 3H, OMe), 2.23 (m, 2H, 
aliphatic OCOCH2C10H21), 1.57 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.31-1.18 
(ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, J 6.5, J 7.0, aliphatic 
OCOC10H20CH3);  
13
C NMR (CDCl3): δ 173.4 (s, C=O), 138.7, 138.4, 138.2 (each s, 
each aromatic C), 128.42, 128.36, 128.32, 128.11, 127.90, 127.75, 127.59, 127.51, 
127.21 (each d, each aromatic CH), 98.7 (d, C-1), 78.9, 76.3, 74.9, 68.4 (each d), 74.6, 
73.63, 73.54 (each t, each CH2Ph), 63.3 (t, C-6), 55.3 (q, OCH3), 34.1, 33.8, 31.9, 
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29.359, 29.45, 29.32, 29.26, 29.12, 24.9, 24.8, 22.7 (each t, each aliphatic CH2), 14.1 
(q, aliphatic CH3);  LRMS: Found, 664.6 required, 664.9; [M + H2O]
+
;  Anal. Calcd. 
for C40H54O7: C, 74.27; H, 8.41. Found: C, 74.67; H, 8.68.  
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Methyl 6-O-lauroyl-α-D-glucopyranoside (37a) - Compound 45a (0.34 g, 0.2 mmol) 
was dissolved in ethanol (1 mL) and Pd-C (0.1 g) was added.  The mixture was 
allowed to shake under hydrogen atmosphere of 2 psi until all protecting groups had 
been removed as verified by t.l.c. to yield 37a.  The suspension was filtered and 
concentrated in vacuo.
6
  (0.17 g, 86%);  []D 19º
 
(c 0.02, CHCl3);  FTIR (KBr): 3734, 
3445, 2955, 2924, 2850, 2359, 2341, 1728. cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 4.75 
(d, 1H, J1,2 3.5, H-1), 4.33 (m, 2H, H-6), 3.75-3.73 (overlapping signals, 2H, H-3,5), 
3.35 (apt t, 1H, J3,4 9.5, J4,5  9.5, H-4), 3.54 (dd, 1H, J2,3 9.5, H-2), 3.41 (s, 3H, OMe), 
2.35 (t, 2H, J 7.5, aliphatic OCOCH2C10H21), 1.63 (m, 2H, aliphatic 
OCOCH2CH2C9H19), 1.38-1.23 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, 
J 7.0, aliphatic OCOC10H20CH3);  
13
C NMR (CDCl3): δ 174.2 (s, C=O), 99.4 (d, C-1), 
74.1, 71.9, 70.4, 69.8 (each d), 63.5 (t, C-6), 55.2 (q, OCH3), 34.2, 31.9, 29.66, 29.64, 
29.5, 29.4, 29.3, 29.2, 24.9, 22.7 (each t, each aliphatic CH2), 14.1 (q, aliphatic CH3);  
LRMS: Found, 399.3 required, 399.5; [M + Na]
+
;  Anal. Calcd. for C19H36O7: C, 
60.61; H, 9.64. Found: C, 60.69; H, 9.83. 
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Methyl 6-O-lauroyl-β-D-glucopyranoside (37b) - Treatment of 45b (2.0 g, 3.0 mmol) 
as described for 45a gave  37b.  (0.86 g, 75%);  []D –25.5º
 
(c 0.05, CHCl3);  FTIR 
(KBr): 3421, 2921, 1744, 1703, 1016 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 4.40 (d, 
1H, J1,2 11.5, H-1), 4.28 (dd, 1H, J2,3 6.0, H-2), 4.21 (d, 2H, J5,6 7.5, H-6), 3.54 (s, 3H, 
OCH3), 3.49 (m, 1H, H-3), 3.39-3.31 (overlapping signals, 2H, H-4,5), 2.34 (m, 2H, 
aliphatic OCOCH2C10H21), 2.02 (s, 3H, OH), 1.62 (m, 2H, aliphatic 
OCOCH2CH2C9H19), 1.28-1.26 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, 
J 6.5, aliphatic OCOC10H20CH3);  
13
C NMR (CDCl3): δ 174.2 (s, C=O), 103.6 (d, C-
1), 76.5, 73.9, 73.4, 70.3 (each d), 63.6 (t, C-6), 57.0 (q, OCH3), 34.2, 31.9, 29.61, 
29.60, 29.5, 29.3, 29.2, 29.1, 24.9, 22.7 (each t, each aliphatic CH2), 14.1 (q, aliphatic 
CH3);  LRMS: Found, 399.1 required, 399.5 [M + Na]
+
;  Anal. Calcd. for C19H36O7: 
C, 60.61; H, 9.64. Found: C, 60.25; H, 9.91. 
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Methyl 6-O-lauroyl-α-D-mannopyranoside (37c) - Treatment of 45c (3.3 g, 5.0 mmol) 
as described for 45a gave 37c.  ( 1.4 g, 75%);  []D 33.3º
 
(c 0.01, CHCl3);  FTIR 
(KBr): 3421, 2923, 1736, 1466, 1197, 1057 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 
4.70 (s, 1H, H-1), 4.45 (br s, 1H, OH), 4.36 (d, 2H, J 4.0, H-6), 3.96-3.92 
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(overlapping signals, 2H, OH, H-2), 3.78 (dd, 1H, J2,3 2.5, J3,4 9.0, H-3), 3.71 (m, 1H, 
H-5), 3.62 (apt t, 1H, J4,5 9.5, H-4) 3.36 (s, 3H, OMe), 2.35 (t, 2H, J 7.5, J 7.5, 
aliphatic OCOCH2C10H21), 1.61 (m, 2H, aliphatic OCOCH2CH2C9H19), 1.29-1.25 
(ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, J 6.5, J 7.0, aliphatic 
OCOC10H20CH3); );  
13
C NMR (CDCl3): δ 174.7 (s, C=O), 100.9 (d, C-1), 71.5, 70.5, 
70.4, 67.7 (each d), 63.9 (t, C-6),  54.9 (q, OCH3), 34.2, 31.9, 29.7, 29.6, 29.5, 29.4, 
29.36, 29.34, 29.19, 24.9, 22.7 (each t, each aliphatic CH2), 14.1 (q, aliphatic CH3);  
LRMS: Found, 377.3 required, 377.5; [M + H]
+
;  Anal. Calcd. for C19H36O7: C, 60.61; 
H, 9.64. Found: C, 60.71; H, 9.53. 
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Methyl 6-O-lauroyl-α-D-galactopyranoside (37d) - Treatment of 45d (2.8 g, 4.4 
mmol) as described for 45a gave 37d.  ( 1.43 g, 86%);  []D 56.25º
 
(c 0.01, CHCl3);  
FTIR (KBr): 3250, 2918, 1741, 1467, 1194, 1025cm
-1
;  
1
H NMR (400 MHz, CDCl3): 
δ 4.63 (apt t, 1H, J 6.5, J 5.0, OH-3), 4.57 (d, 1H, J 6.5, OH-2),  4.55 (d, 1H, J1,2 3.5, 
H-1), 4.13 (dd, 1H, J5,6a 8.0, J6a,6b 11.5, H-6a), 4.07 (dd, 1H, J5,6b 4.0, H-6b), 3.75 (dd, 
1H, H-5), 3.68 (apt t, 1H, J3,4 3.5, J4,5  3.0, H-4), 3.58 (ddd, 1H, J2,3 10.0, J2,OH 16.5, 
H-2), 3.52 (m, 1H, H-3), 3.24 (s, 3H, OMe), 2.28 (t, 2H, J 7.5, aliphatic 
OCOCH2C10H21), 1.63 (t, 2H, J 7.0, aliphatic OCOCH2CH2C9H19), 1.28-1.23 (ms, 
16H, aliphatic OCOC2H4C8H16CH3), 0.85 (t, 3H, J 7.0, aliphatic OCOC10H20CH3);  
13
C NMR (CDCl3): δ 178.2 (s, C=O), 104.8 (d, C-1), 74.9, 74.1, 73.7, 73.1 (each d), 
68.8 (t, C-6), 59.8 (q, OCH3), 38.9, 36.5, 34.24, 34.10, 33.97, 33.93, 33.75, 29.5, 27.3, 
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(each t, each aliphatic CH2), 18.9 (q, aliphatic CH3);  LRMS: Found, 399.3 required, 
399.5; [M + Na]
+
;  Anal. Calcd. for C19H36O7: C, 60.61; H, 9.64. Found: C, 60.60; H, 
9.88. 
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Methyl 2,3,4-tri-O-benzyl-6-O-octanoyl-α-D-glucopyranoside (46a) - Compound 44a 
(5.0 g, 8.5 mmol) was dissolved in THF anhydrous (150 mL) and was cooled to 0
o
C.  
Tetrabutylammonium fluoride (2.2 g, 8.5 mmol) was added and the solution was 
warmed to room temperature and stirred for 1 h.
7
  The mixture was then concentrated 
in vacuo and the resulting 6-OH residue was dissolved in pyridine anhydrous (100 
mL).  A catalytic amount of 4-dimethylaminopyridine and octanoyl chloride (2.9 mL, 
17 mmol) was added and the mixture was stirred at room temperature for 24 h.
8
  The 
solution was then concentrated under reduced pressure and purified by 
chromatography (petroleum ether-EtOAc) to give 46a.  (3.9 g, 63%);  []D 20.8º
 
(c 
0.07, CHCl3);  FTIR (KBr): 2927, 1738, 1497, 1454, 1360, 1163, 1093, 738, 697 cm
-
1
;  
1
H NMR (400 MHz, CDCl3): δ 7.37-7.26 (ms, 15H, aromatic H), 4.93, (AB d, 2H, 
J 10.5, OCH2Ph), 4.74, (AB d, 2H, J 12.0, OCH2Ph), 4.73 (AB d, 2H, J 10.5, 
OCH2Ph), 4.60 (d, 1H, J1,2 3.5, H-1), 4.28 (d, 2H, J5,6 3.0, H-6), 4.01 (apt t, 1H, J2,3 
9.5, J3,4 9.5, H-3), 3.81 (m, 1H, H-5), 3.54 (dd, 1H, H-2), 3.48 (dd, 1H, J4,5 10.5, H-4), 
3.37 (s, 3H, OCH3), 2.31 (m, 2H, aliphatic OCOCH2C6H13), 1.62 (m, 2H, aliphatic 
OCH2CH2C5H11), 1.30-1.05 (ms, 8H, aliphatic OC2H4C4H8CH3), 0.87 (m, 3H, 
aliphatic OC6H12CH3);  
13
C NMR (CDCl3): δ 173.8 (s, C=O), 138.8, 138.3, 138.1 
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(each s, each aromatic C), 128.7, 128.6, 128.3, 128.29, 128.27, 128.3, 128.25, 128.20, 
128.1 127.9 (each d, each aromatic CH), 98.3 (d, C-1), 82.2, 80.2, 77.8, 68.9 (each d), 
76.1, 75.3, 73.6 (each t, each OCH2Ph), 63.1 (t, C-6), 55.4 (q, OCH3), 34.4, 31.9, 
29.2, 25.0, 22.8, 17.9 (each t, each aliphatic CH2), 14.3 (q, aliphatic CH3);  LRMS: 
Found, 613.4 required, 613.7; [M + Na]
+
;  Anal. Calcd. for C36H46O7: C, 73.19; H, 
7.85. Found: C, 73.25; H, 7.61 
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Methyl 6-O-octanoyl-α-D-glucopyranoside (38a) - Treatment of 46a (3.6 g, 6.2 mmol) 
as described for 45a gave  38ª.  (1.44 g, 73%);  []D 27.9º
 
(c 0.4, CHCl3);  FTIR 
(KBr): 3388, 2922, 1712, 1465, 1193, 1106, 724 cm
-1
;  
1
H NMR (400 MHz, CDCl3): 
δ 5.82 (s, 3H, each OH), 4.76 (d, 1H, J1,2 3.5, H-1), 4.35 (d, 2H, J5,6 4.0, H-6), 3.78-
3.72 (overlapping signals, 2H, H-3,5), 3.54 (dd, 1H, J2,3 9.5, H-2), 3.41 (s, 3H, 
OCH3), 3.36 (dd, 1H, J3,4 9.5, J4.5 10.0, H-4), 2.35 (m, 2H, aliphatic COCH2C6H13)  
1.64 (t, 2H, J 7.0, aliphatic COCH2CH2C5H11), 1.31-1.05 (ms, 8H, aliphatic 
COC2H4C4H8CH3), 0.88 (t, 3H, J 5.5, J 7.0, aliphatic COC6H12CH3);  
13
C NMR 
(CDCl3): δ 179.5 (s, C=O), 99.4 (d, C-1), 74.1, 72.0, 69.7, 70.3 (each d), 63.4 (t, C-6), 
55.3 (q, OCH3),  34.1, 31.7, 31.6, 29.9, 28.9, 24.8 (each t, each aliphatic CH2), 14.1 
(q, aliphatic CH3);  LRMS: Found, 343.1 required, 343.4; [M + Na]
+
;  Anal. Calcd. 
for C15H28O7: C, 56.23; H, 8.81. Found: C, 56.47; H, 8.73.  
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Methyl 2,3,4-tri-O-benzyl-6-O-dodecanyl-α-D-glucopyranoside (48) - Compound 44a 
(3 g, 4 mmol) was dissolved in THF anhydrous (80 mL) and was cooled to 0
o
C.  
Tetrabutylammonium fluoride (1 g, 4 mmol) was added and the solution was allowed 
to warm to room temperature and stir for 1 h.
7
  It was then concentrated in vacuo and 
approximately 3 mmol of the resulting 6-OH sugar was dissolved in DMF anhydrous 
(10 mL).  1-Chlorododecane (2.2 mL, 9.5 mmol) was added and the suspension was 
cooled to 0
o
C before NaH (0.38 g, 9.5 mmol) was added portion wise.  The solution 
was then allowed to warm to room temperature and stirred for 24 h.  Methanol (50 
mL) was added to quench the mixture which was stirred for 1 h.
5
  It was then 
concentrated in vacuo and purified by chromatography (petroleum ether-EtOAc) to 
give the benzylated ether 48.  (0.70 g, 35 %);  []D 3.3º
 
(c 0.03, CHCl3);  FTIR (KBr): 
2924, 2853, 1496, 1454, 1360, 1160, 1072, 736 cm
-1
;  
1
H NMR (400MHz, CDCl3): δ 
7.37-7.25 (ms, 15H, aromatic H), 4.91, (AB d, 2H, J 11.0, OCH2Ph),  4.75, (AB d, 
2H, J 11.0, OCH2Ph),  4.71 (AB d, 2H, J 13.0, OCH2Ph), 4.62 (d, 1H, J1,2 3.5, H-1), 
3.98 (apt t, 1H, J2,3 9.0, J3,4 9.0, H-3), 3.71 (m, 1H, H-5), 3.68-3.59 (overlapping 
signals, 3H, H-4,6a,6b), 3.55 (dd, 1H, H-2), 3.37 (s, 3H, OCH3), 1.55 (m, 2H, 
aliphatic OCH2C11H23), 1.31-1.23 (ms, 20H, aliphatic OCH2C10H20CH3), 0.88 (t, 3H, 
J 7.0, aliphatic CH3);  
13
C NMR (CDCl3): δ 139.1, 138.7, 138.4 (each s, each aromatic 
H), 128.7, 128.63, 128.60, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8 (each d, each 
aromatic CH), 98.4 (d, C-1), 82.4, 80.1, 78.0, 70.3 (each d), 76.0, 75.3, 73.6, 72.0 
(each t), 69.4 (t, C-6), 55.4 (q, OCH3), 32.1, 29.9, 29.86, 29.82, 29.7, 29.6, 26.4, 22.9 
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(each t, each aliphatic CH2), 14.4 (q, aliphatic CH3);  LRMS: Found, 655.4; required, 
655.87; [M + Na]
+
. After this step an attempt was made to remove the benzyl groups 
from compound 48 using the same method as for compound 45a, however during the 
reaction, the dodecanyl ether group was also removed leaving methyl-α-D-
glucopyranoside 7a confirmed by t.l.c. 
 
O
TIPSO
PMBO
PMBO
PMBO
50a
OMe
 
Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-triisopropylsilyl-α-D-glucopyranoside 
(50a) - A solution of 7a (5.0 g, 25.0 mmol) in DMF anhydrous (120 mL) was treated 
with triisopropylsilyl chloride (15 mL, 75 mmol) and imidazole (5 g, 75 mmol) and 
allowed to stir at room temperature for 24 h.  The crude TIPS protected intermediate 
was then concentrated in vacuo and the resulting residue dissolved in ethyl actetate.  It 
was then washed with 10% HCl, water, followed by sat. aq. NaHCO3, and finally sat. 
aq. NaCl before being dried over anhydrous MgSO4 and concentrated under reduced 
pressure.
7
  The TIPS protected crude residue was then split in two and half was 
dissolved in DMF anhydrous (30 mL) and THF anhydrous (20 mL).  This solution 
was then added dropwise at 0
o
C to a suspension of NaH (2.5 g, 62.5 mmol) in DMF 
anhydrous (10 mL) and THF anhydrous (7 mL), paramethoxybenzyl chloride (17 mL, 
125 mmol) and tetrabutylammonium iodide (18.5 g, 50 mmol).  This was stirred at 
approximately 10
o
C for 30 min and then allowed to warm to room temperature and 
stir for 24 h.   Methanol (50 mL) was added to quench the mixture which was stirred 
for 1 h.  The solution was then concentrated under diminished pressure and dissolved 
in ethyl acetate.  It was washed with water, dried over anhydrous MgSO4 and 
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concentrated in vacuo.
3
  The resulting residue was purified by chromatography 
(petroleum ether-EtOAc) to give 50a.  (5.15 g, 59%);  []D 11.6º
 
(c 0.05, CHCl3);  
FTIR (KBr): 3479, 2936, 2864, 1464, 1421, 1360, 1302, 883, 820. cm
-1
;  
1
H NMR 
(400 MHz, CDCl3): δ 7.34-6.73 (ms, 12H, aromatic H), 4.88 (AB d, 2H, J 10.5 
OCH2Ph), 4.78 (d, 1H, J1,2 5.0, H-1), 4.75, 4.71 (each AB d, 2H, J 12.0 OCH2Ph), 
4.63 (m, 1H, H-2), 3.99 (apt t, 1H, J3,4 9.0, J4,5 9.0, H-4), 3.89 (m, 2H, H6), 3.77 (m, 
9H, each PhOCH3), 3.57-3.49 (overlapping signals, 2H, H-3,5), 3.39 (s, 3H, OCH3), 
1.28 (m, 3H, each TIPS CH), 1.16-1.06 (ms, 18H, each TIPS CH3);  
13
C NMR 
(CDCl3): δ 159.6, 159.5, 159.4, 131.6, 131.4, 131.0 (each s, each aromatic C), 129.99, 
129.93, 129.8, 114.13, 114.08, 113.6 (each d, each aromatic CH), 98.1 (d, C-1), 82.2, 
80.2, 77.8, 72.1 (each d), 75.8, 74.9, 73.2 (each t, each OCH2Ph), 63.1 (t, C-6), 55.47, 
55.40, 55.36 (each q, each PhOCH3), 55.0 (q, OCH3), 18.27, 18.25 (each q, each TIPS 
CH3), 12.3 (d, each TIPS CH);  LRMS: Found, 733.3 required, 733.9 [M + Na]
+
. 
 
O
TIPSO
PMBO
PMBO
PMBO
50b
OMe
 
Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-triisopropylsilyl-β-D-glucopyranoside 
(50b) - Treatment of 7b (4.5 g, 23.17 mmol) as described for 7a gave 50b.  (10.1 g, 
61%);  []D 4.8º
 
(c 0.05, CHCl3);  FTIR (KBr): 2939, 1586, 1464, 883, 821, 760, 683. 
cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 7.30-6.84 (ms, 12H, aromatic H), 4,85, 4.80, 
4.73 (each AB d, 2H, J 10.5, OCH2Ph), 4.27 (d, 1H, J1,2 7.5, H-1), 3.95 (m, 1H, H-
6a), 3.87 (dd, 1H, J4,5 11.0, J5,6 4.5, H-5), 3.78 (m, 9H, PhOCH3), 3.59 (m, 1H, H-3), 
3.53 (s, 3H, OCH3) 3.36 (apt t, 1H, J2,3 9.0, H-2), 3.29-3.24 (overlapping signals, 2H, 
H-4,6b), 1.10-1.04 (ms, 21H, TIPS);  
13
C NMR (CDCl3): δ 159.5, 159.4, 131.2, 131.1, 
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130.9, (each s, each aromatic C), 129.9, 129.8, 128.7, 114.1, 114.04, 114.01 (each d, 
each aromatic CH), 104.7 (d, C-1), 84.7, 82.6, 77.5, 76.2 (each d), 75.7, 74.9, 74.7 
(each t, each OCH2PH), 62.7 (t, C-6), 56.8 (q, OCH3), 55.5 (each q, each PhOCH3), 
18.3, 18.2 (each q, each TIPS CH3), 12.2 (d, each TIPS CH);  LRMS: Found, 733.3; 
required, 733.9 [M + Na]
+
. 
 
O
O
PMBO
PMBO
PMBO
51a
OMe
H23C11
 
Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-dodecanyl-α-D-glucopyranoside (51a) - 
Compound 50a (4.0 g, 5.5 mmol) was dissolved in THF anhydrous (100 mL) and was 
cooled to 0
o
C.  Tetrabutylammonium fluoride (1.4 g, 5.5 mmol) was added and the 
solution was allowed to warm to room temperature and stir for 1 h.
7
  The mixture was 
then concentrated in vacuo and the resulting 6-OH residue was dissolved in DMF 
anhydrous (100 mL).  1-Chlorododecane (1.8 mL, 11 mmol) was added and the 
solution was cooled to 0
o
C before NaH (0.11 g, 2.75 mmol) was added portion wise.  
The mixture was then allowed to warm to room temperature and was stirred for 24 h.  
Methanol (50 mL) was added to quench the solution which was stirred for 1 h.
5
  The 
crude PMB protected ether was then concentrated under diminished pressure and 
purified by chromatography (petroleum ether-EtOAc) to give 51a.  (1.89 g, 50%);  [
]D –8.6º
 
(c 0.06, CHCl3);  FTIR (KBr): 2924, 2854, 1613, 1586, 1464, 1359, 1301, 
1248, 1172, 1037, 820 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 6.85-7.30 (ms, 12H, 
aromatic H), 4.92 (d, 1H, J1,2 10.5, H-1), 4.85 (AB d, 2H, J 10.5, OCH2PhOCH3), 
4.74 (dd, 1H, J2,3 9.5, H-2), 4.69, (AB d, 2H, J 10.5, OCH2PhOCH3), 4.60 (AB d, 2H, 
J 11.5 OCH2PhOCH3), 4.55 (apt t, 1H, J3,4 9.5, H-3), 3.95 (m, 1H, H-5), 3.80 (s, 9H, 
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each PhOCH3), 3.53-3.37 (overlapping signals, 3H, H-4,6a,6b), 3.36 (s, 3H, OCH3), 
1.60 (m, 2H, aliphatic CH2C11H23), 1.30-1.25 (ms, 20H, aliphatic CH2C10H20CH3), 
0.89 (t, 3H, J 7.0, aliphatic C11H20CH3);  
13
C NMR (CDCl3): δ 159.6, 159.5, 159.4, 
131.3, 131.0, 130.6 (each s, each aromatic C), 130.0, 129.8, 129.6, 114.07, 114.05, 
114.03 (each d, each aromatic CH), 98.5 (d, C-1), 82.1, 79.8, 77.7, 70.2 (each d), 75.7, 
74.9, 73.3 (each t, each OCH2Ph), 72.0 (t, aliphatic OCH2C11H23), 69.5 (t, C-6), 55.5 
(q, PhOCH3), 55.3 (s, OCH3), 32.2, 29.94, 29.91, 29.89, 29.87, 29.84, 29.7, 29.5, 28.4 
(each t, each aliphatic CH2), 14.4 (q, aliphatic CH3);  LRMS: Found, 745.5; required, 
745.9; [M + Na]
+
;  Anal. Calcd. for C43H62O9: C, 71.44; H, 8.64. Found: C, 71.09; H, 
8.73. 
 
O
O
PMBO
PMBO
PMBO
51b
OMe
H23C11
 
Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-dodecanyl-β-D-glucopyranoside (51b) - 
Treatment of 50b (3.2 g, 4.5 mmol) as described for 50a gave 51b.  (0.55 g, 85%);  [
]D 2º
 
(c 0.01, CHCl3);  FTIR (KBr): 2923, 2851, 1614, 1464.40, 1421, 1359, 1302, 
1254, 1173, 1072, 813 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 7.29-6.84 (ms, 12H, 
aromatic H), 4.79, 4.75, 4.67 (each AB d, 2H, J 10.5, OCH2Ph), 4.26 (d, 1H, J1,2 7.5, 
H-1), 3.79-3.58 (overlapping signals, 2H, H-3,5), 3.79 (m, 9H, PhOCH3), 3.68 (m, 
2H, H-6a,6b), 3.56 (s, 3H, OCH3), 3.43-3.39 (overlapping signals, 2H, H-2,4), 1.63 
(m, 2H, aliphatic OCH2C11H23), 1.29-1.24 (ms, 20H, aliphatic OCH2C10H20CH3), 0.88 
(t, 3H, J 7.0, aliphatic OC11H22CH3);  
13
C NMR (CDCl3): δ 159.3, 159.2, 159.1, 
130.9, 130.8, 130.5 (each s, each aromatic C), 129.8, 129.6, 129.5, 113.8, 113.7 (each 
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d, each aromatic CH), 104.8 (d, C-1), 84.4, 82.1, 77.7, 75.3 (each d), 74.9, 74.6, 74.4 
(each t, each OCH2Ph), 71.9 (t, aliphatic CH2), 69.7 (t, C-6), 57.1 (q, OCH3), 55.3, 
55.2 (each q, each PhOCH3), 31.9, 29.7, 29.68, 29.65, 29.63, 29.5, 29.4, 26.2, 22.7 
(each t, each aliphatic CH2), 14.1 (q, aliphatic CH3);  LRMS: Found, 745.3; required, 
745.9; [M + Na]
+
;  Anal. Calcd. for C43H62O9: C, 71.44; H, 8.64. Found: C, 71.19; H, 
8.70. 
 
O
O
HO
HO
HO
39a
OMe
H23C11
 
Methyl 6-O-dodecanyl-α-D-glucopyranoside (39a) - Compound 51a (1.45 g, 2.0 
mmol) was dissolved in a mixture of MeCN:H2O (3:1, 21 mL) and cerric ammonium 
nitrate (8.85 g, 16.16 mmol) was added.  The solution was allowed to stir at room 
temperature for 24 h.
9
  It was then concentrated in vacuo and purified by 
chromatography (petroleum ether-EtOAc) to give 39a.  (0.53 g, 73%);  []D 78.8º
 
(c 
0.04, CHCl3);  FTIR (KBr): 3416, 2919, 2851, 1467, 1372, 1128, 1043, 1019 cm
-1
;  
1
H NMR (400 MHz, CDCl3): δ 4.98 (br s, 1H, OH), 4.75 (d, 1H, J1,2 3.5, H-1), 4.34 
(br s, 1H, OH), 4.01 (br s, 1H, OH), 3.75 (apt t, 1H, J2,3 9.5, J3,4 9.5, H-3), 3.66 (m, 
2H, H-6), 3.54-3.44 (overlapping signals, 3H, H-2,4,5), 3.37 (s, 3H, OCH3), 1.58 (m, 
2H, aliphatic CH2C11H23), 1.28-1.25 (ms, 20H, each aliphatic CH2C10H20CH3), 0.88 
(t, 3H, J 6.5, J 7.0, aliphatic C11H20CH3);  
13
C NMR (CDCl3): δ 99.7 (d, C-1), 74.5, 
72.3, 72.2, 71.2 (each d) 70.6 (t, aliphatic CH2), 69.5 (t, C-6), 55.4 (q, OCH3), 32.1, 
29.9, 29.88, 29.86, 29.83, 29.7, 29.6, 26.3, 22.9 (each t, each aliphatic CH2), 14.3 (q, 
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aliphatic CH3);  LRMS: Found, 385.2; required, 385.5; [M + Na]
+
;  Anal. Calcd. for 
C19H38O6: C, 62.95; H, 10.57. Found: C, 62.60; H, 10.67. 
 
O
O
HO
HO
HO
39b
OMe
H23C11
 
Methyl 6-O-dodecanyl-β-D-glucopyranoside (39b) - Treatment of 51b (0.44 g, 0.6 
mmol) as described for 51a gave 39b.  (0.17 g, 76%);  []D –1º
 
(c 0.03, CHCl3);  FTIR 
(KBr): 3405, 2922, 2850, 1470, 1391, 1128, 1109, 1048 cm
-1
;  
1
H NMR (400 MHz, 
CDCl3): δ 4.20 (d, 1H, J1,2 7.5, H-1), 3.89 (s, 1H, OH), 3.74 (m, 2H, H-6a,6b), 3.66 
(m, 1H, H-5), 3.54 (s, 3H, OCH3), 3.52-3.44 (overlapping signals, 2H, H-3,4), 3.35 
(apt t, 1H, J2,3 8.0, H-2), 1.58 (m, 2H, aliphatic OCH2C11H23), 1.28-1.11 (ms, 20H, 
aliphatic OCH2C10H20CH3), 0.88 (t, 3H, J 6.5, J 7.0, aliphatic OC11H22CH3);  
13
C 
NMR (CDCl3): δ 103.5 (d, C-1), 76.5, 74.4, 73.4, 72.1, (each d), 71.6 (t, aliphatic 
CH2), 70.9 (t, C-6), 57.1 (q, OCH3), 31.9, 29.7, 29.66, 29.65, 29.58, 29.53, 29.4, 26.0, 
22.7 (each t, each aliphatic CH2), 14.1 (q, aliphatic CH3);  LRMS: Found, 385.2; 
required, 385.5; [M + Na]
+
;  Anal. Calcd. for C19H38O6: C, 62.95; H, 10.57. Found: C, 
62.83; H, 10.36. 
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O
O
PMBO
PMBO
PMBO
52
OMe
H23C11
O
 
Methyl 2,3,4-tri-O-paramethoxybenzyl-6-O-lauroyl-β-D-glucopyranoside (52) - 
Compound 50b (3.2 g, 4.5 mmol) was dissolved in THF anhydrous (150 mL) and was 
cooled to 0
o
C.  Tetrabutylammonium fluoride (1.2 g, 4.5 mmol) was added and the 
solution was allowed to warm to room temperature and stir for 1 h.
7
  The mixture was 
then concentrated in vacuo and the resulting PMB protected residue was divided up 
and approximately 1 mmol was dissolved in pyridine anhydrous (25 mL).  Lauroyl 
chloride (0.42 mL, 1.8 mmol) and a catalytic amount of 4-dimethylaminopyridine was 
added to the solution which was stirred at room temperature for 24 h.
8
  It was then 
concentrated under reduced pressure and purified by chromatography (petroleum 
ether-EtOAc) to give 52.  (0.56 g, 85 %);  []D 7.8º
 
(c 0.05, CHCl3);  FTIR (KBr): 
2924, 1737, 1600, 1501, 1464, 1302, 1249, 1173, 821 cm
-1
;  
1
H NMR (400MHz, 
CDCl3): δ; 7.29-6.84 (ms, 12H, aromatic H), 4.77, 4.70, 4.63 (each AB d, 6H, J 10.5, 
OCH2Ph), 4.28 (d, 1H, J1,2 7.5, H-1), 4.25 (dd, 1H, J2,3 12.0, H-2), 3.61 (m, 1H, H-5), 
3.56 (s, 3H, OCH3), 3.52-3.47 (overlapping signals, 3H, H-4,6a,6b), 3.39 (apt t, 1H, 
J3,4 8.0, H-3), 2.31 (m, 2H, aliphatic OCOCH2C10H21), 1.61 (t, 2H, J 7.0, aliphatic 
OCOCH2CH2C9H3), 1.29-1.24 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (t, 3H, 
J 8.0 aliphatic OCOC10H20CH3);  
13
C NMR (CDCl3): δ 173.6 (s, C=O), 159.4, 159.3, 
159.2, 130.7, 130.6, 129.9 (each s, each aromatic C), 129.8, 129.7, 129.5, 113.9, 
113.82, 113.80 (each d, each aromatic CH), 104.7 (d, C-1), 84.3, 81.9, 77.3, 72.9 
(each d), 75.4, 74.7, 74.4 (each d, each OCH2Ph), 62.9 (t, C-6), 57.1 (q, OCH3), 55.3 
(q, each PhOCH3), 31.9, 29.6, 29.5, 29.3, 29.2, 29.1, 24.9, 22.7 (each d, each aliphatic 
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CH2), 14.1 (q, aliphatic CH3);  LRMS: Found, 759.3; required, 759.9; [M + Na]
+
. 
After this step an attempt was made to remove the paramethoxybenzyl groups from 
compound 52 using the same method as for compound 51b, however during the 
reaction, the lauroyl ester group was also removed leaving methyl-β-D-
glucopyranoside 7b confirmed by t.l.c. 
 
OO
BnO
BnO
23
OMe
OPh
 
Methyl 2,3-di-O-benzyl-4,6-di-O-benzylidene-α-D-glucopyranoside (23) - A solution 
of 7a (1.0 g, 5.2 mmol), p-toluenesulfonic acid (10 mg) and benzaldehyde 
dimethylacetal (1.5 mL, 10.3 mmol) in acetonitrile anhydrous (25 mL) was stirred for 
24 h at room temperature.  Trimethylamine (0.5 mL) was added to neutralise the 
solution which was then stirred for 1 h.  The product was filtered off as a white solid, 
washed with petroleum ether and dried.
3
  The benzylidene protected intermediate was 
then dissolved in DMF anhydrous (15 mL) and the solution was cooled to 0
o
C.  NaH 
(0.74 g, 18.4 mmol) was added slowly followed by benzyl bromide (2.5 mL, 20 
mmol).  The mixture was then warmed to room temperature and stirred over night.  
Methanol (10 mL) was added to quench the solution which was stirred for a further 1 
hr.  The mixture was then concentrated under diminished pressure and purified by 
chromatography (petroleum ether-EtOAc) to give 23.  (2.0 g, 95%);  []D 0.7º
 
(c 0.05, 
CHCl3);  FTIR (KBr): 3063, 3031, 1109, 1088, 735, 692 cm
-1
;  
1
H NMR (400 MHz, 
CDCl3): 7.50-7.22 (ms, 15H, each aromatic H), 5.54 (s, 1H, CHPh), 4.85 (AB d, 2H, 
J 4.0, OCH2Ph), 4.82 (AB d, 2H, J 12.0, OCH2Ph), 4.59 (d, 1H, J1,2 3.5, H-1), 4.26 
(dd, 1H, J5,6a 10.0, J6a,6b 4.5, H-6a), 4.05 (apt t, 1H, J2,3 9.0, J3,4 9.0, H-3), 3.83 (m, 
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1H, H-5), 3.70 (apt t, 1H, J5,6b 10.5, H-6b), 3.62-3.54 (overlapping signals, 2H, H-
2,4), 3.39 (s, 3H, OCH3);  
13
C NMR (CDCl3): δ 138.7, 138.1, 137.4 (each s, each 
aromatic C), 128.89, 128.43, 128.29, 128.20, 128.10, 128.01, 127.90, 127.57, 126.0 
(each d, each aromatic CH), 101.2 (d, C-1), 99.2 (d, CHPh), 82.1, 79.2, 78.6, 62.3 
(each d), 75.3, 73.8 (each t), 69.1 (t, C-6), 55.3 (q, OCH3);  LRMS: Found, 463.3 
required, 463.5; [M + H]
+
;  Anal. Calcd. for C28H30O6: C, 72.71; H, 6.54. Found: C, 
72.31; H, 6.56.  
 
O
O
BnO
BnO OMe
OH23C11
O
H23C11
O
53
 
Methyl 2,3-di-O-benzyl-4,6-di-O-lauroyl-α-D-glucopyranoside (53) - Compound 23 
(1.7 g, 3.6 mmol) was dissolved in Methanol (50 mL) and a catalytic amount of TsOH 
was added.  The solution was stirred at room temperature overnight after which Et3N 
(1 mL) was added to quench the reaction.
3
  The mixture was concentrated under 
diminished pressure and the crude diol residue was dissolved in pyridine anhydrous 
(70 mL).  A catalytic amount of 4-dimethylaminopyridine and lauroyl chloride (3.3 
mL, 14.4 mmol) was added and the reaction was stirred at room temperature for 3 h.
8
  
The solution was then concentrated under diminished pressure and purified by 
chromatography (petroleum ether-EtOAc) to give 53.  (1.0 g, 38%);  FTIR (KBr): 
2925, 2853, 1743, 1455, 1360, 1167, 1105, 1045, 734 cm
-1
;  
1
H NMR (400 MHz, 
CDCl3): 7.34-7.26 (multiple signal, 10H, each aromatic H), 5.01 (dd, 1H, J3,4 9.5, 
J4,5 10.0, H-4), 4.78 (AB d, 2H, J 11.5, OCH2Ph), 4.73 (AB d, 2H, J 12.0, 
OCH2Ph),4.59 (d, 1H, J1,2 3.5, H-1), 4.15 (dd, 1H, J5,6a 5.5, J6a,6b 12.5, H-6a), 4.04 
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(dd, 1H, J5,6b 2.0, H-6b), 3.92 (apt t, 1H, J2,3 9.5, H-3), 3.87-3.82 (m, 1H, H-5), 3.59 
(dd, 1H, H-2), 2.36-2.27 (m, 4H,  each aliphatic OCOCH2C10H21), 1.67-1.56 (m, 4H, 
each aliphatic OCOCH2CH2C9H19), 1.26-1.16 (ms, 32H, each aliphatic 
OCOC2H4C8H16CH3), 0.88 (t, 6H, J 6.5, J 7.0, each aliphatic OCOC10H20CH3);  
13
C 
NMR (CDCl3): δ 173.6, 172.4 (each s, each C=O), 138.4, 137.9 (each s, each 
aromatic C), 128.51, 128.32, 128.18, 128.05. 127.69, 127.57 (each d, each aromatic 
CH), 98.2 (d, C-1), 79.51, 79.18, 69.5, 67.7 (each d), 75.4, 73.6 (each t, each CH2Ph), 
62.2 (t, C-6), 55.4 (q, OCH3), 34.15, 34.03, 33.99, 31.9, 29.62, 29.60, 29.49, 29.44, 
29.35, 29.34, 29.28, 29.26, 29.15, 29.13, 29.07, 24.76, 24.70, 22.69 (each t, each 
aliphatic CH2), 14.1 (q, aliphatic CH3). 
 
O
O
HO
HO OMe
OH23C11
O
H23C11
O
74
 
Methyl 4,6-di-O-lauroyl-α-D-glucopyranoside (40) - Compound 53 (0.84 g, 1.14 
mmol) was dissolved in Ethanol (2.5 mL) and Pd-C (0.3 g) was added.  The mixture 
was allowed to shake under hydrogen atmosphere of 2 psi until all protecting groups 
had been removed as shown by t.l.c. to yield 40.  The suspension was filtered and 
concentrated in vacuo.
6
  (0.47 g, 75%);  []D 4.33º
 
(c 0.03, CHCl3);  FTIR (KBr): 
3456, 2918, 2849, 1737, 1701, 1468, 1301, 1240, 1187, 1046 cm
-1
;  
1
H NMR (400 
MHz, CDCl3): δ 4.87 (dd, 1H, J3,4 9.5, J4,5 10, H-4), 4.82 (d, 1H, J1,2 4.0, H-1), 4.23 
(dd, 1H, J5,6b 2.0, J6a,6b 12.0, H-6b), 4.12 (dd, 1H, J5,6a 2.0, H-6a), 3.91 (ddd, 1H, H-5), 
3.84 (apt t, 1H, J2,3 9.5, H-3), 3.64 (m, 1H, H-2), 3.44 (s, 3H, OMe), 2.37-2.32 (m, 
4H, each aliphatic OCOCH2C10H21), 1.68-1.55 (m, 4H, each aliphatic 
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OCOCH2CH2C9H19), 1.30-1.26 (multiple signals, 32 H, each aliphatic 
OCOC2H4C8H16CH3), 0.88 (t, 6H, J 6.5, J 7.0, each aliphatic OCOC10H20CH3);  
13
C 
NMR (CDCl3): δ 173.63, 173.58 (each s, each C=O), 99.0 (d, C-1), 72.9, 72.7, 70.3, 
67.7 (each d), 62.2 (t, C-6), 55.5 (q, OMe), 34.2, 34.1, 34.0, 31.9, 29.63, 29.61, 29.50, 
29.47, 29.45, 29.36, 29.30, 29.27, 29.14, 29.08, 24.84, 24.82, 24.70, 22.70 (each t, 
each aliphatic CH2), 14.1 (q, aliphatic CH3);  LRMS: Found, 559.5 required, 559.8; 
[M + H]
+
;  Anal. Calcd. for C31H58O8: C, 66.63; H, 10.46. Found: C, 66.66; H, 10.79. 
 
Lauroylation of Pentaerythritol: 
 
OHHO
HO OH Cl C11H23
O
+
A B  
 
Pentaerythritol 6 (1.0 g, 7.3 mmol), lauroyl chloride (4.8 mL, 21 mmol) and a 
catalytic amount of 4-dimethylaminopyridine were dissolved in pyridine anhydrous 
(50 mL) and stirred at 50
o
C for 24 h.  The solution was then concentrated in vacuo 
and the following mono lauroyl 41, di lauroyl 54 and tetra lauroyl 55 products were 
isolated by chromatography (petroleum ether-EtOAc): 
 
OHO
HO OH
70d
C11H23
O
 
Mono lauroyl pentaerythritol (41) - (0.33 g, 14%);  FTIR (KBr): 3462, 2914, 2848, 
1737, 1712, 1476, 1187, 1038, 1005 cm
-1
;  
1
H NMR (400 MHz, CDCl3): 4.10 (s, 
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2H, CH2OC=O), 3.80-3.61 (overlapping signals, 9H, 3 x CH2OH, 3 x OH), 2.34 (t, 
2H, J 6.0, J 7.0,  aliphatic OCOCH2C10H21), 1.61 (m, 2H, aliphatic 
OCOCH2CH2C9H19), 1.26 (ms, 16H, aliphatic OCOC2H4C8H16CH3), 0.88 (m, 3H, 
aliphatic OCOC10H20CH3);
  13
C NMR (CDCl3):  175.0 (s, C=O), 62.7, 62.4 (each t, 
each CH2O), 45.3 (s, C(CH2)4), 34.2, 31.9, 29.59, 29.57, 29.44, 29.30, 29.23, 29.15, 
24.9, 22.6 (each t, each aliphatic CH2), 14.1 (q, aliphatic CH3);  LRMS: Found 341.2, 
required 341.45 [M+Na]
+
;  Anal. Calcd. for C17H34O5: C, 64.12; H, 10.76. Found: C, 
64.08; H, 10.79.  
 
OO
HO OH
70b
C11H23
O
H23C11
O
 
Di lauroyl pentaerythritol (54) - (1.074 g, 29%);  FTIR (KBr): 3351, 2915, 2850, 
1739, 1701, 1471, 1163, 978, 719 cm
-1
;  
1
H NMR (400 MHz, CDCl3): 4.12 (s, 4H, 
each CH2OC=O), 3.58 (s, 4H, each CH2OH), 3.22 (br s, 2H, each OH) 2.34 (t, 4H, J 
7.5, J 7.5,  each aliphatic OCOCH2C10H21), 1.62 (t, 4H, J 6.5, J 6.5, each aliphatic 
OCOCH2CH2C9H19), 1.29-1.26 (ms, 32H, each aliphatic OCOC2H4C8H16CH3), 0.88 
(t, 6H, J 6.5, J 6.5, each aliphatic OCOC10H20CH3);
  13
C NMR (CDCl3):  174.4 (s, 
each C=O), 62.4 (t, each CH2O), 44.7 (s, C(CH2)4), 34.2, 31.9, 29.56, 29.29, 29.21, 
29.11, 24.9, 22.6 (each t, each aliphatic CH2), 14.1 (q, each aliphatic CH3);  LRMS: 
Found 501.5, required 501.75 [M+H]
+
;  Anal. Calcd. for C29H56O6: C, 69.56; H, 
11.27. Found: C, 69.64; H, 11.31.  
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O O
70a
C11H23
O
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H23C11
H23C11
O
O O
 
Tetra lauroyl pentaerythritol (55) - (0.39 g, 6%);  FTIR (KBr): 2917, 2849, 1735, 
1336, 1299, 1250, 1154, 1111, 1002 cm
-1
;  
1
H NMR (400 MHz, CDCl3): 4.11 (s, 
8H, each CH2OC=O), 2.30 (t, 8H, J 7.5, J 8.0,  each aliphatic OCOCH2C10H21), 1.60 
(t, 8H, J 6.5, J 7.0, each aliphatic OCOCH2CH2C9H19), 1.41-1.26 (ms, 64H, each 
aliphatic OCOC2H4C8H16CH3), 0.88 (t, 12H, J 6.5, J 7.0, each aliphatic 
OCOC10H20CH3); 
 13
C NMR (CDCl3):  173.2 (s, each C=O), 62.1 (t, each CH2O), 
41.8 (s, C(CH2)4), 34.1, 31.9, 29.59, 29.45, 29.31, 29.23, 29.11, 24.8, 22.7 (each t, 
each aliphatic CH2), 14.1 (each q, each aliphatic CH3);  LRMS: Found 888.7, required 
888.36 [M+Na]
+
;  Anal. Calcd. for C53H100O8: C, 73.56; H, 11.65. Found: C, 73.60; 
H, 11.58.  
 
O
O
O
O
O
O
H23C11
56
 
3-O-dodecanyl-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (56) - Diacetone-D-
glucose 32 (1 g, 3.84 mmol) was dissolved in DMF anhydrous (10 mL) and 1-
chlorododecane (3.63 ml, 15.35 mmol).  The mixture was cooled to 0
o
C and NaH 
(0.92 g, 23.04 mmol) was added portion wise.  The solution was then warmed to room 
temperature and stirred for 24 h.  The mixture was cooled to 0
o
C and methanol (10 
mL) was added to quench the mixture which was stirred for 1 h.
5
  The solution was 
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concentrated in vacuo and purified by chromatography (petroleum ether-EtOAc) to 
give 56.  (1.43 g, 89 %);  []D –21.3º
 
(c 0.2, CHCl3);  FTIR (KBr): 2927, 2855, 1457, 
1371, 1216, 1166, 1074, 1022, 721 cm
-1
;  
1
H NMR (400MHz, CDCl3): δ 5.87 (d, 1H, 
J1,2 3.5, H-1), 4.42 (dd, 1-H, J2,3 4.0, H-2), 4.13 (dd, J4,5 3.0, 1H, J5,6a 8.0, H-5), 4.08 
(dd, 1H, J5,6b 8.5, 1H, J6a,6b 6.0, H-6b), 3.98 (dd, 1H, J3,4 6.0, H-4), 3.85 (d, 1H, H-6a), 
3.61 (apt t, 1H, H-3), 3.51 (m, 2H, aliphatic OCH2C11H23), 1.55 (m, 2H, aliphatic 
OCH2CH2C10H21), 1.49, 1.42, 1.35, 1.31 (each s, each CH3), 1.30-1.26 (ms, 18H, 
aliphatic OC2H4C9H18CH3), 0.88 (t, 3H, J 6.5, J 7.0, aliphatic OC11H22CH3);  
13
C 
NMR (CDCl3): δ 111.8, 106.9 (each s), 105.4 (d, C-1), 82.7, 82.2, 81.3, 72.7 (each d), 
70.8 (t, aliphatic CH2), 67.3 (t, C-6), 32.0, 29.9, 29.8, 29.8, 29.7, 29.6, 29.5, 29.3, 
26.2, 22.8 (each t, each aliphatic CH2) 26.9, 26.8, 26.4, 25.5 (each q), 14.2 (q, 
aliphatic CH3);  LRMS: Found, 451.5 required, 451.6; [M + Na]
+
;  Anal. Calcd. for 
C39H54O9: C, 67.26; H, 10.35. Found: C, 67.17; H, 10.35. 
 
O
HO
O
HO
57
HO
OHH23C11
 
3-O-dodecanyl-(α/β)-D-glucopyranoside (57) - Amberlite-IR 120 (H+) (3 g) was 
added to a suspension of 56 (1.43 g, 3.34 mmol) in H2O (15 mL).  The mixture was 
then stirred at reflux for 4 h
5
 however at this stage t.l.c indicated the presence of 
several products.  
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H23C11
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3-O-lauroyl-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (58) - Diacetone-D-
glucose 32 (0.5 g, 2 mmol) was dissolved in pyridine anhydrous (25 mL).  A catalytic 
amount of 4-dimethylaminopyridine and lauroyl chloride (0.56 ml, 2.4 mmol) was 
added and the solution was allowed to stir at room temperature for 24 h.
8
  It was then 
concentrated in vacuo and the crude ester derivative was purified by chromatography 
(petroleum ether-EtOAc) to give 58.  (0.71 g, 79 %);  []D –24.2º
 
(c 0.03, CHCl3);  
FTIR (KBr): 2924, 1747, 1457, 1373, 1160, 1022, 943, 722 cm
-1
;  
1
H NMR (400MHz, 
CDCl3): δ 5.87 (d, 1H, J1,2 4.0, H-1), 5.27 (d, 1H, J3,4 1.0 H-3), 4.47 (d, 1H, J2,3 3.5, 
H-2), 4.21 (dd, 1H, J4.5 4.0 H-4), 4.11 (m, 2H, H-6a,6b), 4.01 (m, 1H, H-5), 2.36-2.32 
(ms, 2H, aliphatic COCH2C10H21), 1.69-1.60 (ms, 2H, aliphatic COCH2CH2C9H19), 
1.52-1.26 (overlapping signals, 28H, aliphatic COC2H4C8H16CH3, each acetonide 
CH3), 0.88 (t, 3H, J 7.0, aliphatic COC10H20CH3);  
13
C NMR (CDCl3): δ 172.4 (s, 
C=O), 112.3, 109.3 (each s), 105.0 (d, C-1), 83.4, 79.9, 75.8, 72.5 (each d), 67.3 (t, C-
6), 34.3, 31.9, 29.7, 29.6 (each t, each aliphatic CH2), 29.5, 29.3, 29.2, 29.0 (each q), 
26.8, 26.7, 26.2, 25.3, 24.9, 22.7 (each t, each aliphatic CH2);  LRMS: Found, 465.2 
required, 465.6; [M + Na]
+
;  Anal. Calcd. for C36H46O7: C, 65.13; H, 9.57. Found: C, 
65.01; H, 9.63. 
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